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The human vagina and the bacterial communities that reside therein exist in a finely 
balanced mutualistic association. Dysbiotic states of the vaginal microbiota, including 
bacterial vaginosis (BV), are characterized by a paucity of Lactobacillus spp., the 
presence of a wide array of strict and facultative anaerobes, and a pH >4.5. Symptoms 
such as odor and discharge can accompany these microbial dysbiotic states, however, 
epidemiologically, vaginal dysbioses have been associated with increased 
susceptibility to STIs, including chlamydia. The mechanisms by which vaginal 
microbiota protect or increase the risk to infections remain unknown. This thesis 
aimed to identify the molecular factors that control host cellular responses to 
Lactobacillus spp.-dominated and dysbiotic microbiota. Chapter 2 characterized the 
in vivo host microRNA (miRNA) response to different types of vaginal microbiota to 
gain insight into host functions that play a role in vaginal homeostasis. Leveraging 
daily collected vaginal samples in conjunction with a machine learning approach, 
 
eight miRNAs were discovered to be differently controlled by vaginal microbiota. Of 
these, expression of miR-193b, known to regulate host cell proliferation, was 
increased by Lactobacillus spp.-dominated microbiota. In vitro, vaginal epithelial 
cells exposed to Lactobacillus spp. culture supernatants exhibited reduced epithelial 
cell proliferation, high miRNA-193b expression and decreased abundance of cyclin 
D1. More importantly, epithelial cell proliferation was identified as a requirement for 
efficient Chlamydia trachomatis infection. Chapter 3 characterized the in vitro 
transcriptome of epithelial cells exposed to Lactobacillus spp. relative to Gardnerella 
vaginalis, a surrogate for dysbiotic vaginal microbiota. Immune response and cell 
cycle pathways were found to be among the most modulated by Lactobacillus spp. 
Longitudinal gene expression suggested a role of histone deacetylases (HDAC) as an 
intermediary between immune stimulation and cell proliferation. Additionally, the 
epidermal growth factor receptor (EGFR), required for C. trachomatis infection, was 
decreased when epithelial cells were exposed to Lactobacillus spp. These findings 
contribute to the fundamental understanding of the vaginal microbiota’s role in 
cellular homeostasis as a requirement for resistance to STI agents such as C. 
trachomatis, and ultimately will lead to improved preventive strategies against STIs 
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Chapter 1 Introduction 
 
The Role of the Vaginal Microbiota in Women’s Health1 
 
Characterization of the vaginal microbiota 
 
The assemblages of microbes (microbiota) associated with the human body 
have been shown to affect human physiology, immunity and nutrition [1]-[4]. In the 
vagina, microbes exist in a finely tuned mutualistic relationship with the host and 
provide the first line of defense against the colonization by opportunistic pathogens. 
Throughout a woman’s lifespan, the vaginal microbiota undergoes major changes 
associated with transitional reproductive periods such as puberty and menopause [5]. 
During these periods, the vaginal microbiota can affect host reproductive physiology 
but can also be affected by host physiology.  
 Recent high-throughput 16S rRNA gene sequencing studies examining 
vaginal bacterial species composition and abundance in reproductive-aged women 
have shown that there are at least five major types of vaginal microbiota called 
community state types (CST) [6]-[8]. Four of these CSTs are dominated by either 
Lactobacillus crispatus (CST-I), L. iners (CST-III), L. gasseri (CST-II) or L. jensenii 
(CST-V) and one, CST-IV, does not contain a significant number of Lactobacillus 
spp. but is comprised of a polymicrobial mixture of strict and facultative anaerobes 
                                                
1 This section adapted from Smith, S. B. and Ravel, J. (2017), The vaginal 
microbiota, host defence and reproductive physiology. J Physiol, 595: 451–463. 
doi:10.1113/JP271694 
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including species of the genera Gardnerella, Atopobium, Mobiluncus, Prevotella and 
other taxa in the order Clostridiales (Figure 1.1) [6], [7], [9], [10]. The frequency of 
these CSTs has been shown to differ in different ethnic backgrounds, with CST-IV 
more common (~40%) in black and Hispanic women [6]. The polymicrobial 
condition known as bacterial vaginosis (BV) is compositionally similar to CST-IV 
since it is defined by a loss of Lactobacillus spp., the presence of anaerobes and strict 
anaerobes, and sometimes associated clinical symptoms including discharge, odor 
and irritation. In research settings, a Gram-staining scoring procedure that relies on 
the identification of bacterial morphotypes known as the Nugent test is used to 
establish a BV diagnosis [11] [appropriately renamed Nugent-BV by [12]]. Clinically, 
the diagnosis of BV is accompanied by an evaluation of the following signs and 
symptoms: discharge, malodor, the presence of clue cells and vaginal pH>4.5 as 
defined by the Amsel criteria [13]. 
 Daily fluctuations in the composition of the vaginal microbiota have been 
previously documented by microscopy and cultivation studies [14]-[16]. These 
findings were confirmed and extended in longitudinal culture-independent analyses 
such as those of women who self-collected vaginal swabs twice weekly for 16 weeks 
[7], [17], [18], or daily for 10 weeks [19] or 4 weeks [20]. It was observed that some 
vaginal microbial communities transitioned in and out of CST-IV while others 
remained relatively stable either within a Lactobacillus spp.-dominated CST or CST-
IV (Figure 1.2). The amount of time spent in a particular CST could vary individually 
as some women experienced consistent and stable CST longitudinal patterns (defined 
as community class), while others frequently transitioned between CSTs and most 
 3 
frequently to CST-IV [7], [19]. In some cases, CST transitions were triggered by 
menstruation or sexual behaviors, but in other cases they seem to be driven by 
uncharacterized factors [7]. These longitudinal studies highlight the highly dynamic 
nature of vaginal microbial communities and emphasize the need to better understand 
the underlying biological factors modulating fluctuations in composition and 
functions that affect host physiology. 
Historically, Lactobacillus spp.-dominated vaginal microbial communities 
have been associated with healthy reproductive-aged women and are characterized by 
the production of copious amounts of lactic acid and thus an acidic pH (<4.5) 
(reviewed in [21]-[23]). This acidic environment is thought to be highly protective 
against infections or colonization of the vagina by pathogens and non-indigenous 
microbes. An additional benefit of Lactobacillus spp. (i.e., L. crispatus and L. 
gasseri) is the supply of bacteriocins or bacteriocin genes (i.e., gassericin T, acidocin 
lF221A, type-A lantibiotic, and Bacteriocins IIa, IIc and J46) to inhibit growth of 
undesirable species (i.e., Klebsiella spp., Staphylococcus aureus, Escherichia coli or 
Enterococus faecalis) [24], [25]. However, the notion that a Lactobacillus spp.-
dominated vaginal microbiota is necessarily the norm has been called into question 
since mounting evidence suggests that about 25% of asymptomatic women do not 
possess a Lactobacillus spp.-dominated microbiota at any given time, a staggering 
proportion which does not support a diseased state [6], [26], [27]. These differences 
between women appear to be driven by a combination of cultural, behavioral, genetic, 
and other unknown underlying factors [6], [7], [26]. However, a strong association 
between CST-IV (as established by Nugent-BV) and increased risk to sexually 
 4 
transmitted infections [28]-[30], including human immunodeficiency virus (HIV) 
[31]-[34], and reproductive tract and obstetric sequelae has been established through 
thorough epidemiological studies [35]-[39]. Hence, while CST-IV might be normal 
(asymptomatic) in some women, it is still associated with significantly increased risk 
to adverse outcomes. An illustration of how CST-IV can help further foster infections 
is in the case of chlamydial infection, where interferon-γ (IFN-γ) production is 
thought to be critical for chlamydia clearance. IFN-γ activates the human enzyme 
indoleamine 2,3-dioxygenase, which catabolizes tryptophan, eventually leading to 
tryptophan starvation and chlamydia clearance since genital chlamydia cannot 
synthesize tryptophan. However, production of indole compounds by anaerobes and 
strict anaerobes comprised in CST-IV affords chlamydia to shunt its deficiency and 
produce tryptophan, thus by-passing this host defense mechanism and establishing a 
long-term infection (discussed in [40]). Similarity, relative to other Lactobacillus 
spp.-dominated community states, CST-IV-like communities increase the risk to HIV 
infection [26], [41]. However, not all Lactobacillus spp. are necessarily beneficial and 
protective since, for example, some strains of L. iners might carry pathogenicity 
factors, such as inerolysin, a cholesterol-dependent cytolysin (CDC) and a host 
epithelial cell pore-forming enzyme, which was found to be up-regulated at least 6-
fold in women with BV [42], [43]. Therefore, when considering the impact of the 
microbiota on host defense and reproductive physiology, it is important to place it in 
the context of these dynamic and individualized relationships.  
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Figure 1.1 Representative vaginal microbiota community state type generated by hierarchical 
clustering of microbial taxa composition and relative abudance.   
Hierarchical clustering shows that the vaginal microbiota of reproductive-aged women clusters into 
at least  five distinct community state types, four of which are dominated by Lactobacillus spp. 
(Lactobacillus crispatus (CST-I), L. iners (CST-III), L. gasseri (CST-II) or L. jensenii (CST-V)) and 
the fifth (CST-IV) is comprised of a polymicrobial mixture of strict and facultative anaerobes 
including species of the genera Atopobium, Megasphera, Mobiluncus, Prevotella and other taxa in 
the order Clostridiales. Figure reproduced from [6] 
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Figure 1.2 Representative longitudinal profiles of vaginal microbiota from women who self-sampled 
daily for 10 weeks.  
Longitudinal plots of four participants over a 10-week study [19] who are either (A) consistently CST-I, (B) 
consistently CST-IV and (C-D) transition between CST-IV and CST-III. From top to bottom for each subject, 
panels show the profile of relative bacterial abundance based on 16S rRNA gene sequencing, Nugent score (0 
to 10), pH (4 to 7) and metadata including reported menstruation (red dots), tampon use, douching, vaginal 
intercourse, anal and oral sex, finger penetration, sex toy use, lubricant use, vaginal irritation, vaginal itching, 
vaginal burning, vaginal odor, vaginal discharge, medication (e.g. antibiotics) and finally BV clinical 
diagnosis at approximately week 1, 5, and 10 (square is no clinical finding, open circle is asymptomatic 
Amsel-BV, filled circle is symptomatic Amsel-BV, star is UTI). Horizontal red lines in Nugent score plot 
indicate Nugent score 3 or 7 and lines in pH plot indicate pH 4.5. Red bars in Nugent score, pH and metadata 











































































































































































































































































The effect of the microbiota on host defense 
 
The vagina contains a number of immune-related cells and receptors to help 
sense the microbial environment [44]. Surveillance for microbes within the female 
genital tract of both commensal and pathogenic microbes is generally achieved by 
pattern recognition receptors (PRRs) such as Toll-like Receptors (TLRs) or the 
Dectin-1 receptor (which helps recognize the fungal pathogen Candida albicans [45], 
[46]), and nucleotide-binding oligomerization domain (NOD) receptors present in and 
on both squamous epithelial cells lining the vagina and the columnar cells lining the 
upper female genital tract (as reviewed in [44], [47]-[49]). Microbial stimulation of 
PRRs initiates cytokine/chemokine signaling cascades, for example secretion of IL-
1β, IL-6, IL-8 and tumor necrosis factor-α (TNF-α), to recruit/activate specialized 
cells, such as NK cells, macrophages, CD4+ helper T-cells, and CD8+ cytotoxic T-
cell lymphocytes and B lymphocytes as reviewed in [44], [50], [51]. Genetic variants 
of PRRs such as the IL-1R antagonist, TLR4, TLR9, IL-1R2, or TNF-α may play a 
role in how a woman responds to a particular microbial challenge or pregnancy 
outcome, as evidenced by several genetic-disease association studies [52]-[58]. 
Women with CST-IV states show significant increases in IL-1α, IL-1β, TNF-α, IFN-
γ, IL-4, IL-8, IL-10, IL-12p70, and fms-like tyrosine kinase 3 ligand relative to CST-I 
as well as significantly higher IFN-γ in CST-III relative to CST-I. Specifically, in one 
study, Prevotella amnii, Mobiluncus mulieris, Sneathia amnii, and Sneathia 
sanguinegens (all commonly found in CST-IV) were found to induce higher levels of 
IL-1α, IL-1β, and IL-8 relative to L. crispatus dominated communities (CST-I), 
whereas L. iners dominated communities (CST-III) induced moderate IL-8 levels 
 8 
relative to CST-I. The authors also showed how there were significant increases in 
IL-1α, IL-1β and TNF-α longitudinally in subjects that transition from a CST-I, to 
CST-III and to a CST-IV [26]. Conversely, mock communities dominated by L. 
crispatus (CST-I) and L. jensenii (CST-V) on reconstructed three-dimensional 
vaginal epithelial models do not strongly elicit cytokine IL-1β or IL-8 secretion 
relative to medium control, and also inhibit some pro-inflammatory responses after 
TLR 2/6 and 3 agonist induction [59]. These studies continue to support the notion 
that the innate immune response is largely driven by vaginal bacterial community 
states, with CST-IV potentially having a larger pro-inflammatory response than CST-
I or CST-II, and with CST-III triggering an intermediate response. 
Additional factors contributing to vaginal defense include mannose binding 
lectin (MBL), vaginal antimicrobial peptides (AMPs) and immunoglobulin A and G 
(IgA, IgG). As its name suggests, MBL binds mannose, N-acetylglucosamine and 
fucose carbohydrate moieties present on microbial cell surfaces. Eventually, this 
interaction leads to cell lysis or targeting for the immune system [60], [61]. IgA and 
IgG may help to prevent vaginal epithelial cell adherence and uptake, as well as 
contribute to the neutralization and clearance of infectious microbes from the vagina 
[62], [63]. Vaginal AMPs exist in various classes and may recruit immune cells via 
chemotaxis or possess anti-endotoxin activity. Mechanisms for each AMP have been 
thoroughly reviewed elsewhere [64]-[66], and while the specific association between 
AMPs and vaginal microbiota has not been extensively investigated, key findings are 
emphasized here. Defensins are a class of cationic and amphipathic AMPs with 
diverse mechanisms of action against common vaginal bacteria, pathogens and 
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viruses including HIV, herpes simplex virus (HSV) and human papillomavirus 
(HPV). In organotypic models of the vaginal epithelium, human α-defensin-2 (HBD-
2) expression, but not that of HBD-1, was associated with colonization by L. iners, 
Atopobium vaginae and Prevotella bivia [67], while in another study using similar 
experimental in vitro conditions, L. jensenii but not Gardnerella vaginalis were 
shown to induce HBD-2 transcription [68]. As expected, many human defensins bind 
to viral-specific proteins to prevent viral attachment to a human cell surface, as for 
example, with retrocyclin-1, retrocyclin-2, human neutrophil peptide-1 (HNP-1), 
HNP-2, HNP-3 and to a much lesser degree HNP-4 [69]-[74]. In addition to 
defensins, other AMPs are found in the human vagina and include the secretory 
leukocyte protease inhibitor (SLPI), human epididymis protein 4 (HE4), LL-37, and 
Surfactant protein A (SP-A) and Surfactant protein D (SP-D). SLPI expression is 
associated with BV organisms [75] but not with L. crispatus, L. iners, A. vaginae or 
P. bivia [67], [76]. HE4 is associated with G. vaginalis [76] and LL-37 inactivates the 
sexually transmitted pathogen Neisseria gonorrhoeae while having no effect on L. 
crispatus, L. jensenii and comparatively little effect on L. iners [77]. The lack of 
AMP stimulation in response to some Lactobacillus spp. is associated with their 
needed maintenance in the vagina [78]. Similar to defensins, SP-A and SP-D 
contribute to viral inhibition, including HIV where they act via binding to the viral 
protein gp120 and human CD4, but with SP-A simultaneously enhancing gp120 
binding to dendritic cells and therefore also facilitating HIV uptake [79], [80]. Thus, 
overall, microbes, environments, immune regulatory actions and genes tightly interact 
to govern homeostasis of the vaginal environment. 
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Bacterial Vaginosis and Aerobic Vaginitis.  
 
As mentioned, a vaginal microbiota can be characterized by one of five CSTs, 
with CST-IV lacking a relatively high abundance of Lactobacillus spp. Generally, 
CST-IV can clinically manifest as aerobic vaginitis (AV) or BV, so the immune 
response to CST-IV outlined above overlaps considerably with BV or AV. AV is 
mainly differentiated from BV by the presence of an inflammatory response 
predominately associated with aerobes, such as group B Streptococcus, 
Staphylococcus aureus, Escherichia coli, and Enterococcus [81], [82]. The AV 
inflammatory response manifests symptomatically as itching or burning, molecularly 
as increased IL-6, IL-1β, and cellularly as the presence of leukocytes or primary 
blood cells in a microscopic wet mount [83]. In contrast, the clinical definition of BV 
does not involve any overt inflammatory responses such as recruitment of 
neutrophils, redness, itching or burning (reviewed in [84]), but involves fishy odor 
and heavy discharge. A number of immune factors including IL-1β, IL-2, IL-4, IL-6, 
IL-8, IL-10, IL-12, TNF-α, IFN-γ, chemokine C-C motif ligand 5 (CCL5) and SLPI 
have been variably and inconsistently associated with BV (summarized in [47]). 
These conflicting findings may be due to different study designs (longitudinal versus 
cross-sectional, or in vitro versus in vivo), different definitions of BV (symptomatic 
versus asymptomatic BV or Nugent-BV versus BV diagnosed according to the Amsel 
criteria) or that additional features actively suppress the inflammatory response in 
BV, such as IgA degradation, TLR expression inhibition, or immune-related genetic 
variants [85], [86]. As an example of BV’s effect on host defense, cytokine analysis 
from a vaginal epithelial cell model co-colonized with mock communities 
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representing CST-I to -IV as well as Nugent scores corresponding to respective BV 
diagnosis showed significant increases in IL-1β, IL-8, TNF-α, CCL5 and IL-1RA in 
CST-III or CST-IV, but not CST-I or CST-II (Figure 1.3) [41]. The ability of 
individual BV-associated bacterial species to elicit an in vitro immune response has 
also been studied, as in the cases of A. vaginae which induces expression of 
chemokine C-C motif ligand 20 (CCL20), HBD-2, IL-1β, IL-6, IL-8, and TNF-α via 
the NF-κB, TLR2 and MyD88 signaling pathways; G. vaginalis which induces IL-6, 
IL-8 transcripts; and L. iners which stimulates PRR signaling but not downstream 
inflammatory response cytokines IL-6, IL-8 or mucins [67], [87]. Bacteria-derived 
Short Chain Fatty Acids (SCFAs), namely acetate, butyrate, propionate and succinate, 
some of which exist at relatively higher proportions during BV, can induce a pro-
inflammatory response under a hypothesis that SCFAs may act to ultimately inhibit 
chemotaxis and inflammation in BV [7], [88]-[91]. Relatively high concentrations (2-
Figure 1.3 Typical BV and Lactobacillus spp. immune interactions in the vaginal epithelium. 
 Shown are immune responses associated with different vaginal microbiota CSTs. See text for details and 
abbreviations. Horizontal arrows from CST-I or CST-II to CST-III or CST-IV/BV indicate immune 
responses associated with transitions from/to these CSTs.  Red shapes indicate either CST-I or CST-II 


































20 mM) of acetate and butyrate, but not propionate, induce cytokine IL-6, IL-8 and 
IL-1β secretions and also induce IL-8, TNF-α with TLR2 and TLR7 ligand 
stimulation in a dose- and time-dependent manner in vitro [90]. However, whether or 
not the host is actively downplaying the sensing of BV-associated microbes or a 
specific attribute of BV is evading inflammation remains to be demonstrated since the 
etiology of BV is still unknown and the necessary longitudinal studies are lacking 
[92]. 
Lactic acid and host defense 
 
Lactic acid is produced mainly by vaginal microbes [93] and helps maintain 
healthy host physiological functions since it has been shown to directly inhibit 
Chlamydia trachomatis infection [94], and potentially both HSV-2 and HIV in vitro 
and in vivo if there is sufficient lactic acid to acidify the vagina to pH<4 (Figure 1.4) 
[95]-[98]. Lactic acid also inactivates a broad range of BV-associated microbes at 
pH<4.5 [99]. When Lactobacillus spp. dominate the vaginal microbiota, they acidify 
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the vagina to a strongly acidic mean pH of 3.5 +/-0.2 that likely helps protect against  
a  broad range of infections [89]. Recent studies aim to uncover the mechanism by 
which lactic acid can directly affect host immune functions, and showed that lactic 
acid can directly inhibit pro-inflammatory responses IL-6, IL-8 and IL-1RA, [100], 
induce the Th17 lymphocyte pathway via IL-23 in a dose-dependent manner upon 
lipopolysaccharide co-stimulation [101], and help release mediators from vaginal 














Figure 1.4 Interaction of the human vaginal microbiota with physiology, host defense and reproduction.  
The host supplies glycogen and glycogen breakdown products via stimulation by estrogen production as a 
carbon source to the vaginal microbiota, therefore favoring Lactobacillus growth. In turn, lactic acid and 
bacteriocins produced mainly by Lactobacillus spp. contribute to the host defense while species associated 
with CST-IV, AV, or BV (such as G. vaginalis or L. iners) contribute to mucosa degradation and 
susceptibility to other infections. Specific host defenses including the innate immune response/inflammation, 
cell recruitment (such as NK cells or macrophages, pink and yellow circles, respectively), cytokines (pink “Y” 
shapes) and AMPs (blue circles) are dependent on host genetic polymorphisms, CST and pathogen presence 
(such as C. trachomatis and HIV) and may also have a negative effect on reproduction and pregnancy. Gram 
stain images of Lactobacillus spp. and CST-IV are unpublished data. All other images are in the public 
domain (Creative Commons License). 
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epithelial cells and stimulate antiviral response by release of transforming growth 
factor-β [102]. In the gut, lactate and acetate from L. casei and Bifidobacterium breve 
inhibit cell proliferation, but whether these molecules play a similar role in vagina has 
not been studied [103]. Interestingly, lactic acid isomers may also play a role in 
determining host response and the subsequent host-microbiota relationship. Lactic 
acid exists in the vagina in both D(-) and L(+) isomers, with the host contributing 
only about 4-30% of the total lactate [93], suggesting a large reliance on microbes to 
supply the majority of lactic acid for protection. In one study, only D(-) lactic acid 
was correlated with α-amylase, SLPI, hyaluronidase-1 (HYAL1), neutrophil 
gelatinase-associated lipocalin (NGAL), and matrix metalloproteinase 8 (MMP-8) 
expression in vitro [75]. The authors suggest that epithelial cell exfoliation and 
subsequent breakdown of glycogen helps favor Lactobacillus spp. growth, and thus 
helps sustain D(-) lactic acid production (see discussion on α-amylase and glycogen 
below). Moreover, women with BV were found to be deficient in both isomers, while 
those with vulvovaginal candidiasis have elevated L(+) lactic acid as well as CD147 
and MMP-8 genes [104]. L. iners does not produce D(-) lactic acid and fails to 
produce the L(+) lactic acid in abundance as high as L. crispatus or L. gasseri while 
L. jensenii produces only D(-) lactic acid [105], suggesting potential Lactobacillus 
species-specific effects on the host. Consequently, the composition of the vaginal 
microbiota, and specifically the ability of vaginal microbes to produce D(-) lactic 
acid, may help to inhibit pathogens and inflammatory responses while also favoring 
Lactobacillus spp. survival by using host cells resources for carbon sources.  
   
 15 
The effect of the microbiota on the vaginal mucosa 
 
The vaginal mucosa plays an important role as a physical barrier to separate 
host epithelial environment from harmful pathogens, including HIV [106], [107], 
whereas vaginal microbes can affect the integrity of the mucosa [108]. The BV-
associated species G. vaginalis secretes sialidases, which have been shown to 
deglycosylate secretory immunoglobulin A (sIgA) and other sialoglycan substrates 
via the cleavage of sialic acid from gylocoprotein at the α-2–3 and α-2– 6 linkage 
Neu5Ac present on both N- and O-glycans, thereby hydrolyzing protective mucosal 
sialoglycoproteins [109]. G. vaginalis can consume and neutralize liberated sialic acid 
residues to further evade the host response [110]. In addition, G. vaginalis produces 
vaginolysin, a cholesterol-dependent cytolysin that could contribute to BV 
symptomology by forming pores in the vaginal epithelium with or without CD59 
[111], [112]. BV-associated bacteria quantified by Nugent score also significantly 
associates with Mucins-1, -4, -5AC and -7 [113]. Conversely, certain types of vaginal 
communities could enhance the integrity of the mucosal barrier. A recent study 
showed that L. crispatus-dominated vaginal microbiota were able to reinforce the 
diffusional barrier properties of cervicovaginal mucus against HIV, hence hindering 
HIV penetration, while communities dominated by L. iners facilitated the penetration 
of HIV through the cervicovaginal mucus barrier [106]. Thus, a change in vaginal 
community composition and function is strongly associated with the integrity of the 
protective mucus layer, as such, vaginal bacteria, including species of Lactobacillus, 
can reduce or increase susceptibility to infectious agents, including HIV. 
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The effect of the microbiota on reproductive functions 
 
The vaginal microbiota in combination with other factors is associated with 
adverse reproductive and obstetric outcomes. For example, a meta-analysis revealed 
that BV-like vaginal microbiota are significantly more prevalent in women with tubal 
infertility when compared to women with other causes of infertility, but is not 
associated with decreased conception rates [114]. Preterm labor and delivery has been 
thought to be in part associated with changes in the vaginal microbiota composition, 
namely bacteria found in CST-IV (i.e., G. vaginalis and Ureaplasma), AV or BV 
(where preterm labor and delivery are defined in each study as occurring before 37 
weeks in either Caucasian women [115], mostly African American women [116], and 
mostly Caucasian women [117]). Jakovljević et al assessed differences of gestational 
time to delivery in BV versus non BV women, with a statistically significant 
difference of 37.72 ± 3.9 versus 39.59 ± 1.1 weeks [118]. However, another study did 
not find any association between CST-IV and preterm births (defined as 28–33.1 
weeks versus term births of 38.8-40.7 weeks in mostly African American women) 
even though the study was well-powered and preterm births were phenotypically 
well-controlled [119]. It should be noted that differences in ethnicity, definition of 
preterm birth and analytical methods of microbiota data could explain these different 
observations. The possibility remains that functional differences exist and that 
hypotheses should be further explored using metagenomics or metatranscriptomics 
based approaches.  
The interplay between host polymorphism and the vaginal microbiota could 
play an important role in the mechanisms by which microbes affect reproductive 
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health. Polymorphisms in genes that control inflammatory response (protein kinase 
C-α, fms-like tyrosine kinase 1, IL-6 and TNF-α) are associated with preterm delivery 
in combination with CST-IV vaginal microbiota, although the direct functional 
impact of these polymorphisms is unknown (Figure 1.4) [120], [121]. These studies 
and others have suggested that the inflammatory and antimicrobial peptide response, 
associated with certain vaginal microbiota, exhibit a role in rupturing and invading 
cervical plug or amniotic membranes, eventually triggering pro-inflammatory 
cascades that could lead to premature labor and delivery (reviewed in [64], [122], 
[123]). In a rhesus monkey model infected with group B Streptococcus, there was an 
observed increase in amniotic fluid of cytokines TNF-α, IL-1β, and IL-6 occurring 
before uterine contractility or any clinical signs of infection, suggesting a direct role 
of infection in preterm labor [124]. Specific AMPs are expressed upon exposure in 
vitro and in vivo to the BV-associated bacteria A. vaginae (CCL20, HBD-2) or 
pathogens, such as C. trachomatis (elafin) and N. gonorrhoeae (SLPI), but not L. 
crispatus or L. jensenii [67], [87], [125]-[127]. The immune response to pathogens 
can trigger signaling cascades, which could ultimately lead to miscarriage, 
intrauterine infection, preterm labor, and tubal and ectopic pregnancy. For example, if 
C. trachomatis ascends past the cervix, such an infection in the upper genital track 
could lead to tubal scarring and potentially tubal infertility, ectopic pregnancy, and 
chronic pelvic pain ([128] and discussed in [129]). C. albicans triggers IL-6 secretion 
in the placenta ultimately leading to an increase in NF-κB and an inflammatory 
response [130]. A study measuring the effects of immunomodulation in pregnant 
women with BV found that C. albicans and Trichomonas vaginalis but not C. 
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trachomatis or N. gonorrhoeae had no effect on vaginal cytokines, and none of these 
pathogens had any effect on anti-G. vaginalis hemolysin IgA, sialidase or prolidase 
activity [131]. Clearly there is still much to learn about the dynamics, the function 
and mechanisms driving the role of the vaginal microbiome in reproduction health.  
Physiology affects vaginal microbiota composition 
 
The composition of the vaginal microbiota changes throughout a woman’s 
lifetime from birth, through puberty, reproductive age and menopause. At birth, 
Lactobacillus spp., if transferred from the mother, can colonize a baby girl vagina 
where the epithelium is mature and contain glycogen driven by the presence of 
circulating maternal estrogen [132]. After three to four weeks of age and until 
puberty, no estrogen is present or produced and the vaginal microbiota comprises a 
variety of anaerobes, diphtheroids, coagulase-negative staphylococci, and E. coli. 
Postmenopausal women often experience a loss of Lactobacillus spp. associated with 
the decrease in estrogen controlling vaginal epithelial proliferation, maturation, and 
accumulation of glycogen which is directly or indirectly nutritionally necessary for 
the maintenance of Lactobacillus spp. [133]-[137]. Indeed, estrogen levels peak 
during reproductive age and contribute to shaping the composition of the vaginal 
microbiota. In menopause, vaginal application of estrogen cream is associated with 
vaginal epithelial maturation, the accumulation of glycogen and acidic pH (<4.0), the 
latter indicative of the presence of high number of Lactobacillus spp. [138]. 
Interestingly, Lactobacillus spp. were originally thought to directly ferment glycogen 
in the vagina. However, this idea was gradually refuted and recent evidence suggests 
that human α-amylase catabolizes glycogen into smaller polymers, namely maltose 
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and maltotriose, which can then be used by Lactobacillus spp. for metabolism, even 
in newborns who have residual circulating maternal estrogen [139]-[143]. This model 
puts forward that the influence of estrogen, glycogen and especially α-amylase 
provides a positive selection pressure for a Lactobacillus spp.-dominated microbiota 
(Figure 1.4) [142]. These findings highlight the tight interplay between host 
physiology and the vaginal microbiota. 
Concluding remarks 
 
The human vaginal ecosystem is a dynamic environment in which microbes 
can affect host physiology but also where host physiology can affect the composition 
and function of the vaginal microbiota (Figure 1.4). Species of Lactobacillus have 
been historically associated with vaginal health in reproductive-age women due to the 
direct and indirect protective nature afforded by Lactobacillus products, such as lactic 
acid and bacteriocin among others, against mucus degradation and inhibition of 
pathogens. The reported inconsistent innate immune response observed with non-
Lactobacillus spp.- or L. iners-dominated microbiota (CST-IV, BV, AV and CST-III, 
respectively), coupled with recent findings that question the definitions of normality, 
highlight the need for more in-depth functional understandings of the interaction 
between the vaginal microbiota and host physiology, reproduction and defense. 
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microRNAs As Regulatory Molecules to Host Responses  
miRNA biogenesis and function 
 
microRNAs (miRNA) are members of a class of non-coding regulatory RNA 
(ncRNAs) typically 20-22 nucleotides in length that have numerous roles in 
regulating biological processes via gene expression modulation, including organism 
development and innate immune signaling [144], [145]. Other ncRNAs include 
tRNA, rRNA, snoRNA, siRNA PIWI-interacting RNAs and long-non coding RNAs 
[146]. miRNA biogenesis, regulation and mechanisms have been studied using 
various model organisms including poriferans, cnidarians, Arabidopsis thaliana, 
Caenorhabditis elegans, Drosophila melanogaster,  Danio rerio, Gallus gallus, 
Rattus norvegicus, Mus musculus, and  Homo sapiens [144], [147], [148]. miRNA 
mechanisms in plants are largely distinct from metazoans and therefore not discussed 
[144]. Furthermore, where appropriate, human-specific mechanisms are only 
discussed.  
The canonical metazoan miRNA biogenesis pathway begins in the cell’s 
nucleus by RNA polymerase II-dependent transcription of pri-miRNA (Figure 1.5) 
[149], [150]. Pri-miRNAs possess both a 5’ 7-methyl guanylate (m7G) cap and a 3’ 
poly(A) tail [150] identical to those found in coding messenger RNA (mRNA). Pri-
miRNAs exist as part of both long non-coding RNAs and in miRNA family clusters 
[151]. A bioinformatic analysis suggested some miRNAs are co-transcribed with their 
host genes while others are transcribed by themselves [152]. A non-exhaustive list of 
transcription factors that regulate miRNAs include tumor protein p53 (TP53),   
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Figure 1.5  Canonical microRNA biogenesis and mechanism. 
Pri-miRNAs are transcribed from DNA as transcripts containing a 7-methylguanosine cap and poly(A) tail. The 
hairpin structures that form on pri-miRNA are recognized by Drosha and DCGR8 which cleave the hairpin structure 
from the transcript, resulting in pre-miRNA. Pre-miRNA is exported from the nucleus by Exportin 5, then the loop 
structure is cleaved by Dicer. The mature strand is loaded onto miRISC which contains at minimum AGO2, GW182, 
Dicer and TARBP2. miRISC typically binds to the 3’ UTR of a target mRNA and has been shown to repress protein 
translation by disrupting PABP from binding to eIF4G and other scaffold proteins including eIF4E. Transcriptional 
degradation has also been observed via mRNA de-capping and de-adenylase factors including CCR4-NOT and 
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myelocytomatosis oncogene (MYC), myoblast determination protein 1 (MYOD1), 
zinc finger E-box binding homeobox 1 (ZEB1), and ZEB2, with additional pri-
miRNA transcriptional control mechanisms still being an active research area [146]. 
Pri-miRNAs form hairpin structures after they are transcribed [11] and are recognized 
and cleaved by the nuclear proteins DCGR8 and the RNAse-III like enzyme Drosha, 
initiating pre-miRNA processing and forming ~65 nucleotide hairpin structures [153]. 
Pre-miRNAs are exported from the nucleus into the cytoplasm by Exportin 5 
requiring RanGTP [154]-[156].  
Nucleus-exported pre-miRNAs are further processed into mature miRNA in 
the cytoplasm by a second RNAse-III enzyme Dicer, which recognizes and cleaves a 
22 nucleotide long dsRNA from both the 3’ and 5’ ends (Figure 1.5) [157], [158]. 
One of the two mature complimentary hairpin strands (the guide strand) is loaded into 
the miRNA-Induced Silencing Complex (miRISC) comprised of the Argonaute 2 
(AGO2) protein, GW182 (a 182 kD protein containing glycine (G) and tryptophan 
(W) repeats [159]), RNAse-III like enzyme Dicer and human immunodeficiency virus 
trans activating response RNA-binding protein 2 (TARBP2) while the second strand 
(the passenger strand) is degraded [160] [161]. Characteristics that determine which 
strand becomes the guide strand include thermodynamic stability, 5′ nucleotide 
identity and structure, and the presence of co-factors TARBP2 or protein activator of 
interferon induced protein kinase EIF2AK2 (PRKRA) [162]. Argonaute is not only 
critical to the miRNA biogenesis pathways, but was found to be fatal after deletion in 
mouse embryonic cells [163].  
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Eukaryotic protein translation of an mRNA proceeds in three stages: 
initiation, elongation and termination where each stage is highly orchestrated, 
consisting of many co-factors, ribosomal RNA and transfer RNA [164]. During 
initiation, the mRNA is circularized through the binding of the mRNA’s 7mG cap to 
its poly(A) tail through binding and scaffold proteins including poly(A) binding 
protein (PABP) and eukaryotic translation initiation factor 4 gamma 1 (eIF4G) and 
eIF4E [165], [166]. Although an active area of research is the exact mechanisms, co-
factors and kinetics by which translational inhibition and transcriptional degradation 
is achieved, there are two currently accepted mechanisms by which miRNAs exert 
their repression of target genes: translational initiation inhibition and mRNA 
degradation (Figure 1.5) [167]-[170]. Note these mechanisms are not mutually 
exclusive, and indeed, they are thought to occur almost simultaneously [171]. It has 
been demonstrated that translational inhibition precedes degradation, although 
interestingly in one study, mRNA destabilization explains 66% to ~90% observed 
repression and therefore may ultimately drive gene regulation  [172], [173].  
During translational initiation inhibition, the miRNA that is loaded into the 
miRISC binds to the semi-complementary sequence of an mRNA target molecule 
typically found in the 3’ Untranslated Region (UTR) and is thought to disrupt 
translational machinery through the dissociation of the translational co-factors 
eukaryotic translation initiation factor 4AI (eIF4AI) and eIF4AII from the translation 
complex [174] and inhibiting circulation by repressing PABP and eIF4G binding 
[175], [176]. Interestingly, some miRNAs have been found to bind to the 5’ UTR of 
certain genes and in some instances caused increased translation [38]-[42]. 
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Additionally, AGO2 possesses motifs that resemble the binding domain of eIF4E to 
the m7G cap-binding domain suggesting that Argonaute is able to bind to the cap 
structure instead of eIF4E during translational initiation [177]. Depleting eIF6 in 
human cells, a factor involved in assembling the 80S ribosome, removed miRNA-
mediated effects [178] suggesting it is required for effective inhibition. 
miRNA-induced mRNA degradation has also been characterized in certain 
contexts. Components of the miRISC have been observed to recruit or associate with 
de-adenylase complexes and de-capping enzymes that destabilize or actively degrade 
mRNA, including the de-adenylase associated complexes CCR4-NOT and PAN2-
PAN3 [179]-[182]. Studies suggest that the GW182-mediated recruitment of the 
CCR4–NOT complex helps release PABP from the poly(A) tail [183]. In Drosophila 
melanogaster, miRISCs promote de-capping through recruitment of Decapping 
protein 1 (DCP1), maternal expression at 31B (Me31B) and Protein associated with 
topo II related-1 (Patr-1) independently of de-adenylation [184]. One study found that 
Argonaute, GW182, CCR4–NOT and DEAD-box helicase 6 (DDX6)/Me31B repress 
and degrade polyadenylated mRNA targets during ribosome scanning independent of 
eIF4A [185].  
Non-canonical miRNA biogenesis pathways have also been discovered. Some 
miRNAs originating from introns (mitrons) and the spliceosome machinery can be 
processed without Drosha, which then enter the canonical pathway beginning with 
Exportin 5 export [186], [187]. In another non-canonical biogenesis pathway, most of 
the miR-105 and let-7 families belong to miRNAs that have a 3’ mono-uridylation 
added by TUTase, which is required for recognition by Dicer [188]. Drosha- and 
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Dicer-independent pathways and miRNAs have also been described but are believed 
to occur less frequently [189], while recent evidence has challenged the requirement 
of Dicer and Exportin 5 as miRNAs were found to be processed or loaded onto 
AGO2 but with reduced efficiency [189]. Indeed, vertebrate pre-miR-451 is Dicer 
independent and is instead cleaved by AGO2 [190]. Finally, miRNAs can exhibit 
either SNP or end modifications which can alter the stability of loading on RISC and 
of mRNA binding [191], [192].  
miRNA role in host response 
 
The host first recognizes microbes  through the innate immune system [48], 
[193], [194]. As such, microbes trigger innate immune response pathways which lead 
to expression and regulation by immune-associated miRNAs. These miRNAs include 
miR-155, miR-146, miR-125, miR-223, miR-21 and the let-7 family which regulate 
immune functions such as the NF-κb response, TLR receptor signaling, and IL-6, IL-
1β and IL-8 cytokine transcription. Interestingly, these immune responses are also 
potentially implicated in BV or vaginal dysbiosis [145], [195]-[200]. As the host must 
balance and regulate the immune response to pathogenic and mutualistic microbe, 
there is growing appreciation for the role that miRNAs might play in the host 
response to different microbiota in general.  
The role of microbiota miRNA-mediated gene regulation has been studied in 
the mouse gut. In one study, differential expression of nine miRNAs in the ileum or 
the colon of germ free mice relative to pathogenic-free microbiota mice was found. In 
this system, the mouse gene Abcc3 (a transporter protein) is regulated by mmu-miR-
665 [201]. Interestingly, the gut microbiota of Dicer-mutant mice, which broadly 
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impacts miRNA processing, show exacerbated colitis, which was eliminated by the 
addition of wild type fecal miRNA administered by gavage at 22.5 µg/day for 7 
consecutive days [202]. In Dicer-null gut epithelial cells, IL-13 induced miR-375, 
which targets Kruppel-like factor 5, believed to be a myeloid transcription factor, to 
maintain mucosal immunity [203], [204]. These studies point to critical roles for 
miRNAs in regulating the innate immune response, and the maintenance of both 
epithelial homeostasis and barrier function. 
Certain bacteria in the mouse and human gut microbiota produce a relatively 
high abundance of the short chain fatty acid butyrate which has been shown to 
decrease cell proliferation via histone deacetylase (HDAC) inhibition and has also 
been shown to alter the expression of many RNA molecules within cell cycle 
pathways [205]-[209]. For example, butyrate decreased human colorectal carcinoma 
HCT-116 cell proliferation by stimulating the expression of cyclin dependent kinase 
inhibitor 1A (CDKN1A, also known as p21) in a dose dependent manner. This effect 
was dampened by adding exogenous miR-106b, which targets CDKN1A and thus 
reversed the inhibition of cell proliferation [210]. Although lactate is known to inhibit 
pro-inflammatory responses in vaginal cells and inhibit cell proliferation in gut cells, 
it is not known whether the same is true for the vaginal environment [100]-[102], 
[211]. Butyrate is transported into the cell via transporter solute carrier family 5 
member 8 (SLC5A8) [212], [213]. More generally, SCFA have been also shown to 
inhibit inflammatory responses in various cell lines [214]. For example, butyrate 
inhibits innate immune responses through NF-kB inhibition [215], [216]. 
Interestingly, acetic and butyric acid at relatively high concentrations (20 mM), in 
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conjunction with TLR ligands, were also found to induce pro-inflammatory cytokine 
responses in part through the release of reactive oxygen species in primary blood 
monocular cells (PBMCs) or neutrophils [90]. Thus, SCFAs released by bacteria in 
the microbiota play a critical role in host cell response, potentially through immune-
related pathways and mediated through miRNA. 
Experimental Methods, Technology and Challenges of Measuring Human RNA  
RNA handling and extraction 
 
Unlike DNA, RNA is highly susceptible to RNases which catalyze RNA 
degradation [217]. High quality RNA, evaluated in biological samples by the 
abundance of intact ribosomal RNA with the RNA Integrity Number (RINe) [218], is 
necessary for RNA sequencing as longer reads generate higher confidence sequence 
alignments to reference genomes. To achieve this goal, tissue and cell samples are 
stored in specialized transport media such as RNAlater [219] designed to inhibit 
RNases and stabilize RNA, prior to RNA extraction. Dedicated RNase-free laboratory 
bench space, equipment and precautions aimed at reducing RNase contamination 
from laboratory personnel’s skin and clothing, is essential for obtaining consistent, 
high quality RNA [217]. RNA handling and extraction therefore involves additional 
labor-intensive processing and handling relative to that of DNA.  
Once extracted and purified from a biological sample, RNA is typically 
characterized and quantified using high throughput sequencing or qPCR (Figure 1.6). 
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Both approaches convert RNA into cDNA using the enzyme reverse transcriptase. 
For miRNA characterization, small RNA-seq or miRNA-qPCR is performed whereas 
with longer RNA transcripts (e.g. mRNA), RNA-seq or qPCR is performed.  Due to 
their small size, reverse transcriptase cannot prime a miRNA template in the same 
manner as longer-length RNAs. Therefore, the template length must be increased 
before RNA is converted into cDNA. The first step in small RNA-seq library 

































miRNA TTTTTTTTTTTTTTT Universal primer + reverse transcriptase
cDNA
miRNA
Hairpin unfolds and acts as universal primer.
cDNA
+ reverse transcriptase
Figure 1.6 RNA extraction, small-RNA-seq, ribo-reduced RNA-seq, and miR-qPCR.  
Total RNA is extracted from samples stored in RNAlater, then prepared for either small RNA-seq, ribo-
reduced RNA-seq or miR-qPCR. Once sequencing libraries are constructed and sequenced, reads are 
aligned to a human genome sequence reference using BWA or Bowtie/Tophat, then genomic features are 
counted using HTSeq. Small RNA-seq libraries must first be ligated with sequencing adaptors before 
creating cDNA, which has the potential to produce adaptor dimers unless special adaptors are used (as is 
available commercially from TriLink). Similarly, miR-qPCR lengthens the target molecule by addition of a 
poly(A) tail or a hairpin probe so that reverse transcriptase can prime the miRNA.  
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universal sequence for the RNA reverse transcriptase to form cDNA. Thus, a major 
challenge of small RNA-seq is to ligate adaptors to small RNA targets and not to each 
other (which form adaptor dimers). Removal of adaptor-dimers by gel purification is 
often difficult as the dimers are close to the size of the library (only differing by 20 
base pairs). A novel commercial method alleviates this problem by using proprietary 
chemically modified adaptors containing end-modified oligonucleotides that 
selectively bind to small RNA but not each other [220]. For qPCR, the two main 
approaches to increase effective template length are adding a poly(A) tail to miRNA 
to bind a universal poly(T) primer [221] [222] or using hairpin loop hybridization 
[223] [224]. Both approaches result in cDNA for qPCR.   
Ribosomal RNA-reduced (ribo-reduced) RNA libraries are constructed by 
first removing abundant human rRNA molecules from the sample using beads that 
hybridize human rRNA [225]. The remaining RNA is reverse transcribed into cDNA 
using random hexamer or poly(T) priming. Sequencing adaptors are added in addition 
to multiplex indices and then sequenced [226]. Sequences produced through the 
process are aligned to the human reference to characterize RNA expression level as a 






Bioinformatic and Computational Approaches to Identify Transcripts Associated with 
Experimental Conditions  
Alignment of RNA-seq reads to reference and transcriptomic feature counting  
 
For both human small RNA-seq and human ribo-reduced RNA-seq, sequence 
reads are mapped to a human reference genome sequence using read mapping 
algorithms, such as BWA [227] or Bowtie/Tophat (Figure 1.6) [228]. Whereas BWA 
is a relatively fast short-read aligner designed to rapidly align sequence reads [227], 
aligners such as Tophat are gap-aware and incorporate splice-junctions [228]. BWA 
and TMM normalization (discussed below) were found to perform optimally with 
small RNA-seq read alignment when compared to Bowtie and other normalization 
methods [229]. Once sequence reads are aligned to the human reference genome 
sequence, the number of reads overlapping with genomic features (e.g. genes) are 
counted based on a known annotation and genomic coordinates, using, for example, 
the popular annotation tool HTSeq. [230]  
Parametric methods to estimate statistically significant gene expression 
 
The human transcriptome can be characterized and measured using RNA-seq 
to understand the transcriptional host response in a given clinical or experimental 
condition. A transcriptomic experiment aims to identify differentially expressed genes 
(defined as a genomic feature under study, e.g., an exon, isoform, or gene transcript) 
between sample groups. Differential expression is typically defined using both a 
relative gene expression difference between one or more conditions, (log-transformed 
fold change of normalized expression values) and a statistical test for significance of 
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the observed expression differences, where one or both values exceed a pre-
determined threshold value. Relative expression values are usually calculated using a 
gene’s mean estimated expression value in the experimental condition relative to a 
control, or using a Generalized Linear Model (GLM)’s coefficient term (detailed 
below). Statistical significance is typically calculated with a parametric test using 
each gene’s expected value and variance estimates. In comparison to microarray data, 
in which observed gene expression takes on a continuous probe intensity value, RNA-
seq data is expressed as discrete sequence read counts and is therefore modeled using 
a discrete random variable. Empirical data have demonstrated that counts from RNA-
seq experiments fit a negative binomial distribution, which is a Poisson distribution 
(encapsulating technical variance) with additional variance due to biological 
replication [231]-[237]. Popular differential expression analysis tools that employ the 
Negative binomial distribution include DESeq [238], DESeq2 [239] and edgeR [233], 
[240] and model an observed RNA-seq count !, from gene " and sample (library) # 
as: 
!$%~'((*$%, ,$%)                  ( 1 ) 
,$% = *$% + 0% ∙ *$%
2  
*$% = 3% ∙ 4$%      ( 2 ) 
Where * is the mean expression, , is the variance, 0 is dispersion, 4 is the 
number of sequence reads aligning to " and 3 is the scaling normalization factor.  
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Additionally, edgeR and DESeq2 use the log-link linear function of the scaled mean: 




The 4 term in equation (2) represents the per-library and method-specific 
normalization scaling factor to correct observed sequence read counts for inter-
sample differences in library size (sequencing depth), gene length and GC content, 
although most RNA-seq normalization methods only account for sequencing depth as 
the intra-gene length and GC content is assumed to remain constant between samples. 
Four relatively straightforward normalization methods include: 1) scaling reads by the 
number of reads per kilobase per million mapped reads for each sample (RPKM) 
[19]; or scaling all gene counts by the 2) total number of reads for each sample and 
multiplied by the mean total read count of all samples (total count, TC), or 3) non-
zero upper quartile (UQ) of counts, or 4) median (Med) non-zero counts [241]. For 
example, the normalization method implemented in DESeq applies a correction factor 
to each gene within a sample based on the median ratio of each gene’s read count 
relative to the geometric mean for all samples.  The Trimmed Mean of M-Values 
(TMM) method, as implemented in edgeR, first trims the extreme read counts from 
the calculation and then computes read count log ratios for each gene against a 
reference sample (M-values) [242]. The weighted mean of M-values is applied as a 
correction factor to each sample. Accurate normalization is paramount to downstream 
analysis such that read count values capture biological instead of technical signal. In 
evaluation tests, RPKM and TC were found to be ineffective as gene length and 
differential gene expression varies and it does not remove bias [241], [243] [241]. 
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Conversely, the UQ, Med, DESeq, and TMM methods performed similarly when 
assessed on results of differential expression analysis, with TMM and DESeq 
methods outperforming others with regard to maintaining a low false positive rate 
without loss of power [243].  
The variance of the negative binomial distribution in equation (1), ,%, is a 
function of the mean, *% and a scalar 0 known as the dispersion parameter which 
governs extra variation (biological variation). For 0 ≪ 0, the variance approaches *% 
and resembles the Poisson distribution [237]. A common task for differential 
expression algorithms is to estimate both the scaling parameter 4 and dispersion 
parameter 0 for subsequent statistical inference testing. However, there are two 
related challenges when estimating dispersion: low number of within-group replicates 
and heteroskedasticity of RNA-seq counts. The first challenge is that of skewed 
dimensionality, termed ‘the curse of dimensionality’, wherein a typical experiment 
has a high number of genes relative to the number of replicates within a sample 
group, making unbiased estimators of dispersion difficult [244]. To resolve the lack 
of power, differential expression tools pool information across genes as per-gene 
variances in a given experiment are assumed to be similar [245]. Therefore, a single 
dispersion or fitted dispersion is estimated across all genes based on the assumption 
they share identical or similar variance. A second challenge is that of 
heteroskedasticity when lower counts tend to have higher variance and if left 
unaccounted, will have greater fold change between conditions and greater dispersion 
relative to the mean count. DESeq, DESeq2 and edgeR correct for heteroskedasticity 
by estimating dispersion as a function of the mean read count for each gene (and 
 34 
therefore dispersion becomes 0 *  instead of a per-sample scalar) [238]. The trended 
dispersion is estimated using a weighted conditional likelihood [232], [233]. In 
DESeq2, shrinkage estimators are used for dispersion and fold change, and therefore 
reduce variance for lower expressed genes at the expense of bias [246].  
GLM methods can be applied to estimate the	8 coefficients in equation (3), 
which are interpreted as fold change (the relative contribution of condition 8 on the 
observed mean count *), and statistical tests are applied to estimate whether 8 is 
significantly different from null (no difference). GLMs as in equation (3) can be 
additionally extended to account for multiple class memberships or interactions. 
edgeR and DESeq [238] both use an inference test similar to Fisher’s exact test 
adapted for over dispersed data for pair-wise comparisons, while DEseq2 uses a Wald 
test [239]. edgeR, DESeq and DESeq2 use a likelihood ratio test to infer significance 
when applied to GLMs [238]-[240], [247]. 
An additional challenge differential expression tools face is to properly 
account for multiple testing correction as typically 104-105 simultaneous statistical 
inference tests are applied to the experiment [28]. This results in high false 
discoveries for a given p-value cutoff (i.e., comparing the observed value to the null 
distribution) and need to be adjusted. The simplest correction is the Bonferroni 
adjustment in which all p-values are divided by the total number of tests, and so the 
significance level 0 becomes 0 >, adjusting the family-wise error rate [248]. An 
alternative approach is to use false discovery rate (FDR) estimation in which the 
proportion of null values are compared to the proportion of observed values at a given 
threshold cutoff [30].  
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In tests evaluating edgeR and DESeq, both methods performed equally well 
with regard to normalization, differential expression detection accuracy and low 
number of false positives, but had poor signal-to-noise ratio versus p-value 
correlation for genes detected in only one condition [249]. In a separate evaluation, 
edgeR and DESeq2 performed equally well regarding power, null hypothesis p-value 
uniformity and FDR control in two metagenomics evaluation datasets [250]. 
Although differential expression tools are invaluable to transcriptomics 
research, most differential expression tools are limited. First, they do not account for 
subject-specific effects or mixed effects. Additionally, tools without a linear model do 
not account for more than two pair-wise class comparisons or interactions among 
terms. Finally, conventional differential expression methods are not designed for 
time-series studies, continual or ordinal response variables, or mixed input variable 
types.  
Machine learning approaches to identify relevant genes 
 
Machine learning algorithms, broadly divided into supervised and 
unsupervised methods, are an alternative approach to classify, predict and identify 
patterns in RNA-seq data. In the context of RNA-seq supervised learning, gene 
products and other metadata (collectively known as “features” or “predictors”) are 
used to predict or classify an outcome (collectively known as a “response variable”, 
e.g., cancer vs. normal or treatment vs. control). Examples of supervised learning 
algorithms include Random Forest and Naïve Bayes. Conversely, in unsupervised 
learning, the goal is to uncover any underlying structure(s) of the data. Examples of 
 36 
unsupervised learning algorithms include hierarchical clustering and k-means 
clustering.  
Supervised machine learning uses features with known response variables to 
train a model, at which point data with unknown response variables can be classified 
or regressed using the trained model and new data. Model performance is assessed 
using a test set withheld during model training and where the correct response 
variable is known. The model is trained using the training set, and then new data 
predictions are compared against the true value to assess model accuracy (in 
classification, the proportion of true calls relative to all training data) and conversely, 
the error (the rate of misclassification). In regression, the mean squared error is often 
used to assess overall error of predicted from actual response:  
1
'




Where I is the known value of sample > of ' total samples and = L  is the 
predicted value of sample >. Furthermore, some algorithms implement a model 
assessment subroutine within the training phase where the training data is iteratively 
split into training and testing: k-fold cross validation or leave-one-out validation. In 
k-fold cross validation, the data is randomly subset into k sets (e.g., 10), then k-1 sets 
are used as the training set and model assessment is performed on the held-out set. 
This is repeated for all k-folds, and the overall model performance is aggregated 
across all folds [251]. In leave-one-out validation, a single sample is held out as the 
test sample [251]. Finally, to optimize model performance, parameters that govern the 
machine learning algorithm can be tuned independently by computing model 
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accuracy as a function of a range of parameter values and selecting the value that 
gives the best performance.  
Random Forest is a supervised learning approach based on an ensemble of 
Classification and Regression Trees (CART). A CART is created by recursively 
partitioning the training set data according to the feature that maximizes the splitting 
criterion, where each split is known as a node [252]. The feature space is continually 
split until nodes are homogeneous. Thus, the root node contains the feature that 
maximally partitions the data, while all daughter nodes contain maximal splits 
conditioned on the criteria splitting the superseding node. Terminal nodes are 
assigned class labels based on the partitioning rules and new data can be therefore 
classified or regressed based on trained rules at each node [253], [254]. Random 
Forest implements the CART algorithm by generating an ensemble of K trees with 
two levels of bootstrapped randomization. The first level only considers a random 
subset of input features to construct each tree known as ‘bagging’, while the second 
level considers a random subset of samples to construct each tree in the forest [255]. 
The data that is not used to build a tree is termed ‘Out of Bag’ (OOB) and can be used 
as a test set to assess OOB error. Thus, the Random Forest procedure is: 
o Bootstrap data 
o Grow N trees using CART 
§ For each node in a tree 
• Select a random subset of variables 
• Find best variable and cut point 
o Determine OOB error using non-bootstrapped data 
o Classify/regress new data using majority vote of N trees 
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The curse of dimensionality is reduced by training numerous decision trees on 
subsets of data, [256] and the effect is a more accurate classifier with high predictive 
value [256] over CART. Random Forest better accounts for variable interactions 
[256] as the random split of data ensures low correlation between trees. Unlike some 
other machine learning algorithms, Random Forest can perform regression. When 
compared to Support Vector Machine, Random Forest approaches showed 10% 
increased accuracy, which was attributed to the model and combined features [257].  
Random Forest algorithms rank feature importance based on the feature’s 
contribution to node purity or OOB prediction error, making them ideal for selecting 
a feature subset. Importance metrics are defined by a feature’s total decrease in Gini 
impurity across all trees, or by the permutation-derived misclassification error 
(classification problems), mean squared error (regression) or sum of squared residuals 
(regression) [258], [259]. Permutations can additionally be used to generate a null 
distribution of randomized class labels to compare to the observed metric to calculate 
a p-value for the observed metric [260]. The number of candidate predictors, size of 
the trees, size of terminal nodes and resampling scheme (i.e. bootstrap samples drawn 
either with or without replacement) can be optimized to minimize OOB error [252]. 
Additionally, uninformative features can be iteratively removed to minimize error 
[261], [262].    
To illustrate their utility, the following examples demonstrate where Random 
Forests were used to identify associations between gene expression and biological 
outcomes. A Random Forest model was used to stratify cancer patient responders to 
FOLFOX cancer therapy based on cancer type and found to be 69.2% accurate as 
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assessed by an independent test set [263]. In another example, a Random Forest 
algorithm was used to identify 196 stress response genes in the bacterium Bacillus 
subtilis wild-type and mutant strains [264]. In a third study, miRNAs were identified 
and shown to be significantly associated with the fold change of mRNAs using local 
importance and permutation [265].  
Concluding Remarks 
 
Extracting RNA carries special considerations given the delicate nature of 
RNA. Additional challenges exist for small or miRNA sequencing or miRNA-qPCR. 
After sequenced reads are mapped to the genome using an alignment tool such as 
BWA or Tophat/Bowtie, experimental questions can be addressed using parametric or 
non-parametric methods which attempt to identify transcripts most associated with a 
given outcome. Parametric methods discussed here rely on the Negative binomial 
distribution to compute differential expression and include edgeR, DESeq and 
DESeq2. Conversely, machine learning approaches attempt to find patterns in data, 
and include Random Forest models which are especially advantageous in situations in 
which data does not fit the design of parametric tools. Ultimately, regardless of the 
approach, the goal is to identify interesting transcripts to address biological questions, 






The vaginal microbiota of reproductive-aged women is a highly dynamic 
environment in which the host senses microbes and microbial products. This process 
requires the coordination of gene transcription regulation which to date has not been 
fully realized. The role of miRNAs in controlling cellular responses to Lactobacillus 
spp.-dominated (CST I, II, III and V) and Lactobacillus-depleted (CST IV) vaginal 
microbiota remains unknown. 
Using daily collected samples coupled with in vitro cell culture experiments, 
this project aims to characterize miRNA and miRNA-associated mRNA regulatory 
expression pathways as a function of vaginal microbiota community differences to 
gain insight into the functional interaction between the host and the microbiota.  
Specific Aim 1  
Determine miRNA differential expression as a function of Lactobacillus spp. 
and non-Lactobacillus community state types using Nugent-BV as the outcome. This 
aim leverages daily collected human vaginal samples to determine the types and 
abundances of human miRNAs to characterize host regulatory mechanisms. A 
machine learning approach was applied to discover miRNAs and their targets that are 
controlled by various vaginal CSTs 
Specific Aim 2  
Identify regulatory target pathways by simultaneously measuring vaginal 
epithelial mRNA transcripts as a function of characteristic vaginal communities. This 
 41 
aim will discover the pathways and genes that play roles in host functions and will 
broaden the understanding of implications found in Chapter 2.   
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Chapter 2 microRNA expression induced by vaginal microbiota 
controls host epithelial cell proliferation and susceptibility to 
Chlamydia trachomatis   
Introduction 
The human vaginal microbiota is comprised of at least five major bacterial 
Community State Types (CSTs), of which four are often dominated by species of 
Lactobacillus (CST I: L. crispatus; CST II: L. gasseri; CST III: L. iners, CST V: L. 
jensenii) while the fifth (CST IV) is characterized by a paucity of Lactobacillus spp. 
and a diverse, more homogenous set of strict and facultative anaerobes such as 
Gardnerella vaginalis, Atopobium vaginae, Prevotella, Megasphaera and Mobiluncus 
among others [6]. Microbiologically, CST IV is similar to the community state found 
in cases of bacterial vaginosis (BV) [9], [266]-[268]. BV is typically diagnosed in one 
of two ways. The Amsel’s criteria, applied in a clinical setting, define Amsel-BV as 
presenting with three of the four following signs: vaginal pH greater than 4.5, fishy 
odor upon exposure of a vaginal smear to potassium hydroxide, presence of clue cells 
upon microscopic examination, and an abnormal discharge [13]. The Nugent scoring 
system, used in research settings, grades the relative presence of Lactobacillus versus 
Gardnerella and Mobiluncus morphotypes on Gram stained vaginal smears, thus 
defining Nugent-BV [11], [12]. Nugent scores range from 0 to 10, with a score 7 to 
10 considered BV, 4 to 6 intermediate, and 0 to 3 normal. Not surprisingly, high 
Nugent scores are often associated with CST IV, and thus encompass both 
symptomatic and asymptomatic BV states. As such, BV (Amsel- or Nugent-BV) is 
often described as a state of dysbiosis, which has been shown to be a risk factor for 
the acquisition of sexually transmitted infections (STIs), including HIV, Neisseria 
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gonorrhoeae, and Chlamydia trachomatis [28]-[30], [269]-[271]. By definition, BV 
does not elicit a consistent and pronounced immune response, and BV-specific 
cytokine and chemokine profiles are varied [47]. Microbes associated with BV may 
actively suppress or induce a low-grade host response [272], or subclinical immune 
response [273]. Alternatively, the host may be tolerant to BV microbes [274]. Thus, 
the host response to different types of vaginal microbiota is poorly understood at the 
molecular level. Characterizing the molecular mechanisms elicited by CST-IV and 
BV may help better understand and manage the condition, and concurrently develop 
strategies to reduce STI susceptibility and other associated co-morbidities.  
Human microRNAs (miRNAs) are ~20-mer oligonucleotides that have been 
shown to regulate a myriad of functions via translational inhibition [144]. Their role 
in controlling cellular responses to Lactobacillus-dominated (CST I, II, III and V) and 
Lactobacillus-depleted (CST IV) vaginal microbiota remains unknown even though 
they may constitute an underappreciated host response to changes in the vaginal 
microbiota. This aim leverages daily collected human vaginal samples to determine 
the types and abundances of human miRNAs and characterize host regulatory 
mechanisms that drive the response to vaginal microbiota communities associated 
with Lactobacillus spp.-dominated states and Nugent-BV. A machine learning 
approach was used to discover miRNAs and their targets that are controlled by 
various vaginal CSTs. From this effort, miR-193b was identified as a candidate 
effector miRNA and its role in suppressing vaginal epithelial cell proliferation in 
Lactobacillus-dominated communities was confirmed in vitro. Furthermore, because 
Nugent-BV is a risk factor for chlamydial infection, epithelial cell proliferation was 
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demonstrated to be required for efficient C. trachomatis infection. These findings are 
critical and contribute to the fundamental understanding of the role of the vaginal 
microbiota in susceptibility or control of STI. Further, this aim has broad clinical 
implications for the management of women’s health and could be leveraged to 
develop novel preventive therapies for STI in general.   
Methods 
Vaginal swab sample collection and metadata 
 
The samples used in this aim were collected as part of a previously assembled 
cohort of 135 reproductive-age non-pregnant women at the University of Alabama at 
Birmingham in which participants were instructed to sample their vagina daily for 10 
weeks [19]. The clinical study protocol was approved by the Institutional Review 
Board of the University of Alabama at Birmingham and the University of Maryland 
School of Medicine. Written informed consent was appropriately obtained from all 
participants. Swabs were stored at -80°C in 2 ml of Amies Transport Media/RNAlater 
(50%/50% v/v), a solution formulated to stabilize RNA (QIAGEN). In that study, 
subjects answered daily questionnaires on sexual activity, menstruation and 
symptomatology among others and provided vaginal swab smears on glass slides for 
subsequent Gram staining and Nugent scoring by a trained technician. Estimated time 
in menstrual cycle as a Random Forest predictor were normalized using previously 
described methods in which the time between self-reported menstrual periods is 
scaled to 28 days [7] and then categorized into either the menses phase (day 1-5), 
proliferative phase (day 6-13) or secretory phase (day 14-28). Subjects also 
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underwent a gynecological exam at enrollment, week 5 and week 10, during which a 
clinician used Amsel criteria for the diagnosis of BV. The composition of vaginal 
microbiota was assessed by metataxonomics using amplicon sequencing of the 16S 
rRNA gene V3-V4 hypervariable regions [7], [275]. Taxonomy was assigned to each 
read using a novel and fast Markov Chain taxonomic classifier (available at 
http://ravel-lab.org/pecan) and taxa frequencies normalized to total per-sample read 
counts. Community State Types (CSTs) were identified by calculating the Jensen-
Shannon divergence among samples, followed by hierarchical clustering with 
complete linkage [6]. Subjects included in NBV, PBV and TBV groups were selected 
per criteria described above.  
Total RNA extraction 
 
Total RNA extraction from vaginal swabs was performed in random order on 
selected samples across multiple days and subjects to minimize batch effects. The 
MasterPure™ Complete DNA and RNA Purification Kit (Epicentre, # MCR85102) 
was used to extract total RNA from 250 µl aliquot of swab storage buffer containing 
RNAlater or confluent adherent VK2 epithelial cells following the manufacturer’s 
recommendations for cell samples. Swab material or cells were centrifuged for 10 
minutes at 13,000 x g, supernatant removed, and lysed with 300 µl Lysis buffer 
containing 50 mg Proteinase K. The pellet was incubated for 15 minutes at 65°C with 
10-second vortexing every 5 minutes, before placing on ice for 5 minutes. Following 
this step, 175 µl Protein Precipitation buffer was added and the mixture vortexed for 
10 seconds, and centrifuged for 10 minutes at 13,000 x g. The supernatant containing 
total nucleic acid was added to 500 µl isopropanol and mixed by inverting the tube 40 
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times to precipitate nucleic acid. Nucleic acids were pelleted by centrifugation for 20 
minutes at 13,000 x g and washed twice with 70% ethanol, left to air-dry for 5-15 
minutes. The pellet was resuspended in 10 µl nuclease-free water. VK2 epithelial 
DNA was then removed by adding 1 µl TURBO DNA-free DNase and incubated for 
30 minutes at 37°C followed by an additional treatment with 1µl of DNAse for 
another 30 minutes (Life Technologies, # AM1907). DNAse was inactivated by 
adding 2 µl DNAse Inactivation Buffer and incubated for 5 minutes at room 
temperature. The mixture was centrifuged at 13,000 x g for 3 minutes and the 
supernatant containing total RNA transferred to a new tube.  The RNA quality and 
quantity was measured using 1 µl of RNA solution with a 2200 Agilent TapeStation 
and RNA screen tape (Agilent # 5067-5576). DNA was then removed by adding 1 µl 
TURBO DNA-free DNase and incubated for 30 minutes at 37°C followed by an 
additional treatment with 1µl of DNAse for another 30 minutes (Life Technologies, # 
AM1907). DNAse was inactivated by adding 2 µl DNAse Inactivation Buffer and 
incubated for 5 minutes at room temperature. The mixture was centrifuged at 13,000 
x g for 3 minutes and the supernatant containing total RNA transferred to a new tube.  
The RNA quality and quantity was measured using 1 µl of RNA solution with a 2200 
Agilent TapeStation and RNA screen tape (Agilent # 5067-5576). Total RNA was 
stored up to 1 week at -80°C until further use. All samples yielded at least 20 ng total 
RNA. Although RIN values were of sub-optimal quality for full-length transcript 
RNA-seq, miRNAs were generally intact and adequate for small RNA-seq as 
evidenced by a lack of correlation between miRNA reads and RINe (Figure 2.2).    
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Small RNA sequencing library construction 
 
All small RNA-seq library preparations were randomized across samples from 
multiple days and subjects to minimize batch effects and were carried out using the 
TruSeq Small RNA kit per manufacturer’s recommendations (Illumina, # RS-200-
0012), with CleanTag Ligation from TriLink Biotechnologies’ modifications (TriLink 
Biotechnologies, # L-3203) at 1:3 5’ and 3’ adaptor dilutions and 15 cycles for library 
enrichment. Briefly, both the 3’ CleanTag Adaptor and 5’ Adaptor were diluted 1:3 in 
nuclease-free water to accommodate 50-100 ng total RNA input. The RNA template 
was denatured for 2 minutes at 70°C, then 1 µl diluted 3’ adaptor, 1µl RNase 
Inhibitor, 1 µl Enzyme 1 and 5 µl Buffer 1 were added to the template, mixed, and 
incubated at 28°C for 1 hour followed by incubation at 65°C for 20 minutes. 
Following this step, 4 µl nuclease-free water, 1µl Buffer 2, 1 µl RNase Inhibitor, and 
2 µl Enzyme 2, was added to the RNA template and the 3’ adaptor mixture. The 
diluted 5’ adaptor was denatured for 2 minutes at 70°C, then 2 µl was added to the 
mixture and incubated at 28°C for 1 h followed by an incubation at 65°C for 20 
minutes. The tagged library underwent reverse transcription by adding 2 µl RT primer 
(TruSeq kit), 1.92 µl RNAse-free water, 5.76 µl RT buffer (SuperScript II/Life Tech), 
1.44 µl dNTPs, 2.88 µl 0.1 mM DTT, 1 µl RNAse Inhibitor, 1µl superScript II (Life 
Technologies), and then incubated at 50°C for 1 hour. The cDNA was enriched by 
PCR by adding 40 µl 2X Phusion High Fidelity Taq Polymerase Mastermix 
(ThermoFisher), and 2 µl each of the universal forward primer and a sample-specific 
index, then PCR amplified using the following conditions: 98°C for 30 seconds, [15 
cycles of 98°C for 10 seconds, 60°C for 30 seconds, 72°C for 15 seconds] and a final 
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extension at 72°C for 10 minutes. The enriched libraries were purified using 
Agencourt AMPure XP beads by adding 80 µl beads to the 80 µl reaction volume and 
incubating for 10 minutes to bind DNA. The beads were magnetized for 4 minutes, 
then the supernatant containing the library was transferred to a new tube where 144 µl 
beads were added and incubated for 10 minutes to bind DNA. The beads were 
magnetized again for 4 minutes, the supernatant discarded, and the beads washed 
twice with 500 µl 70% ethanol. After the wash, the beads were left to air-dry before 
resuspending in 17 µl nuclease-free water for 2 minutes. The solution was re-
magnetized and 15 µl was transferred as the small RNA-seq library. Libraries were 
validated on the LabChip GX (PerkinElmer) (approximately 145 bp size) before 
cluster generation and sequencing.  
Small RNA sequencing, quality control and read mapping 
 
Small RNA-seq libraries were sequenced on a HiSeq 4000 with either 75 bp 
single-end (SE) or 150 bp paired-end (PE) reads, at about 20-40 million reads per 
library (approximately 10% sample per lane). Reads from the R1 fastq file (150 PE) 
or R2 fastq file (75 SE) were trimmed using Trimmomatic-0.33 with the following 
parameters: LEADING:3, TRAILING:3, SLIDINGWINDOW:4:15 and MINLEN:16, 
then visualized for quality using fastqc (version 0.10.0). Reads were aligned with bwa 
(version 0.5.9-r16) using 2 as the maximum number of mismatches between reference 
and read to the following series of references, in which all unaligned reads were 
aligned to the next in series: first, all tRNA from the GtRNAdb 
(http://lowelab.ucsc.edu/GtRNAdb/) [276], then human rRNA (hum5SrDNA and 
humRibosomal each a part of Illumina’s iGenomes available at 
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ftp://illumina.com/Homo_sapiens/UCSC/hg19/Homo_sapiens_UCSC_hg19.tar.gz, 
downloaded August 17, 2015), G. vaginalis ATTC 14019 (NCBI reference 
NC_014644.1) [277], L. iners ATCC 55195 (NCBI reference NZ_GL622333.1), and 
finally human hg19 (also downloaded from Illumina’s iGenomes as above). Reads 
aligning to human miRNA regions were annotated using HTSeq (version 0.5.3p3, 
Python version 2.7) and annotations from primary transcript miRNAs from the 
miRBase v20 (GTF version 3, GRCh37.p5, NCBI Assembly GCA 000001405.6). 
Samples with low miRNA reads were removed from further analysis, which were 
defined as less than 125 reads/human miRNA [125 * 1869 (total number of annotated 
miRNA in GTF) = 233,625 total reads/sample]. An additional QC was performed 
using PCA plots to identify batch or subject-specific effects (prcomp, version 3.3.1, 
ggbiplot, version 0.55, gPCA version 1.0 [278]). Reads surviving trimming and QC 
were normalized using edgeR’s (3.6.8) calcNormFactors function [240], which uses a 
Trimmed-Mean of M values approach as described in [242].  
microRNA qPCR  
 
RNA samples were converted into polyadenylated cDNA for qPCR analysis 
by mixing 7 µl (50-100 ng) total RNA in water with QIAGEN miScript II RT 
(QIAGEN, # 218160) reagents: 2 µl Reverse Transcriptase Mix, 2 µl 10X Nucleic 
acids Mix, 4 µl 5X miScript HiSpec Buffer and 5 µl nuclease-free water. The reaction 
mixture was incubated at 37°C for 1 hour, then heated to 95°C for 5 minutes to stop 
the reaction per the manufacturer’s protocol [221], [279]. The resulting cDNA was 
diluted 1:10 in water before use in the subsequent qPCR assay. 
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qPCR reactions were performed using 1 µl diluted cDNA template, and the 
miScript SYBR Green PCR Kit by mixing 5 µl 1X SYBR Green Mastermix and 1 µl 
each of Universal and miRNA-specific primers in a 10 µl reaction volume (QIAGEN, 
# 218073 and # 218160, miR-specific primers: MS00031549 (miR-193b-3p, 
5’AACUGGCCCUCAAAGUCCCGCU) and MS00033740 (RNU6-2-11)). qPCR 
was carried out on a 7900HT thermocycler at the following cycle conditions: 95°C 
for 15 minutes, then 40 cycles of: 94°C for 15 seconds, 55°C for 30 seconds and 70°C 
for 30 seconds. Ct values were calculated using Applied Biosystems SDS software 
and used to compare targets within and between samples by normalizing the within-
sample mean miR-193b Ct to the within-sample mean Ct for RNU6-2-11 (ΔCt) [280], 
[281]. For small RNA-seq validation, a linear mixed-effect model (nlme package 
version 3.1-128) was used to compute the probability that the effect due to PBV 
relative to NBV ΔCt is not zero, while controlling for subject specific (random) 
effects. For all other qPCR experiments, the ΔΔCt method was used to compute the 
ΔCt between miR-193b and RNU-6 within a sample, and then the ΔCt between 
Lactobacillus spp. BCS and cell culture medium or G. vaginalis BCS (non-
Lactobacillus spp.) [281]. The ΔΔCt standard deviation was computed using σΔΔCt 
=(σ,ΔCt Lactobacillus spp.2 + σ,ΔCt non-Lactobacillus spp.2)1/2, where σ is the standard deviation.  A 
two-tailed t-test was applied to each ΔΔCt, with p<0.05 considered significant.  
Identification of BV-associated taxa and BV-associated miRNAs using Random 
Forest 
 
Random forest models were applied to select taxa or miRNAs that best predict 
non-BV from BV status defined either as Amsel-BV or Nugent-BV by utilizing a 
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combination of the R software packages rfPermute (version 2.0.1, [282]), 
randomForest (version 4.6-12, [259]) and custom subroutines (available in the R 
scripts ‘rfSubjectSpecific.R’ and ‘Smith_et_al_AnalysisScript.Rmd’ included in 
Appendix 2). All models were trained using 70% of available data (training set) while 
model performance was assessed using the remaining 30% of the held-out data 
(testing set). Because Amsel diagnosis data is not available for most of the samples in 
the study, another Random Forest model was trained on the larger sample cohort to 
classify a sample’s Amsel diagnosis based on metataxonomic data (expressed as taxa 
relative abundance, available in SRA under project PRJNA208535) and other 
metadata (normalized mensuration as described above, vaginal pH, vaginal 
intercourse, oral sex, anal sex, finger penetration, sex toy use, hormonal birth control 
use, BV symptoms (vaginal odor and discharge) and non-BV symptoms (vaginal 
itching, burning and irritation)). The trained model was then used to assign proxy-
Amsel-BV diagnoses to each of the samples in the study given taxa relative 
abundance and metadata (which was available for 83 samples). Each sample’s Nugent 
score (discrete 0-10, inclusive) or proxy-Amsel diagnosis (classification of “NBV” or 
“PBV”) were used as the response variable to determine the most important miRNAs 
or metadata that predicted BV state (models termed Nugent-RF or proxy-Amsel-RF, 
respectively). The Nugent score was used in a regressive capacity as it best captures 
the ordinal relationship reflective of differences in bacterial morphotypes on Gram 
stained slides. Because of the continuous nature of the Nugent score values in the 
model prediction, accuracy assessment was calculated using mean error: 
O
M
CAEP#?@EPJ − F?@BF5JMJNO , where N is the number of test set samples. Accuracy 
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for the Amsel Random Forest and proxy-Amsel scoring were assessed using the 
Amsel-BV diagnosis or proxy-Amsel-BV diagnosis from the test set, respectively.  
In both Nugent-RF and proxy-Amsel-RF models, the log2 transformed 
normalized miRNA counts in addition to metadata (normalized mensuration as 
described above, vaginal intercourse, oral sex, anal sex, finger penetration, sex toy 
usage, hormonal birth control usage, BV symptoms (vaginal odor and discharge) and 
non-BV symptoms (vaginal itching, burning and irritation)) were used as predictors. 
To increase the confidence of feature calls, miRNAs with zero counts in any sample 
were excluded, as zero miRNA counts could be due to under sampling. Each model 
underwent 10-fold cross-validation, with 500 permutations to determine the null 
distribution for p-value calculation. Default parameters for ntree (500) and mtry 
(sqrt(1558)= 39 for proxy-Amsel-RF, 1558/3=519 for Nugent-RF) were used. The 
algorithm accounted for non-independent samples that originated from the same 
subject by evenly splitting each cross-fold iteration among subjects using an in-house 
script (available in Appendix 2  as ‘rfSubjectSpecific.R’). Importance metrics and p-
values were calculated based on rfPermute and randomForest R packages [259], 
[282]. The importance metrics for the proxy-Amsel-RF model were mean decrease in 
accuracy and mean decrease in Gini coefficient while the importance metrics for the 
Nugent-RF model were increase in mean squared error and increase in node purity 
[256], [283]. Statistically significant features were defined as features with p-
value<0.05 for any importance metric within a model result.  
Experimentally validated miRNA targets were identified using the “strong 
evidences” list from miRTarBase, Release 6.0 (Sept 15, 2015) [284].  The Gene 
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Ontology DIRECT process terms from DAVID (release 6.8, May 2016, [285]) were 
mapped to experimentally validated miRNA targets. The proportion of targets for 
each GO DIRECT term were computed for each miRNA.  
Scratch assay using Bacterial Culture Supernatant (BCS)  
 
VK2 epithelial cells (ATCC CRL-2616, cell line authentication report in 
Appendix 3) were cultured at 37°C in 5% CO2 then seeded at 7.5x104 cells/well and 
grown to confluence in VK2 complete medium [Keratinocyte SFM, TheromoFisher # 
17005042, with bovine pituitary extract (0.05 mg/ml), epidermal growth factor (0.1 
ng/ml) and CaCl2 (0.4 mM)]. VK2 cells were starved using base medium 
(Keratinocyte SFM only) for 24 hours before making scratches in the monolayer with 
a 1 ml sterile pipette tip. BCSs were created by seeding 1x107 bacteria/mL of either L. 
crispatus (ATCC 33197), L. jensenii (ATTC 25258), L. iners (ATTC 55195) or G. 
vaginalis (ATCC 14018) in 10 mL culture media (NYC-III for L. crispatus, L. 
jensenii and L. iners, TSB for G. vaginalis), grown anaerobically for 48 hours, 
centrifuged at 3,000 x g for 10 minutes, sterile filtered (2.2µm filter) and stored at -
20°C. Lactic acid conditioned media were prepared using 0.1% or 0.06% of either D(-
)- lactic acid, (Sigma, #L0625), or L(+)-lactic acid (Sigma, #L1750) in VK2 cell 
culture medium as the 0.1% concentrations approximated the concentration found in 
20% BCS (as quantified by D/L lactic acid assay kid, R-Biopharm # 11112821035). 
pH buffered 7.66 1% DL-lactic acid was prepared using approximately 10% (v/v) 1N 
hydrochloric acid into 1% racemeric DL-lactic acid. BCSs were diluted to 20% (v/v) 
using complete VK2 cell culture medium and added to VK2 cells for a period of up to 
24 hours. Images were taken at 100X under phase contrast using a Zeiss Primovert 
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microscope at 0 and 13 hours post BCS exposure. ImageJ software (version 1.50i, 
[286]) was used to quantify the proportion of cells occupying the scratched area 
relative to time 0 h in three fields per well. After imaging for cell proliferation, 300 µl 
RNAlater was added to wells, cells were mechanically detached from plate, and RNA 
was extracted from cells using the total RNA extraction protocol described above. 
Replicate wells were separately stained for viability/cytotoxicity per manufacturer’s 
instructions (4 µM Calcein AM and 4 µM Ethidium homodimer III in PBS, Biotium, 
# 30002) and imaged using a Nikon TE2000-E2 fluorescence microscope at 100X 
using a FITC (viable) or a TRITC (cytotoxic) filter. To monitor cells for active DNA 
synthesis, EdU (5-ethynyl-2’-deoxyuridine) was added to cell culture medium at 10 
µM with cells grown on coverslips at the 0 h time point. Cells were fixed using 100% 
methanol at the end time point, washed with 3% BSA, permeabilized using 0.5% 
Triton® X-100 in PBS, washed with 3% BSA and stained for 15 minutes with Alexa 
488 mixture per manufacturer’s instructions (ThermoFisher, # C10337). Cell nuclei 
were stained for 15 minutes using Hoechst 33342 at a 1:1,000 dilution in PBS 
(ThermoFisher), then rinsed once in PBS before being imaged at 100X using a Zeiss 
Axio Imager Z1 fluorescence microscope and the GFP (EdU) or Dapi (Hoechst) 
filters. The amount of DNA synthesis was calculated using CellProfiler (version 2.2.0 
rev 9969f42, [287]) by counting the number of green nuclei (EdU stained) relative to 
blue nuclei (DAPI stained) in five fields per duplicate coverslip.  A two-tailed t-test 
was applied to test whether differences between means of each scratch assay and EdU 
experimental conditions were equal to 0, with p<0.05 considered significant (See 
Appendix 2 for script). 
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Cell Cyclin D1 (CCND1) Western blot 
 
VK2 epithelial cells were grown and exposed to respective BCSs as above for 
13 hours, then media removed and washed once with cold PBS. Total protein was 
extracted using 500 µl RIPA buffer (Cell Signaling, #9806S) for 5 minutes on ice. 
Cell debris was pelleted by centrifugation at 13,000 x g for 15 minutes and 
supernatant containing total cell lysate stored at -80°C until further use. Protein 
quantification was determined using the Bradford method assay (Bio-Rad # 500-
0205). Tris-glycine precast gels, 4-15% (Bio-Rad # 456-1086), were loaded with 20 
µg total protein per well and run for 35 minutes at 140 V before transferring to a 
PVDF membrane at 20V for 20 minutes. Membranes were blocked using Odyssey 
PBS blocking buffer (Li-Cor part # 927-40000) for 1 hour. Primary antibodies for 
purified mouse anti-human Cyclin D1, clone G124-326 (1:300, BD Pharmingen, # 
554180, lot # 5357909) and rabbit anti ß-actin (1:5,000, Abcam, # 8227, lot 
GR297401-1) were incubated with blocking buffer and 0.2% Tween-20 for 1 hour.  
Membranes were washed four times with PBS-0.1%Tween-20 and then incubated 
with 1:15,000 secondary antibodies (Li-Cor, IRDye 680RD goat anti-rabbit, lot # 
C60920-09 and IRDye 800CW goat anti-mouse, lot # C61012-06) before a final wash 
and imaging using Odyssey® CLx Imager and Image Studio software (version 5.2).  
Protein band intensities were measured using Image Studio software, then CCND1 
intensity values were normalized to ß-actin loading control value.  
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C. trachomatis infection and inhibition of cell proliferation 
 
C. trachomatis serovar L2 (L2) was propagated in HeLa monolayers as 
described previously [288]. Briefly, L2 was cultivated in 100 mm2 tissue culture 
dishes in Dulbecco’s modified Eagle’s medium (DMEM) (Mediatechm) 
supplemented with 10% FBS at 37°C, 5% CO2. Monolayers were gently rocked for 2 
hours, rinsed, fresh media added and the infection allowed to progress for 48 hours. 
Elementary Bodies were harvested, (stock 9.6 x 107 IFU/ml), and stored at -80°C. L2 
was used directly from -80°C stock for all experiments.  
A2EN human cervical epithelial cells (kindly provided by Dr. Quayle, cell 
line authentication report in Appendix 3) [289] were cultured at 37°C in 5% CO2 in 
EpiLife Media supplemented with EpiLife Defined Growth Supplement (EDGS) and 
L-glutamine (ThermoFisher , GIBCO M-EPI-500-CA, GIBCO S-012-5 and 
#25030156). A2EN cells were seeded at 1x105 on coverslips and grown overnight, 
then rinsed with PBS and exposed to starvation medium (EpiLife medium without 
EDGS supplement) for 18 hours. Coverslips were exposed to 300µl of either 
complete medium (control), CDK4 inhibitor CAS 546102-60-7 (400nM, Millipore 
#219476) or Fascaplysin (350nM, Millipore #341251) in complete medium. 
Concurrently, C. trachomatis serovar L2 was added at MOI 2 to each coverslip and 
rocked for 2 hours at room temperature. A2EN cells were rinsed with PBS and 
exposed to complete medium or inhibitors in the presence of EdU (1nM) as described 
above for an additional 22 hours at 37°C in 5% CO2, then washed with 500 µl PBS 
and fixed with 95% methanol for 10 minutes (Sigma #M3641). Cells were incubated 
in the dark for 1 hour in 1:10 MicroTrak (Trinity Biotech #8H019UL) to stain C. 
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trachomatis cells. EdU (Alexa Fluor 555, ThermoFisher #C10638) and cell viability 
staining and imaging were performed as outlined above. The proportion of infected 
A2EN cells and new DNA synthesis were determined using manual counting and 
CellProfiler as above, respectively. A two-tailed t-test was applied to test whether 
differences between means of each EdU or infection experimental conditions were 
equal to 0, with p<0.05 considered significant. A linear model was fitted to mean 
percent cells stained with EdU versus the mean proportion of infected A2EN cells 
using R lm package (version 3.2.3) (See Appendix 2 for script).  
Results 
Subject vaginal microbiota profile selection and small RNA-seq 
 
From vaginal microbiota profiles previously characterized by metataxonomics 
analysis (16S rRNA gene sequencing) of samples collected daily over 10 weeks by 
135 reproductive-aged women (parent cohort) [19], subsets of samples were selected 
(Figure 2.1) that were characterized by: 1) CSTs that were persistently dominated by 
Lactobacillus spp. with few or no reported vaginal  symptoms and no diagnosis of 
BV based on Amsel criteria for all three clinical visits during the study period 
(“Negative BV-state”, NBV), 2) persistent Nugent-BV-associated CSTs (“Persistent 
BV-associated state”, PBV) that were sometimes accompanied by vaginal symptoms, 
and the subject was Amsel-BV positive for at least one of the three clinical visits 
during the study period, and 3) at least one transition between Lactobacillus spp.  
dominance and Nugent-BV associated CSTs (“Transition NBV-PBV”, TBV). Neither 




associated with the differences in vaginal microbiota composition and structure of 
vaginal communities of participants as previously demonstrated [7], [19].  
Five subjects each were selected from the NBV and PBV groups and six 
subjects were chosen from the TBV group. From these, vaginal samples (1-16 per 
subject) were sequenced using small RNA-seq (Appendix 4). These sequences and 
their abundances were used in a comparative analysis of NBV and PBV states 
identified in the three groups (Figure 2.1). Of the 113 samples sequenced, 13 failed 
QC due to low miRNA read counts, leaving 100 samples from 16 subjects from the 
NBV, PBV and TBV groups that were used in the final post-QC analysis (Table 2.1, 
Appendix 5). The median RNA Integrity Number (RINe) score of all samples was 
6.6, with 60% of the samples having a RINe greater than 7 (Appendix 6). There was 
no relationship between the number or percentage of human genome (version 19, 
hg19) aligned miRNA reads and the RINe values (Figure 2.2), so that a RNA quality 
threshold was not imposed for inclusion in the study. PCA plots before and after 
sample removal and after normalization do not support batch effects (guided PCA p-
values 0.99, 0.26, and 0.12, respectively), or subject-specific effects (guided PCA p-
values 0.29, 0.48, and 0.29, respectively, Figure 2.2). The median (minimum-
maximum) percentage of miRNA reads relative to all hg19 mapped and total reads 
was 26.6% (3%-58.2%) and 4.2% (0.5%-21%), respectively. The median number of  
Figure 2.1  Longitudinal profiles of vaginal microbiota for each subject in the study. 
 From top to bottom for each subject, panels show the profile of relative bacterial abundance, Nugent score 
(0 to 10), pH (4 to 5.5) and metadata including reported menstruation (red dots), odor (blue dots, middle 
row) and discharge (blue dots, lower row). Greyed vertical blocks within the profiles represent days in 
which a vaginal swab was collected but not analyzed while non-greyed blocks are samples used in the 
study. An asterisk above a sample indicates that it was dropped after failing QC. Note that not all 
longitudinal windows are the same length as TBV subjects were generally sampled more frequently to 
capture changes in vaginal microbiota composition. Red bars in Nugent score and pH bar plots denote 
missing data.  
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Table 2.1 Sample groups and number of samples pre- and post-
sequencing QC, per subject	
BV	Group Subject	ID Number	Samples	before	QC 
Number	Samples	after	
QC 
NBV EM12 5 5 
NBV UAB007 5 5 
NBV UAB093 3 3 
NBV UAB102 3 1 
NBV UAB117 4 4 
PBV UAB008 5 3 
PBV UAB021 4 3 
PBV UAB022 5 4 
PBV UAB055 6 5 
PBV UAB116 5 4 
TBV UAB003 16 16 
TBV UAB005 6 5 
TBV UAB006 13 12 
TBV UAB015 14 14 
TBV UAB115 9 9 
TBV UAB121 10 7 
 
post-QC hg19 mapped miRNA reads was 1,204,913 with a minimum of 239,758 
reads and a maximum of 4,642,910 reads. Thus, despite a low proportion of miRNA 
reads, the estimated coverage ranged from 128X-2,484X across the entire miRNome 
database of 1,869 annotated miRNAs (Appendix 6).  
Prediction of Amsel-BV diagnosis (proxy Amsel-BV) using metataxonomic data and 
metadata  
 
An assessment of BV status using Amsel criteria was only done at three time 
points during the 10-week study (enrollment, 5-week and 10-week clinical visits,  
[19]), thus to identify miRNA associated with Amsel-BV, a model to predict Amsel 
diagnosis (proxy-Amsel-BV) using metataxonomic data and metadata was first 
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developed. This was accomplished by applying a Random Forest model trained with 
the metataxonomic data and metadata from 117 subjects of the parent cohort that 
included 281 samples for which both metataxonomic data and Amsel diagnosis was 
available (Amsel subset) (Appendix 7, Appendix 8 and Appendix 9). In the Amsel 
subset, asymptomatic or symptomatic BV diagnoses represented 25.3% (71/281) of 
the Amsel test performed (Appendix 7), a figure closely matching the reported 
prevalence of 29.2% for BV in similar populations [290]. The Amsel Random Forest 
model accuracy was tested using a hold-out set and found to be 94.9% accurate in 
correctly assigning NBV diagnosis and 72.0% accurate in correctly assigning PBV 
diagnosis. Multiple (34) important microbial (taxa and their relative abundance) or 
metadata features were predictive of the Amsel diagnosis: Aerococcus, Aerococcus 
vaginalis, A. vaginae, Bacteroides coagulans, Bifidobacterium bifidum, BVAB1, 
BVAB2, BVAB3, Candidate Division TM7 vaginal, Dialister sp. type 2, Eggerthella, 
Eubacterium rectale, G. vaginalis, Gemella, L. crispatus, Lactobacillus helveticus, 
Leptotrichia amnionii, Megasphaera sp. type 1, menstruation, Mobiluncus, 
Mobiluncus mulieris, Parvimonas micra, Peptoniphilus lacrimalis, vaginal pH, 
Porphyromonas endodontalis, Porphyromonas sp. type 1, Porphyromonas uenonis, 
Prevotella genogroups 1- 4, Prevotella melaninogenica and Streptococcus salivarius 
(Appendix 7). A proxy-Amsel-BV diagnosis was then assigned to each sample for 









Figure 2.2 Quality Control (QC) figures of small RNA-seq samples.  
(A and B) Relationship of total RNA quality (RINe, x-axis) versus miRNA mapped reads colored by 
sequencing batch as (A) a percentage of all hg19 mapped reads or (B) total number of miRNA reads. PCA 
plot of log2 transformed miRNA read counts (C and D) before and (E and F) after low count read removal 
and (G and H) after normalization, colored by sequencing batch (left column) or subject (right column).  
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BV or TBV sub groupings, based on available metataxonomic relative abundances 
and behavioral metadata (Appendix 9)  
Feature selection to identify miRNAs predictive of Nugent-BV and Proxy-Amsel-BV 
 
Two different Random Forest models were built to identify miRNAs 
predictive of Nugent score (Nugent-RF model) or proxy-Amsel-BV diagnosis (proxy-
Amsel-RF model). The Nugent-RF and proxy-Amsel-RF models used 178 predictors 
including 169 non-zero log2 transformed miRNA read counts and 9 metadata 
variables as inputs to rank feature importance (Appendix 9). The accuracy of the 
proxy-Amsel-RF model classification was 82.3% for NBV and 80.3% for PBV and 
the Nugent-RF model on average correctly predicted the Nugent score within 2 
values. There were 20 and 30 miRNAs with model importance permutation p-value < 
0.05 identified using proxy-Amsel-RF and Nugent-RF, respectively (Figure 2.3, 
Table 2.2, Appendix 10).  A total of 8 miRNAs were identified by both models: miR-
193b, miR-182, miR-203b, miR-378a miR-3607, miR-324, miR-500a, and miR-146a. 
The expression profiles of these 8 miRNAs as a function of CST, Nugent score and 
proxy-Amsel-BV prediction are shown in Figure 2.3.  
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 Gene Ontology (GO) processes of experimentally validated miRNA targets 
for each of the common miRNAs (ranked by the number of GO processes per group) 
include transcription, cell growth and cell cycle, signaling, development, hypoxia and 
immune response (Figure 2.4, Table 2.2).  
 
  
Figure 2.3  Random Forest variable importance ranking for proxy-Amsel-RF and Nugent-RF models and 
miRNA expression of the eight miRNAs identified by both models.  
Random Forest model variable ranking using either (A) proxy-Amsel-BV diagnosis or (B) Nugent score. 
Features ranked by variable importance metric for mean decrease in accuracy (proxy-Amsel-BV) or increase in 
node purity (Nugent). The most significant features are listed for each model. Importance metrics are colored by 
–log10 p-value. (C) log2 normalized miRNA expression values are shown versus Nugent score. Circles indicate 
predicted PBV by proxy-Amsel-BV diagnosis and triangles indicate predicted NBV by proxy-Amsel-BV 
diagnosis for each sample. Each point is additionally colored by community state type. The plots are ordered left 
to right by linear model adjusted R2 values between miRNA expression and Nugent score: 0.40 (miR-193b), 0.21 
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Table 2.2 Experimentally validated gene targets for each miRNAs found in proxy-Amsel-RF or Nugent-RF 
miRNA RF Model Targets 
let-7a-2 Amsel-RF NA 
let-7e Amsel-RF AGO1,AURKB,CCND1,COPS6,COPS8,EIF3J,EZH2,GPS1,HMGA2,IGF1,IGF1R,LIN28A,MMP9,MPL,MYCN,SMC1A,TNFRSF10B,WNT1 
miR-100 Amsel-RF AKT1,ATM,BMPR2,CTDSPL,CYR61,FGFR3,FKBP5,FLT1,HOXA1,HS3ST2,IGF1R,IGF2,MMP13,MTOR,NCOR2,PLK1,RAP1B,SMARCA5,THAP2,ZNF215 
miR-10b Amsel-RF BCL2L11,BUB1,CCNA2,CDKN1A,CDKN2A,DDX58,HOXD10,HTATIP2,KLF4,MAPRE1,NCOR2,NF1,NOTCH1,NR4A3,NRP2,PAX6,PDCD4,PIEZO1,PLK1,PPARA,PTEN,SDC1,SRSF1,TFAP2C,TIAM1,TP53,TPM1,TRA2B 
miR-16-1 Amsel-RF CCND1,CCNE1 
miR-183 Amsel-RF AANAT,AKAP12,BMI1,BTRC,DKK3,EGR1,EZR,FOXO1,GSK3B,IDH2,ITGB1,KIF2A,LRP6,NFIL3,PDCD4,PPP2CB,PPP2R4,SMAD4,SNAI2,ZEB1,ZFPM1 
miR-184 Amsel-RF AGO2,AKT2,BCL2,EZR,INPPL1,MYC,NFATC2,SOX7 
miR-320a Amsel-RF AQP1,AQP4,ARF1,BANP,BMI1,GNAI1,HSPB6,IGF1R,ITGB3,MAPK1,MCL1,NFATC3,NPR1,NRP1,Polr3d,POLR3D,PTEN,RAC1,TAC1,TFRC,TRPC5 
miR-342 Amsel-RF BMP7,DNMT1,GEMIN4,ID4,SREBF1,SREBF2 
miR-362 Amsel-RF CD82,CYLD,E2F1,PTPN1,USF2 
miR-4510 Amsel-RF NA 










miR-193b Both AKR1C2,CCND1,ESR1,ETS1,KRAS,MAX,MCL1,NF1,PLAU,PRAP1,SHMT2,SMAD3,YWHAZ 
miR-203b Both NA 
miR-324 Both CREBBP,DVL2,GLI1,SMO,WNT2B,WNT9B 
miR-3607 Both NA 
miR-378a Both CDK6,CYP19A1,GALNT7,GRB2,IGF1R,KSR1,MAPK1,MSC,MYC,NODAL,NPNT,SUFU,TOB2,TUSC2,VEGFA,VIM 
miR-500a Both CYLD,OTUD7B,TAX1BP1 
miR-101-2 Nugent-RF NA 
miR-130a Nugent-RF Acvr1,APP,ATG2B,ATXN1,CSF1,DICER1,ESR1,GJA1,HOXA10,HOXA5,IFITM1,IL18,KLF4,MAFB,MEOX2,PPARA,PPARG,RUNX3,SMAD4,TAC1,TGFB1,TNF,XIAP 
miR-140 Nugent-RF ADA,ALDH1A1,CD38,DNMT1,DNPEP,FGF9,HDAC4,HDAC7,IGF1R,LAMC1,MMD,NRIP1,OSTM1,PAX6,PDGFRA,RALA,SOX2,SOX9,TGFBR1,VEGFA 
miR-149 Nugent-RF AKT1,BBC3,E2F1,FGFR1,FOXM1,GIT1,GPC1,IL6,MYBL2,MYD88,PTGER2,SP1,ZBTB2 





miR-15b Nugent-RF AXIN2,BCL2,CCND1,CCNE1,CRIM1,EIF4A1,FOXO1,FUT2,HNF1A,IFNG,KDR,PPM1D,PURA,RECK,SMAD7,SMURF1,VEGFA 
miR-16-2 Nugent-RF RARB 
miR-191 Nugent-RF CCND2,CDK6,CEBPB,CTDSP2,EGR1,IL1A,LRRC8A,MDM4,NDST1,SATB1,SLC16A2,SOX4,TMC7,YBX3 
miR-197 Nugent-RF BMF,CD82,MTHFD1,NSUN5,PMAIP1,TUSC2 































miR-224 Nugent-RF AP2M1,API5,BCL2,CDC42,CXCR4,DIO1,DPYSL2,EDNRA,EYA4,FOSB,HOXD10,KLK10,KRAS,MBD2,NCOA6,NIT1,PAK2,PEBP1,PHLPP1,PTX3,SERPINF2,SMAD4,TCEAL1,TPD52,TRIB1 
miR-3653 Nugent-RF NA 
miR-365a Nugent-RF ACVR1,BAX,BCL2,CCND1,CDC25A,IL6,KRAS,MAX,PAX6,SHC1 
miR-375 Nugent-RF ADIPOR2,C1QBP,ELAVL4,ERBB2,FZD8,IGF1R,JAK2,KCNQ2,KIAA1524,LDHB,MAP3K8,MTDH,MTPN,PDK1,PHLPP1,PIK3CA,PLAG1,RASD1,RHOA,SP1,TIMM8A,TP53,USP1,YAP1,YWHAZ,YY1AP1 









   
   


















   















   












































Figure 2.4 Gene Ontology processes of common significant miRNAs based on their 
experimentally validated gene targets.  
Gene Ontology processes mapped to at least one miRNA gene target in at least four of the top 
miRNAs are grouped by involvement in transcription, cell cycle/growth, signaling, development, 
hypoxia or immunity. Table in upper left corner contains the number of gene targets per miRNA. 
miR-203b and miR-3607 did not have experimentally validated targets in miRTarBase. 
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Overexpression of miR-193b is associated with NBV 
 
  miR-193b was one of the best annotated, highest ranked, and most highly 
expressed (log2 normalized reads >5 in all samples) miRNA in both Random Forest 
models. Its expression was negatively correlated with Nugent score and proxy- 
Amsel-BV diagnosis, and was therefore chosen for further study to determine its 
functional consequences (Figure 2.3, Table 2.3). The expression of miR-193b was 
validated using qPCR in a subset of samples representing NBV or PBV subjects, and 
normalized to a non-variable miRNA reference (hsa-RNU6). Using a mixed effect 
linear model, the ΔCt of miR-193b was increased by 1.4 (p= 0.03) in NBV samples 
relative to PBV, confirming the results found by small RNA-seq.  
Table 2.3 Gene Ontology processes for miR-193b based on the most number of experimentally validated 
targets. 
Gene Ontology Process Validated Targets 
GO:0007165~signal transduction ESR1, NF1, PLAU, YWHAZ 
GO:0001666~response to hypoxia ETS1, NF1, PLAU, SMAD3 
GO:0008284~positive regulation of cell proliferation AKR1C2, ETS1, KRAS, SHMT2 
GO:0006366~transcription from RNA polymerase II promoter ESR1, ETS1, MAX 
GO:0000122~negative regulation of transcription from RNA 
polymerase II promoter CCND1, ESR1, SMAD3 
GO:0006351~transcription, DNA-templated CCND1, ESR1, SMAD3 
GO:0042981~regulation of apoptotic process ESR1, ETS1, MCL1 
GO:0006355~regulation of transcription, DNA-templated ESR1, MAX, SMAD3 
GO:0045893~positive regulation of transcription, DNA-
templated ESR1, ETS1, SMAD3 
GO:0045944~positive regulation of transcription from RNA 
polymerase II promoter ESR1, ETS1, SMAD3 
GO:0001889~liver development KRAS, NF1, SMAD3 
GO:0032355~response to estradiol CCND1, ESR1, ETS1 


















































































































































































































































































































































































































Table 2.4 Tabular data for the qPCR time-course assay 
Supernatant Reference Exposure Time Delta delta Ct pP-value Significant 
L. crispatus G. vaginalis 0.5hr 0.178732 0.245022418 NA 
L. crispatus Cell Culture Medium 0.5hr 1.1185685 0.001421724 * 
L. jensenii G. vaginalis 0.5hr 1.128874333 0.002282757 * 
L. jensenii Cell Culture Medium 0.5hr 2.068710833 0.000209732 * 
L. iners G. vaginalis 0.5hr 0.012059333 0.904120521 NA 
L. iners Cell Culture Medium 0.5hr 0.951895833 0.001567842 * 
L. crispatus G. vaginalis 1hr -0.781816 0.001082257 * 
L. crispatus Cell Culture Medium 1hr -1.052936667 0.000335036 * 
L. jensenii G. vaginalis 1hr 0.386265 0.039104475 * 
L. jensenii Cell Culture Medium 1hr 0.115144333 0.397945898 NA 
L. iners G. vaginalis 1hr -0.776163667 0.001601869 * 
L. iners Cell Culture Medium 1hr -1.047284333 0.000511677 * 
L. crispatus G. vaginalis 4hr -0.9462865 0.031002988 * 
L. crispatus Cell Culture Medium 4hr -1.7403015 0.004530639 * 
L. jensenii G. vaginalis 4hr -2.225599667 0.003519165 * 
L. jensenii Cell Culture Medium 4hr -2.358896667 0.006296318 * 
L. iners G. vaginalis 4hr -0.637242167 0.053215026 NA 
L. iners Cell Culture Medium 4hr -1.431257167 0.002113527 * 
L. crispatus G. vaginalis 11hr -1.200144 0.000427946 * 
L. crispatus Cell Culture Medium 11hr -1.7636755 0.00050202 * 
L. jensenii G. vaginalis 11hr -1.820595167 0.000698491 * 
L. jensenii Cell Culture Medium 11hr -2.384126667 0.000171244 * 
L. iners G. vaginalis 11hr -0.2266815 0.091781785 NA 
L. iners Cell Culture Medium 11hr -0.790213 0.012239309 * 
L. crispatus G. vaginalis 13hr -0.715701667 0.084691969 NA 
L. crispatus Cell Culture Medium 13hr -1.283486333 0.002812047 * 
L. jensenii G. vaginalis 13hr -3.138402 0.000211718 * 
L. jensenii Cell Culture Medium 13hr -3.297535667 5.81E-06 * 
L. iners G. vaginalis 13hr 0.082877333 0.777175984 NA 
L. iners Cell Culture Medium 13hr -0.484907333 0.056296014 NA 
L. crispatus G. vaginalis 22hr -0.495473333 0.01026127 * 
L. crispatus Cell Culture Medium 22hr -0.874167 0.000678162 * 
L. jensenii G. vaginalis 22hr -1.874163 0.003754038 * 
L. jensenii Cell Culture Medium 22hr -1.100347667 0.019514594 * 
L. iners G. vaginalis 22hr 0.020131333 0.84189057 NA 
L. iners Cell Culture Medium 22hr -0.358562333 0.007923684 * 
0.06% D-lactic acid G. vaginalis 4hr -0.079507333 0.65509605 NA 
0.06% D-lactic acid Cell Culture Medium 4hr -0.223330667 0.178680764 NA 
0.06% L-lactic acid G. vaginalis 4hr -0.122743 0.528962086 NA 
0.06% L-lactic acid Cell Culture Medium 4hr -0.266566333 0.169632494 NA 
0.06% L-lactic acid 0_06_D 4hr -0.043235667 0.816123785 NA 
L. crispatus G. vaginalis 0.5hr 0.178732 0.245022418 NA 
1% lactic acid, pH 7.66 G. vaginalis 4hr -0.032712667 0.905280424 NA 
1% lactic acid, pH 7.66 Cell Culture Medium 4hr -0.022210333 0.936530483 NA 
0.1% D-lactic acid G. vaginalis 4hr -1.530791 0.001908557 * 
0.1% D-lactic acid Cell Culture Medium 4hr -1.520288667 0.002569712 * 
0.1% D-lactic acid 0.1% L-lactic acid 4hr -0.184439667 0.12271634 NA 
0.1% L-lactic acid G. vaginalis 4hr -1.346351333 0.00627162 * 
0.1% L-lactic acid Cell Culture Medium 4hr -1.335849 0.007659905 * 
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The relationship between miR-193b expression and the vaginal bacteria that typify 
various CSTs was further investigated in vitro.  A monolayer of vaginal VK2 
epithelial cells was grown in cell culture medium conditioned with 20% L. crispatus, 
L. jensenii, L. iners or G. vaginalis bacterial culture supernatant (BCS) for 0.5, 1, 4, 
11, 13 or 22 hours, after which the relative expression (∆∆Ct) of miR-193b was  
quantified using qPCR (Figure 2.5,Table 2.4). The ∆∆Ct was computed by comparing  
one of the three Lactobacillus BCS to either VK2 cell culture medium alone or G.  
vaginalis BCS as a reference for each time point, i.e., ∆Ct L. crispatus - ∆Ct cell 
culture medium, ∆Ct L. crispatus - ∆Ct G. vaginalis, ∆Ct L. jensenii - ∆Ct cell culture 
medium, ∆Ct L. jensenii - ∆Ct G. vaginalis, ∆Ct L. iners - ∆Ct cell culture medium 
and ∆Ct L. iners - ∆Ct G. vaginalis. The -∆∆Ct of miR-193b in L. jensenii BCS 
versus cell culture medium exposed cells were highest overall, with the maximal 
difference of -3.3 at 13 hours post BCS exposure. Notably, all miR-193b -∆∆Ct 
values except L. iners BCS relative to G. vaginalis BCS remain greater than 0 for the 
entire 22-hour time course not including the first hour. Interestingly, cells exposed to 
pH 7.66 buffered 1% DL lactic acid had inhibited cell proliferation similar to the 
Lactobacillus spp. conditions (7.2 +/- 1.8% filled scratch area, p= 2.0x10-2 when 
compared to G. vaginalis BCS and p= 2.5x10-2 when compared to cell culture 
medium), but miR-193b expression was not significant in these cells relative to non-
Lactobacillus treatments (Figure 2.6, Table 2.4). Additionally, the -∆∆Ct of miR-
193b expression after 4 hours of exposure to 0.1% L-lactic acid relative to 0.1% D-
lactic acid or 0.06% L-lactic acid relative t0 0.06% D-lactic acid was not-significant 
(Figure 2.6, Table 2.4), but the expression of each isomer on miR-193b relative to 
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either G. vaginalis BCS or cell culture medium reflected that of Lactobacillus spp. at 
0.1% concentration (Figure 2.6, Table 2.4).  The in vitro profiles reflect the in vivo 
results, where Lactobacillus spp. dominated vaginal microbiota are associated with 
higher miR-193b expression than those depleted of Lactobacillus spp. and typified by 
G. vaginalis BCS in this experiment. 
 
 
Figure 2.6 Relative expression of miR-193b following 4h exposure of D- or L-lactic acid.  
Repeated are the 4h -∆∆Ct expression value conditions Figure 2.5 in addition to D-lactic acid and L-lactic acid 
exposed VK2 cells. Statistically significant samples are noted with an “*” within the plot point (p < 0.05). Data 







Epithelial cell proliferation decreased when exposed to Lactobacillus spp. Bacterial 
Culture Supernatants 
 
The function of miR-193b is broadly annotated as a tumor suppressor as miR-
193b inhibits several genes associated with cell proliferation and metastasis in a 
variety of cell lines and mechanisms. A literature search identified the following 
transcripts as specific targets: tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta (YWHAZ), serine hydroxyl transferase 
(SHMT2), aldo-keto reductase family 1 member C2 (AKR1C2) [291], cell cyclin D1 
(CCND1) [292], estrogen receptor-α (ESR1) [293], ETS proto-oncogene 1 
transcription factor (ETS1) [294], KRAS proto-oncogene, GTPase (KRAS), MYC 
associated factor X (MAX) [295], neurofibromin 1 (NF1) [296], and urokinase-type 
plasminogen activator (PLAU/ PRAP1) [297]. Interestingly, miRNA-193b expression 
is also associated with increased cell proliferation in different cells or via different 
pathways (i.e. TGF-β signaling, targeting SMAD3 or PLAU in gastric cancer or 
human glioma, respectively) [298], [299]. The in vivo discovery of the relationship 
between the expression of miR-193b and different types of vaginal microbiota 
coupled with the in vitro reconstruction experiments validating these findings and the 
well-characterized functions of miR-193b, strongly suggested that miR-193b inhibits 
vaginal epithelial cell proliferation when exposed to metabolites produced by 
Lactobacillus spp.  To test this directly, cell proliferation was quantified using a 
scratch assay and exposing VK2 cell monolayers to L. crispatus, L. jensenii, L. iners, 
or G. vaginalis BCSs for 13 hours, i.e. the time point at which the maximum effect of 
BCS on proliferation was empirically observed. All three Lactobacillus spp. BCS-
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exposed VK2 cells displayed significant decreases in cell proliferation quantified by 
both proportion of cells present in the scratch area (Figure 2.7, Table 2.5) and cells 
synthesizing DNA (positive for 5-ethynyl-2'-deoxyuridine, EdU) (Figure 2.8, Table 
2.5) relative to both G. vaginalis BCS and cell culture medium, coinciding with 
higher levels of miR-193b (Figure 2.5). There was also a significant decrease in filled 
scratch area and DNA synthesis in G. vaginalis BCS relative to VK2 culture medium 
(Figure 2.7, Figure 2.8, Table 2.5). Differences between Lactobacillus spp. BCS and 
G. vaginalis BCS were not explained by differences in cell proliferation between 
Lactobacillus NYC III culture medium alone and G. vaginalis culture medium alone 
(Figure 2.9). Taken together, the evidence suggests that a Lactobacillus spp.-
dominated vaginal microbiota is associated with elevated miR-193b expression in 
vaginal epithelial cells relative to vaginal communities lacking Lactobacillus spp., 










































































































































































































































































































































































































Cell Cyclin D1 protein expression at 13 hours is reduced in vaginal epithelial cells 
exposed to L. crispatus and L. jensenii BCS but not L. iners BCS.  
 
Cell Cyclin D1 (CCND1) protein expression in VK2 epithelial cells after 13-
hour exposure to each BCS was assessed using Western blot immunofluorescence 
labeling (Figure 2.10). Relative to cell culture medium-exposed VK2 epithelial cells, 
the normalized expression of CCND1 protein was 85% and 75% less in L. crispatus 
and L. jensenii BCS-exposed VK2 cells, respectively, and 34% and 8% more in L. 
iners and G. vaginalis BCS-exposed VK2 cells, respectively. Thus, CCND1 
production was decreased after exposure for 13h to L. crispatus and L. jensenii BCS, 
supporting that increased miR-193b expression is associated with reduced expression 
of at least CCND1. 
Table 2.5 Tabular data for cell proliferation assay 
Lactobacillus spp. BCS Reference p-value Difference of means Significant 
L. crispatus L. jensenii 0.213260924 -2.3829448 N.S. 
L. crispatus L. iners 0.241477195 2.616009733 N.S. 
L. crispatus G. vaginalis 0.015938865 23.86782947 * 
L. crispatus Cell Culture Medium 0.024237079 68.3016191 * 
L. jensenii L. iners 0.064219442 4.998954533 N.S. 
Figure 2.8  VK2 cell proliferation scratch assay, quantified by EdU (following page) 
(A) Representative fluorescence microscopy EdU Staining of Images taken at 100X for VK2s after 13-hour 
exposure to L. crispatus (top row), L. jensenii (second row) L. iners (third row), and G. vaginalis (fourth row) 
BCS and cell culture medium (fifth row). Left column shows EdU (green) staining for new DNA synthesis, 
middle column shows HOERST staining (blue) for nucleus and right column is the merged image. (B) 
Quantification of proportion of VK2 cells after 13 hours BCS or medium exposure positive for EdU 
nucleobases. Statistically significant comparisons (p < 0.05) are denoted with an “*” above the comparison line. 












































Figure 2.9 VK2 Cell proliferation scratch assay following 13-hour exposure to NYC-III (Lactobacillus 
spp.) or TSB (G. vaginalis) culture medium.  
VK2 epithelial cells were scratched and exposed to respective bacterial culture medium for 13 hours. (A) 
Scratch assay microscopy at 100X of VK2 cells exposed to 20% NYC-III or TSB bacterial culture medium at 
0 and 13 hours post exposure; (B) Proportion of VK2 cells after 13-hour medium exposure filling the scratch 
area. Proportion of filled scratch area is not statistically significant (p=0.45). Data are represented as mean 








NYC-III (Lactobacillus spp.) TSB (G. vaginalis)













































Figure 2.10 Western Blot of CCND1 after 13h exposure to BCS.  
Protein expression of CCND1 (36 KD) after 13h BCS exposure in VK2 cells (β-actin used as loading control, 
42 KD). Numbers under blot are normalized ratio of each BCS CCND1 intensity relative to VK2 cell culture 
medium. Quantification of cell images as percentage of cells. Band at ~70 KD is an uncharacterized protein as 




C. trachomatis infectivity is reduced in non-proliferating cervical epithelial cells  
 
A2EN cervical epithelial cell proliferation was inhibited using one of two 
validated CDK4/cyclin D1 (proliferation) inhibitors, CAS 546102-60-7 [300] and 
Fascaplysin [301], and then challenged with C. trachomatis. Relative to culture 
medium-exposed cells, cervical epithelial cell proliferation evaluated by EdU 
incorporation, a marker of DNA synthesis, was decreased by 35.2% (p=6.1x10-5) and 
28.5% (p=3.5x10-4) when cells were exposed to CAS 546102-60-7 and Fascaplysin, 
respectively (Figure 2.11, Table 2.6) After exposure of the epithelial cells to CAS 
546102-60-7 and Fascaplysin, C. trachomatis infection was decreased by 53.4% 
(p=3.3 x10-4) and 44.6% (p=1.0 x10-3), respectively (Figure 2.11, Table 2.6). These 
results indicate that epithelial cell proliferation is required for efficient C. trachomatis 
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This Aim characterized miRNA expression profiles of human vaginal samples 
associated with different vaginal microbiota community state types leveraging a large 
collection of specimens collected daily for 10 weeks and for which metataxonomic 
data and extensive metadata were available [19]. Among cellular functions known to 
be controlled by these miRNAs, epithelial cell proliferation was identified as a key 
mechanism impacted by changes in the vaginal microbiota with potential 
consequences on susceptibility and resistance to STI. In vitro experiments confirmed 
the in vivo findings by demonstrating the critical role of Lactobacillus spp. in 
maintaining the epithelial cells’ protective homeostatic state. Lastly, the results show 
that chemically-induced arrest of epithelial cell proliferation is associated with 
reduced risk of C. trachomatis infection. 
A total of 8 miRNAs had expression patterns that differed depending on the 
community state type of the vaginal microbiota. The ontology of genes targeted by 
these miRNAs included gene transcription, cell proliferation, migration, 
differentiation, apoptosis, development, immune response and response to hypoxia 
(Figure 2.4). miR-193b, whose expression was elevated concomitant with 
Table 2.6 Tabular data for C. trachomatis infectivity assay 
Assay Inhibitor Reference p-value Mean difference Significant 
EdU CAS 546102-60-7 Fascaplysin 0.149 -6.62 N.S. 
EdU CAS 546102-60-7 Cell Culture Medium 6.11E-05 -35.15 * 
EdU Fascaplysin Cell Culture Medium 0.000353903 -28.53 * 
C. trachomatis 
infectivity CAS 546102-60-7 Fascaplysin 0.015253388 -8.80 * 
C. trachomatis 
infectivity CAS 546102-60-7 
Cell Culture 




Medium 0.001000266 -44.59 * 
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Lactobacillus spp.-dominated vaginal microbiota and low Nugent scores (Figure 2.3) 
was selected for further analysis. miR-193b is known to control cell proliferation and 
has been implicated as a tumor suppressor by inhibiting cell proliferation and 
metastasis in a variety of cell lines (Table 2.3). This miRNA targets CCND1 [Table 
2.3 [292]] and inhibits the G1 to S phase transition of the cell cycle. Production of 
CCND1 is indeed reduced in vitro when cells are exposed for 13h to culture 
supernatants of L. crispatus and L. jensenii, coincidental with a clear lack of cell 
proliferation in the scratch assay. Interestingly, a 13h exposure of VK2 epithelial cells 
to L. iners BCS resulted in increased in CCND1 expression, corresponding with an 
observed decrease in miR-193b expression from 11 to 13h (Figure 2.10, Figure 2.5), 
while maintaining a lack of proliferation (Figure 2.7, Figure 2.8). One would have 
expected increased proliferation, however two hours may have been insufficient for 
proliferation to be observed in the scratch assay resulting in the discordant 
relationship between increased CCND1 protein expression and the absence of 
proliferation. Additionally, L. iners may be unable to induce a sustained effect on 
proliferation, unlike L. crispatus and L. jensenii.  
Bacterial culture supernatants were used in both the miR-193b qPCR assay 
and scratch assay experiments, and therefore strongly suggests that the observed 
effects are at least partially mediated by metabolites produced by Lactobacillus spp. 
Interestingly, two recent studies reported that gastrointestinal lactic acid bacteria and 
BV-associated bacteria both affect epithelial cell proliferation. Wound healing of 
HeLa cells was more significantly reduced upon 24-hour exposure to supernatants of 
G. vaginalis than by those of L. iners or the bacterial culture medium NYC-III [302]. 
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In another study, lactate and acetate produced by Lactobacillus casei and 
Bifidobacterium breve inhibited gut epithelial cell proliferation that correlated with 
downregulation of cyclin D1 and cyclin E1 [211]. These studies provided mechanistic 
support for the interplay between microbiota and epithelial cell homeostasis and 
identify short chain fatty acids, such as lactate or acetate, as potential mediators. The 
results reported here are consistent with how L. casei and B. breve affect 
gastrointestinal cell proliferation, but interestingly inconsistent with G. vaginalis anti-
proliferative effect on HeLa cells. It is likely that the cancerous cervical origin of the 
HeLa cell line makes it a poor model to study proliferation, since it probably carries 
mutations in cell cycle check point systems as suggested by [211]. The VK2 epithelial 
cell line used in our study (validated by genotyping; see analysis certificate in 
Appendix 3) is constructed similarly to the non-cancerous transformed murine 
intestinal crypt cell line m-ICcl2 (eventually used by Matsuki et al. (2013)) and is 
therefore not expected to have large disruptions of cell cycle check points [303], 
[304]. Our findings are further supported by evidence that epithelial cell shedding is 
positively correlated with G. vaginalis and sialidase (produced by G. vaginalis) in a 
murine model and with high Nugent score [305]. This suggests that increased 
proliferation is a host defense mechanism against G. vaginalis, a BV-associated 
bacterial species known for its adherence and biofilm formation properties [306], 
[307]. In BV-associated states, increased epithelial cell shedding may aid in the host’s 
ability to clear adherent bacterial cells from the epithelial surface giving 
Lactobacillus spp. the opportunity to colonize and/or adhere to the new epithelial 
surface, thus effectively displacing G. vaginalis from the vaginal epithelium (Figure 
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2.12) [308]-[310]. Other BV-associated bacterial species including Peptoniphilus 
spp., Fusobacterium nucleatum and A. vaginae have also been shown to adhere to 
ME-180 vaginal epithelial cells in vitro [307] and are predicted to induce a similar 
epithelial cell response. Consistent with these observations, these results 
demonstrated the differential impact of a vaginal microbiota dominated by 
Lactobacillus spp. or BV-associated species on vaginal epithelial cell proliferation.  
 The results additionally suggest Lactobacillus species-specific effects on 
epithelial cell responses as L. jensenii and L. crispatus exhibited the strongest positive 
effects on miR-193b expression, while L. iners was less pronounced, when compared 












Figure 2.12 Vaginal epithelial cell homeostasis.  
Characterization of vaginal epithelial cells revealed increased miR-193b expression and decreased cell 
proliferation when associated with Lactobacillus spp.-dominated relative to non-Lactobacillus spp. vaginal 
microbiota. Increased cell proliferation by estrogen and vaginal cell homeostasis may be influenced by (A) 
Lactobacillus-induced (red/orange shapes) miRNA-193b expression and targeting (B) leading to decreased cell 
proliferation and may result in a more stable microenvironment for Lactobacillus spp. to colonize by adhering to 
mucin or cell surface. Decreased cell proliferation protect from C. trachomatis (purple circles) infection (C), as 
demonstrated in the present study. Conversely, increased cell proliferation in the context of non-Lactobacillus 
spp.-dominated microbiota (oblong blue and circular purple shapes) result in cell shedding along with BV-
associated microbes (D). 
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whether the differential production of L- and D-lactic acid in the three species could 
explain the observed differences. Whereas L. crispatus produces both the L and D 
isomers of lactic acid, L. iners and L. jensenii produce only the L and D forms, 
respectively [311]. The impact of lactic acid isomers on miR-193b expression was 
investigated by quantitative PCR (Figure 2.6). However, although both isomers 
caused increased miR-193b expression relative to G. vaginalis BCS or cell culture 
medium, VK2 epithelial cells were found to express miR-193b in equal abundance 
after 4 hours of exposure to D- or L-lactic acid. Thus, the small differences observed 
in miR-193b expression are not explained by differential production of lactic acid 
isomers and might be due to yet uncharacterized factors. Furthermore, while pH 7.66 
buffered 1% DL lactic acid inhibited cell proliferation, miR-193b expression was not 
increased (Figure 2.6), suggesting that lactate and BCS may act through distinct 
mechanisms converging on similar pathways.  
Estrogen has been shown to increase epithelial cell proliferation in the mouse 
and human vagina via growth factor signaling and the production of epidermal 
growth factor (EGF) receptor R1 (EGFR1) as well as estrogen receptor ⍺ (ERa), 
interestingly both of which are targets of miR-193b (Table 2.2) [312], [313]. The 
observed anti-proliferative effect of Lactobacillus spp. mediated by miR-193b may 
counterbalance the action of estrogen on cell proliferation, and ultimately contribute 
to the maintenance of vaginal epithelial cell homeostasis (Figure 2.12). Lactobacillus 
spp.-dominated microbiota controlled vaginal epithelial cell proliferation repression is 
speculated to be advantageous as it facilitates the rapid proliferative transition of the 
epithelium in response to BV-associated vaginal microbiota states in vivo.   
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Previous studies have shown that epithelial cell proliferation is activated upon 
infection by the sexually transmitted pathogen C. trachomatis, which requires EGFR 
for internalization and regulates cell proliferation by affecting cell transcription, DNA 
repair mechanisms, cyclin E, and PI3K, MEK and ERK growth signaling pathways 
[314]-[317]. The present study suggests that by controlling cell proliferation, the 
vaginal microbiota can counter the proliferation induced by the infecting pathogen 
and thus reduce susceptibility to infection. This is supported by the fact that BV-
associated states are strong predictors of chlamydial infection among women who 
reported exposure to an infected partner. Conversely, women with a Lactobacillus-
dominated vaginal microbiota are less likely to be infected [271]. The rate of 
transmission after contact with a partner infected by C. trachomatis is estimated to be 
25-40% [318]-[320]. Given this, it was determined if decreased cell proliferation 
using chemical inhibitors of CDK4/cyclin D1 (key cell proliferation components) 
reduced C. trachomatis infectivity independent of the presence of Lactobacillus spp. 
Our results show that cervical epithelial cell proliferation is necessary for C. 
trachomatis to establish an infection. These results mechanistically point to cell 
proliferation controlled by the activity of the vaginal microbiota via modulation of 
miRNA expression as a major control center of vaginal epithelial homeostasis and 
thus protection against C. trachomatis. Further, because EGFR is a target of miR-
146a and miR-21, two miRNAs identified in this study (Table 2.2), and is required 
for C. trachomatis EB internalization [316], it is likely that miRNA-driven regulation 
of EGFR contributes to the overall protection against C. trachomatis infection. We 
propose that a dynamic interplay between the vaginal microbiota, miRNA expression, 
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host cell proliferation and C. trachomatis infection exists as represented 
schematically on (Figure 2.12).  
Limitations of the study. Random Forest models were used to discover 
miRNAs associated with Lactobacillus spp.-dominated states. The Nugent-BV 
Random Forest model on average predicted a correct Nugent score within 2 values 
while the proxy-Amsel-BV Random Forest model was 82.3% accurate predicting 
NBV and 80.3 % accurate predicting PBV. Although the accuracy is relatively high, 
Random Forest models can be difficult to interpret and generalize as they incorporate 
all available features for prediction. Thus, although the model provided acceptable 
accuracy and valuable insights in the discovery of BV-associated miRNAs and 
subsequently functional impact of the vaginal microbiota, it should not be used to 
predict outcomes of BV as this was not the goal of the analysis. The Nugent-RF and 
proxy-Amsel-RF predictive models were applied to increase the power to discover 
miRNA associated with Nugent-BV or proxy-Amsel-BV. 
The expression of miR-193b was measured over a course of 22 hours in a 
VK2 epithelial monolayer cell model. Although this model was invaluable in its use 
to demonstrate concordant miR-193b expression between BCS and in vivo data, 
caution should be taken when generalizing to the in vivo vaginal environment. 
Namely, the effect of hormones (i.e. estrogen, progesterone), immune system (i.e. 
macrophages, leukocytes) and the three-dimensional matrix structure (i.e. basal vs. 
apical polarization) as well as microbial organisms (i.e. Lactobacillus spp.) are not 
fully accounted for and provide an additional layer of complexity to epithelial 
homeostasis in the vaginal environment.  
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Nonetheless, this aim provides clear evidence that Lactobacillus-dominated 
vaginal microbiota control the expression of miR-193b which in turns lowers CCND1 
levels and reduce epithelial cell proliferation. More importantly, a low epithelial cell 
proliferative state confers resistance to C. trachomatis infection. Pathways associated 
with proliferative mechanisms should be further investigated as novel therapeutic 
targets to restore homeostasis of the vaginal microbiota and reduce the risk of C. 
trachomatis and other infections.  
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Chapter 3 In vitro vaginal epithelial cell transcriptional response 
to vaginal microbiota 
Introduction 
 
The cells that comprise the human vaginal epithelium sense and respond to 
Lactobacillus spp.-dominated and dysbiotic BV-associated microbiota (characterized 
by a paucity of Lactobacillus spp.) in part through the innate immune response [44]. 
A clear consensus on specific immune factors involved in the host response to 
dysbiotic vaginal microbiota is lacking, but some studies indicate that BV-associated 
microbes such as Gardnerella vaginalis induce IL-6 and IL-8, while Lactobacillus 
crispatus or Lactobacillus jensenii associated microbiota inhibit pro-inflammatory 
responses [41], [47], [59]. The beneficial effect of Lactobacillus spp. is provided 
through yet uncharacterized mechanisms. Chapter 2, however, strongly suggests that 
Lactobacillus spp. can decrease cell proliferation and thus maintain cell homeostasis. 
In some studies, Lactobacillus iners has been found to induce a slight inflammatory 
response, potentially due to the production of inerolysin, a pore-forming cholesterol-
dependent cytolysin [42], [67], [100]. However, it is unclear if all strains of L. iners 
are equally capable of inducing an inflammatory response or express inerolysin in 
vivo. These observations raise questions regarding the ability for certain Lactobacillus 
species or strains to maintain optimal vaginal homeostasis and vaginal health.  
Women harboring dysbiotic microbiota, as defined by Nugent score, have 
been shown to be at increased risk for the acquisition of STIs, including HIV, 
Neisseria gonorrhoeae, and Chlamydia trachomatis [28]-[30], [269]-[271] while 
women with a Lactobacillus spp.-dominated vaginal microbiota are less likely to be 
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infected [271]. The rate of transmission after contact with a partner infected by C. 
trachomatis is estimated to be 25-40% [318]-[320]. The current treatment for C. 
trachomatis infections includes the antibiotics azithromycin or doxycycline [321]. 
However, often the infection is asymptomatic and if left untreated, can ascend to the 
upper genital tract leading to long-term sequelae such ectopic pregnancy and 
infertility [128], [129]. Considering the significant burden this disease has on the 
healthcare system and women’s health, novel protective measures are desperately 
needed. Building on major findings from Chapter 2, optimizing vaginal homeostasis 
will result in reduced risk to STI and can be achieved through research and translation 
of understanding the interaction between the host, the pathogen and the 
cervicovaginal microbiota. Such research could be leveraged to develop novel 
strategies to modulate and maintain a healthy vaginal microbiota.  
In Chapter 2, both in vivo and in vitro longitudinal miRNA expression profiles 
of Lactobacillus spp.-exposed cells were used to elucidate miRNA-mediated gene 
regulation and function. Eight miRNAs were overexpressed in conditions where the 
vaginal microbiota was dominated by Lactobacillus spp. These miRNAs have 
experimentally validated targets associated with various gene ontology processes 
including transcriptional regulation, cell cycle, signaling, development, hypoxia, and 
immune response. When exposed to G. vaginalis Bacteria Culture Supernatant 
(BCS), a surrogate for dysbiotic vaginal microbiota, cultured vaginal epithelial cells 
were found to have decreased expression of miR-193b, which targets the G1-S phase 
cell-cycle checkpoint regulator, cyclin D1 (CCND1), resulting in increased cell 
proliferation. Increased cell proliferation was shown to significantly favor the ability 
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of C. trachomatis to infect cervical epithelial cells. Through the identification of 
miRNAs, a mechanism for the increased risk for C. trachomatis acquisition by 
dysbiotic microbiota has been established and suggests the host response to vaginal 
microbiota includes processes critical for susceptibility to C. trachomatis infection.  
The physiological and biochemical processes associated with and affected by 
decreased vaginal epithelial cell proliferation resulting from Lactobacillus spp. 
exposure have not been characterized. An unaddressed question is how host cell 
sensing of the vaginal environment regulate miRNA expression. As this may be a 
critical defense mechanism unique to humans and their Lactobacillus spp.-dominated 
microbiota, there are likely multiple regulatory pathways that control the expression 
of miR-193b and other miRNAs.  
This chapter characterizes the in vitro transcriptomic response of vaginal 
epithelial cells to L. crispatus, L. jensenii, L. iners and the BV-associated bacteria G. 
vaginalis BCS, as a surrogate for vaginal microbiota exposure over a time course 
sampled at 4h, 13h, and 22h, corresponding to increased miR-193b expression and 
decreased cell proliferation. Exposure to all three Lactobacillus spp. BCSs initially 
activated several immune-related pathways after 4h, however by 13h, L. iners and G. 
vaginalis were found to activate pro-inflammatory immune-related pathways while L. 
crispatus and L. jensenii BCSs minimally activated inflammatory pathways. In line 
with Chapter 2, L. crispatus and L. jensenii BCS decreased activation of cell cycle 
related pathways while L. iners did so moderately. Given the longitudinal differential 
expression patterns of key genes expressed by vaginal epithelial cells under these 
conditions, a model is proposed in which Lactobacillus spp., potentially through 
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metabolites such as lactate, inhibit histone deacetylases (HDACs) and other cell cycle 
regulator genes, leading to decreased cell cycle while the immunomodulation by L. 
iners and G. vaginalis activate immune pathways. The implications of this work 
suggest that vaginal epithelial cell proliferation is attenuated through global 
transcriptional changes mediated by exposure to the vaginal microbiota and open the 
possibility for novel therapeutics targeting vaginal epithelial cell proliferation to 
protect against STIs.  
Methods 
VK2 vaginal epithelial cell culture and bacterial culture supernatant (BCS) exposure 
 
VK2 epithelial cells (ATCC CRL-2616, cell line authentication report in 
(Appendix 3) were cultured at 37°C in 5% CO2 then seeded at 7.5x104 cells/well and 
grown to confluence in VK2 complete medium [Keratinocyte SFM, TheromoFisher # 
17005042, with bovine pituitary extract (0.05 mg/ml), epidermal growth factor (0.1 
ng/ml) and CaCl2 (0.4 mM)]. BCSs were created by seeding 1x107 bacteria/mL of 
either L. crispatus (ATCC 33197), L. jensenii (ATTC 25258), L. iners (ATTC 55195) 
or G. vaginalis (ATCC 14018) in 10 mL culture media (NYC-III for L. crispatus, L. 
jensenii and L. iners, TSB for G. vaginalis), grown anaerobically for 48 h, centrifuged 
at 3,000 x g for 10 minutes, sterile filtered (0.2µm filter) and stored at -20°C. BCSs 
were diluted to 20% (v/v) using complete VK2 cell culture medium and added to 
VK2 cells for a period of 4, 13 or 22h. VK2 cells were starved using base medium 
(Keratinocyte SFM only) for 24 h before adding VK2 cell culture medium containing 
20% BCSs or VK2 cell culture medium alone. Immediately following the exposure 
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time, the cell culture medium was removed, and the cells were washed once with 1X 
PBS and 300 µl RNAlater (QIAGEN) was added to wells. Cells were mechanically 
detached from plate and stored at -80°C for no more than 48 h before total RNA 
extraction.  
Total RNA extraction from BCS exposed VK2 cells 
 
Total RNA from VK2 vaginal epithelial cells exposed to BCS for 4, 13 and 
22h or cell culture medium was extracted using the MasterPure™ Complete DNA 
and RNA Purification Kit (Epicentre, # MCR85102). BCS or cell culture medium 
exposed cells stored at -80°C in RNAlater were thawed and centrifuged for 10 
minutes at 13,000 x g. The RNAlater was removed by pipetting, and cells were lysed 
with 300 µl Lysis buffer containing 50 mg Proteinase K. The pellet was incubated for 
15 minutes at 65°C with 10-second vortexing every 5 minutes, before placing the 
tubes on ice for 5 minutes. Following this step, 175 µl Protein Precipitation buffer 
was added and the mixture vortexed for 10 seconds, and centrifuged for 10 minutes at 
13,000 x g. The supernatant containing total nucleic acids was added to 500 µl 
isopropanol and mixed by inverting the tube 40 times to precipitate nucleic acids, 
which were pelleted by centrifugation for 20 minutes at 13,000 x g, washed twice 
with 70% ethanol, and left to air-dry for 5-15 minutes. The pellet was resuspended in 
10 µl nuclease-free water (Ambion). DNA was then removed by adding 1 µl TURBO 
DNA-free DNase (Life Technologies, # AM1907) and incubated for 30 minutes at 
37°C followed by an additional treatment with 1µl of TURBO DNA-free DNAse for 
another 30 minutes. DNAse was inactivated by adding 2 µl DNAse Inactivation 
Buffer and incubated for 5 minutes at room temperature. The mixture was centrifuged 
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at 13,000 x g for 3 minutes and the supernatant (10 µl) containing total RNA 
transferred to a fresh tube. RNA quality and quantity were measured using 1 µl of 
RNA solution with a 2200 Agilent TapeStation and RNA screen tape (Agilent # 
5067-5576). Samples were used to construct sequencing libraries the following day. 
All samples yielded 226 – 1,120 ng total RNA. 
Ribosomal RNA-depleted (rRNA-depleted) RNA sequencing library construction 
 
All rRNA-depleted RNA-seq libraries were prepared the same day to 
minimize batch effects and were carried out using the TruSeq Ribo-Zero Stranded 
Total RNA kit per manufacturer’s recommendations (Illumina, # RS-122-2203) using 
10 µl of total RNA as extracted above. For each sample, 5 µl of rRNA binding buffer 
and 5µl Ribo-Zero human/mouse/rat rRNA removal mix (Illumina) was added and 
then incubated at 68°C for 5 minutes. Following this step, the entire volume was 
added to 35 µl rRNA removal beads, incubated for 1 minute, and then beads were 
captured on a magnetic plate. The supernatant was mixed with 99 µl RNAClean XP 
beads (Beckman Coulter #A63987), incubated for 15 minutes, then placed on a 
magnetic plate where supernatant was removed and beads were washed once with 70 
% ethanol. Beads were left to dry for 15 minutes, and 11 µl elution buffer was added. 
To elute the rRNA-depleted RNA, the beads were magnetized and the supernatant 
removed by pipetting. An 8.5 µl aliquot of the supernatant was added to 8.5 µl of the 
Elute, Prime, Fragment High mix (Illumina) and incubated at 94°C for 8 minutes, 
then placed on ice.  First strand cDNA was performed by adding 8 µl of previously 
prepared reverse transcriptase mix (50 µl Superscript II (Life Technologies) into 450 
µl First Strand Synthesis Actinomycete D (Illumina)) to the 17 µl of rRNA-depleted 
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RNA. The mixture was incubated at 25°C for 10 minutes, 42°C for 15 minutes, and 
then 70°C for 15 minutes before placing on ice. Second strand synthesis was carried 
out by adding 20 µl Second Strand Marking Master Mix (Illumina) to the mixture and 
incubating at 16°C for 1 hour. The reaction was cleaned using 90 µl of AMPure XP 
beads (Beckman Coulter #A63882), incubated for 15 minutes, then placed on 
magnetic plate and the supernatant discarded. The beads were cleaned using two 
washes with 80% ethanol, then air-dried for 15 minutes before adding 17.5 µl 
resuspension buffer. The beads were magnetized and the solution transferred to a 
fresh tube. To make the fragments compatible with adapters and prevent self-ligation, 
a 3'-adenosine overhang was added by adding 12.5 µl A-Tailing Mix (Illumina) to 
15µl of the solution. The mixture was incubated at 37°C for 30 minutes, then 70°C 
for 5 minutes before being transferred to ice. Adapters were ligated by adding 2.5 µl 
Ligation Mix (Illumina) and 2.5 µl of a unique dual Illumina index to each sample. 
The mixture was incubated at 30°C for 10 minutes and then 5 µl Stop Ligation Buffer 
(Illumina) was added. The ligated cDNA was cleaned using AMPure XP bead clean-
up by adding 42 µl of beads to the mixture, incubating for 15 minutes, placing 
mixture on magnetic stand, removing supernatant, and washing twice with 80% 
ethanol. The beads were resuspended in 52.5 µl Resuspension Buffer (Illumina), 
magnetized and 50 µl of the supernatant was added to 50 µl AMPure XP beads for 15 
minutes. Beads were magnetized, the supernatant discarded, washed twice with 80% 
ethanol and dried for 15 minutes. The beads were resuspended in 22.5 µl 
Resuspension Buffer, magnetized, and 20 µl of the mixture transferred to a fresh tube 
for PCR enrichment. To selectively enrich DNA fragments that have adapter 
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molecules on both ends and to amplify the amount of DNA in the library 5 µl PCR 
Primer Cocktail (Illumina), 25 µl PCR Master Mix (Illumina) were added to the 
mixture and amplification was performed using 15 cycles at 98°C for 10 seconds, 
60°C for 30 seconds and 72°C for 30 seconds, and a final extension at 72°C for 5 
minutes. Enriched libraries were cleaned by adding 50 µl AMPure XP beads, 
incubating for 15 minutes, then placing the tubes on a magnetic stand and discarding 
the supernatant by pipetting. The beads were washed twice with 80% ethanol, air-
dried for 15 minutes, and resuspended in 32.5 µl Resuspension Buffer. The beads 
were magnetized and 30 µl of the supernatant was transferred for subsequent library 
validation and sequencing. Libraries fragment size of 200-500bp range were validated 
on the LabChip GX (PerkinElmer).  
RNA-seq library sequencing 
 
RNA-seq libraries were sequenced on an Illumina HiSeq 4000 using the 150 
bp paired-end protocol at the Institute for Genome Science’s Genomic Resources 
Center (Baltimore, MD, USA). Indexed RNA-seq libraries were multiplexed at 15 
samples per lane.  
Sequence trimming, alignment and feature counting 
 
RNA-seq reads were trimmed using trimmomatic version 0.33 using the 
following parameters: ILLUMINACLIP:2:30:10 LEADING:3 TRAILING:3 
SLIDINGWINDOW:4:15 MINLEN:36 (using Illumina adapter sequences, remove 
the first and last 3 bases below quality 3, with a 4 bp sliding window and trimming 
when quality drops below 15, and dropping reads below 36 bases long) [322]. Reads 
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were aligned to the hg19 human genome reference sequence using TopHat v2.1.0 
with default parameters [323] (Human Genome Reference hg19 (available through 
Illumina at iGenomes 
ftp://illumina.com/Homo_sapiens/UCSC/hg19/Homo_sapiens_UCSC_hg19.tar.gz, 
downloaded August 17, 2015).  Strand-specific genomic feature overlaps were 
counted using HTSeq version 0.5.3p3 [230] with default parameters (mode=union, 
minaqual=0, stranded=’yes’) and the iGenomes annotation as above.  
Read mapping quality control and differential expression 
 
All analysis scripts can be found in Appendix 2. Sample replicates were 
validated by computing the log2 read count linear correlation coefficients between 
replicates. Samples with R2 <0.9 were excluded from further analysis, except where 
dropping a sample would result in a single sample per time point for a given 
treatment. To check for contamination, including the presence of human rRNA not 
aligned to the human reference, the top 10 most abundant unaligned reads per 
treatment were BLASTed against the non-redundant nucleotide collection to 
determine any non-human cross-contamination (from experimental sources or within-
sequencing lane) or human rRNA contamination [324]) Samples having more than 
90% human rRNA sequences were excluded from further analysis. All of the top 10 
most abundant unaligned reads from all samples were of human origin.  
The R package edgeR, version 3.10.5, was used to compute pairwise 
differential expression between combinations of each exposure time and BCS vs. cell 
culture medium [240]. Negative binomial dispersion was estimated for samples 
passing QC by applying the estimateDisp function available through edgeR, which 
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computes a common, trended, and gene-wise dispersion estimate to be used in 
downstream statistical inference. Samples were normalized using the 
calcNormFactors function which implements the Trimmed Mean of M-values (TMM) 
normalization procedure [242]. Reads were fit to a negative binomial generalized 
linear model using the glmFit function available in edgeR, using the sample’s 
treatment as the design matrix. Differential expression using edgeR’s likelihood ratio 
test was computed for each gene using the glmLRT function. Genes with an average 
log counts per million (logCPM) >1 , log2-transformed Fold Change (logFC) > 1 and 
false discovery rate (FDR) < 0.01 [325] were considered differentially expressed 
between treatments. The FDR corrects for multiple hypothesis testing [326]. The 
mean logCPM as calculated by edgeR is the log2 counts per million reads, averaged 
over all the libraries, while log2FC is the coefficient of the Generalized Linear Model 
used by edgeR [240].   
Pathway enrichment to identify commonly expressed pathways 
 
Differentially expressed genes for each comparison were used to generate 
pathway enrichment scores using Ingenuity Pathway Analysis (IPA) (QIAGEN Inc., 
build version 439932M, content version 33559992). IPA computes a pathway 
activation score (z-score) for each pathway comparison based on inferred expression 
directionality using the logFC of each gene [327]. Pathway z-scores or logFC values 
were used to plot each comparison’s time-course using the R library ggplot2 (version 




RNA-seq alignment statistics and quality control 
 
Total RNA was extracted from triplicate VK2 cells exposed for 4h, 13h and 
22h to either 20% (v/v) L. crispatus, L. jensenii, L. iners, or G. vaginalis BCS or cell 
culture medium. The median RINe quality score was 9.7 across 45 samples (range: 
3.1-10) (Figure 3.1). Five of the initial 45 samples failed sequencing or library 
construction (L. crispatus BCS 4h exposure replicate 3, L. jensenii 4h exposure 
replicate 3, L. iners 4h exposure replicate 3, G. vaginalis 22h exposure replicate 1 and 
cell culture medium 22h exposure replicate 2). Sequencing and alignment statistics 
are shown in Table 3.1 and raw read counts are in Appendix 11. L. crispatus BCS 13h 
exposure replicate 3 sample had a relatively high proportion (94.3%) of human rRNA 
Figure 3.1 RINe distribution for RNA samples used in the study 
Histogram of RINe quality scores for all extracted RNA samples used in study (45 samples). Red line indicates 

















reads and cell culture medium 4h exposure replicate 3 sample was poorly correlated 
(R2<0.9) with replicate 1 and 2 samples. Both samples were therefore removed, 
leaving 38 samples for subsequent analysis. The top 10 most abundant unaligned 
reads from each of the remaining sample were found to be human rRNA that was not 
efficiently removed during library construction.  
Vaginal epithelial immune response and cell cycle pathways are associated with BCS 
exposure 
 
Differentially expressed genes were identified for each exposure time point 
using each BCS treatment (L. crispatus, L. jensenii, L. iners or G. vaginalis) 
compared to cell culture medium (Appendix 12). The number of differentially 
expressed genes, computed by edgeR and defined as genes having False Discovery 
Rate (FDR) corrected p-value < 0.01, mean log2 (Counts Per Million (CPM)) > 1 and 
log2 fold change (FC) > 1, for each comparison group are shown in Table 3.2. 
For each BCS vs. cell culture medium comparison, Ingenuity Pathway 
Analysis (IPA) software computed canonical pathway activation scores (z-scores) 
based on the expression of differentially expressed genes (Appendix 13). The z-score 
is a way of assessing the agreement between each pathway’s predicted and observed 
gene activation relationships, where positive z-scores correspond to pathways 
predicted to be activated given the direction (positive/negative) log2-transformed Fold 
Change (logFC) expression values and known gene-gene regulatory interactions 
within the pathway (and conversely, negative z-scores correspond to repressed 
pathway activation) [327]. Among the most 28 most common activated or repressed 
canonical pathways (defined as having absolute z-score greater than 2 in at least 
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L. crispatus BCS 4 1  14,867,552   5,558,855  37.4 
L. crispatus BCS 4 2  6,325,764   1,648,935  26.1 
L. crispatus BCS 13 1  7,782,296   3,386,120  43.5 
L. crispatus BCS 13 2  7,752,780   3,024,389  39.0 
L. crispatus BCS 13 3  2,829,593   161,415  5.7* 
L. crispatus BCS 22 1  5,510,460   1,416,161  25.7 
L. crispatus BCS 22 2  11,631,321   4,392,899  37.8 
L. crispatus BCS 22 3  21,444,118   8,448,815  39.4 
L. jensenii BCS 4 1  6,891,476   1,533,479  22.3 
L. jensenii BCS 4 2  7,347,943   3,206,459  43.6 
L. jensenii BCS 13 1  6,298,882   1,921,098  30.5 
L. jensenii BCS 13 2  8,055,876   2,974,822  36.9 
L. jensenii BCS 13 3  10,203,941   3,802,258  37.3 
L. jensenii BCS 22 1  7,477,077   2,950,478  39.5 
L. jensenii BCS 22 2  7,388,378   2,049,302  27.7 
L. jensenii BCS 22 3  20,070,883   8,633,553  43.0 
L. iners BCS 4 1  7,857,237   2,645,213  33.7 
L. iners BCS 4 2  7,907,060   3,115,872  39.4 
L. iners BCS 13 1  4,323,103   863,055  20.0 
L. iners BCS 13 2  4,547,722   1,729,117  38.0 
L. iners BCS 13 3  14,951,198   6,838,588  45.7 
L. iners BCS 22 1  4,303,383   1,532,055  35.6 
L. iners BCS 22 2  4,508,819   1,021,441  22.7 
L. iners BCS 22 3  12,587,497   5,445,716  43.3 
G. vaginalis BCS 4 1  8,861,783   3,555,610  40.1 
G. vaginalis BCS 4 2  4,989,044   1,880,874  37.7 
G. vaginalis BCS 4 3  12,819,802   5,603,541  43.7 
G. vaginalis BCS 13 1  8,291,229   3,483,930  42.0 
G. vaginalis BCS 13 2  8,136,856   3,155,228  38.8 
G. vaginalis BCS 13 3  22,489,737   10,538,780  46.9 
G. vaginalis BCS 22 2  4,993,600   1,354,926  27.1 
G. vaginalis BCS 22 3  13,341,795   5,545,096  41.6 
Cell culture medium 4 1  9,492,111   3,745,190  39.5 
Cell culture medium 4 2  8,385,668   3,207,936  38.3 
Cell culture medium 4 3  10,862,411   5,132,964  47.3* 
Cell culture medium 13 1  6,133,669   2,030,629  33.1 
Cell culture medium 13 2  11,165,638   4,892,080  43.8 
Cell culture medium 13 3  13,234,638   4,873,897  36.8 
Cell culture medium 22 1  11,354,674   4,670,961  41.1 
Cell culture medium 22 3  14,132,637   7,577,938  53.6 
*Denotes sample was dropped due to QC failure  
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one comparison) were pathways related to the cell cycle (11 pathways, annotated by 
IPA) or immunity/proinflammation (12/7 pathways) (Figure 3.2 and Figure 3.3). The 
remaining 5 pathways did not belong to immunity nor cell cycle (LXR/RXR 
Activation, NRF2-mediated Oxidative Stress Response, PPAR Signaling, Type I 
Diabetes Mellitus Signaling and UVA-Induced MAPK Signaling). 
When compared to cell culture medium exposed cells after 4h, 13h or 22h 
exposure, L. iners and G. vaginalis BCS generally activated immune pathways in 
VK2 cells while L. crispatus BCS generally activated immune pathways only at the 
4h exposure (Figure 3.2). Specifically, comparisons with 4h BCS exposure relative to 
cell culture medium had the greatest number of immune-related pathways with z-
score > 2: G. vaginalis vs. cell culture medium (18 pathways, 8 of which are pro-
inflammatory), L. iners vs. cell culture medium (16 pathways, 7 of which are pro-
inflammatory), and L. crispatus vs. cell culture medium (11 pathways, 5 of which are  
Table 3.2 Number of differentially expressed genes per pairwise comparison 






L. crispatus BCS vs. cell culture medium  4 1022 
L. jensenii BCS vs. cell culture medium  4 868 
L. iners BCS vs. cell culture medium 4 838 
G. vaginalis BCS vs. cell culture medium  4 246 
L. crispatus BCS vs. cell culture medium  13 4098 
L. jensenii BCS vs. cell culture medium  13 2753 
L. iners BCS vs. cell culture medium 13 436 
G. vaginalis BCS vs. cell culture medium  13 122 
L. crispatus BCS vs. cell culture medium  22 5505 
L. jensenii BCS vs. cell culture medium  22 3039 
L. iners BCS vs. cell culture medium 22 585 
G. vaginalis BCS vs. cell culture medium  22 166 
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pro-inflammatory), while L. jensenii vs. cell culture medium at the 4h exposure had 
only 2 immune-related and 2 pro-inflammatory pathways with z-score > 2 (Table 3.3, 
Appendix 13). Conversely, relative to cell culture medium, L. crispatus and L. 
jensenii BCS generally repress cell proliferation pathways at 4h, 13h or 22h exposure 
(Figure 3.3, Table 3.3, Appendix 13). These patterns demonstrate that the VK2 cell 
host responses to L. crispatus BCS and L. jensenii BCS are different from that of L. 
iners BCS or G. vaginalis BCS, which instead trigger similar immune related 
pathways while ineffectively repressing cell proliferation pathways.  
An observation from Figure 3.2, Figure 3.3 and Table 3.3 is that L. crispatus 
BCS comparisons tend to both activate immune related pathways and suppress cell 
cycle related pathways while the same contrasting pattern is not as apparent for L. 
jensenii or L. iners BCS comparisons. At 4h after exposure, L. crispatus BCS 
increased 11 immune-associated pathways relative to cell culture medium, and of 
those, 5 are classified as pro-inflammatory pathways. At the same time, L. crispatus 
BCS exposed cells were among comparisons with the greatest number of decreased 
Table 3.3 Number of immune pathways (Figure 3.2) and cell cycle pathways (Figure 3.3) with absolute z-
score greater than 2. Number of pro-inflammatory pathways within immune pathways in parenthesis. 














L. crispatus BCS vs. cell culture medium  4 3 2 11 (5) 0 (0) 
L. jensenii BCS vs. cell culture medium  4 1 1 2 (2) 0 (0) 
L. iners BCS vs. cell culture medium 4 4 0 16 (7) 0 (0) 
G. vaginalis BCS vs cell culture medium  4 3 1 18 (8) 0 (0) 
L. crispatus BCS vs. cell culture medium  13 1 4 2 (1) 0 (0) 
L. jensenii BCS vs. cell culture medium  13 0 2 1 (1) 1 (0) 
L. iners BCS vs. cell culture medium 13 0 0 7 (4) 0 (0) 
G. vaginalis BCS vs cell culture medium  13 1 0 8 (3) 0 (0) 
L. crispatus BCS vs. cell culture medium  22 0 3 0 (0) 1 (0) 
L. jensenii BCS vs. cell culture medium 22 0 2 1 (1) 1 (0) 
L. iners BCS vs. cell culture medium 22 0 1 3 (1) 0 (0) 
G. vaginalis BCS vs cell culture medium 22 0 0 2 (1) 0 (0) 
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cell cycle expression pathways in 13h and 22h BCS exposure (Table 3.3). The 
longitudinal logFC expression patterns of IL6 and IL8 (Figure 3.4), cytokines that 
have been previously shown to be involved in the immune response to vaginal 
bacteria, both increase over time in L. crispatus comparisons while the remaining 
Lactobacillus spp. comparisons do not show as large of a shift in IL-8 logFC 
expression and show a decreased IL-6 logFC expression after 13h of BCS exposure. 
However, L. crispatus BCS only moderately activates the IL-6 and IL-8 signaling 
pathways (Figure 3.2), with only one comparison having a z-score > 2 (IL-6 signaling 
pathway at 4h after L. crispatus BCS exposure relative to cell culture medium. Figure 
Figure 3.2 Heat map of activation scores (z-score) from pathways associated with immunity for cells exposed 
to each BCS for 4h, 13h or 22h vs. cell culture medium. 
Pathways with absolute z-score greater than 2 in at least 1 comparison revealed decreased activation of immune 
response pathways in L. crispatus and L. jensenii BCS exposed cells. Conversely, L. iners and G. vaginalis BCS 
exposed cells maintain relatively high activation of immune pathways at 13h and 22h exposure. Pathways denoted 
with “*” are proinflammatory response pathways.  
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3.5 shows the IL-6 Signaling canonical pathway from IPA for L. crispatus BCS vs. 
cell culture medium at 13h (z-score 1.3). Note that upstream effectors are mostly 
decreased in L. crispatus, including IL-1R, the receptor for the pro-inflammatory 
cytokine IL-1 (green colors), but increased in downstream (red colors). These 
expression patterns negate the activation of the IL-6 Signaling Pathway and instead 
may indicate downstream genes are activated by a separate pathway other than IL-6 
(Figure 3.4, Figure 3.5). Taken together, this suggests that L iners BCS maintains a 
Figure 3.3 Heat map of activation scores (z-score) from pathways associated with the cell cycle for cells 
exposed to each BCS for 4h, 13h or 22h vs. cell culture medium. 
Pathways with absolute z-score greater than 2 in at least one comparison revealed repression of cell cycle 
pathways after exposure to L. crispatus and L. jensenii BCS. Conversely, L. iners or G. vaginalis BCS are 
ineffective at repressing cell cycle pathways.  













relatively high stimulation of pro-inflammatory pathways over the time course, 
similar to G. vaginalis, while both L. crispatus and L. jensenii BCS initially stimulate 
pro-inflammatory pathways at 4h after BCS exposure. By 13h of exposure, L. 
crispatus BCS decreases host cell cycle pathways while simultaneously minimally 
inducing pro-inflammatory pathways (no pro-inflammatory pathways with z-score 
>2), and L. jensenii BCS primarily decreases host cell cycle with little effect on 
immune responses. 
Histone modification and cell cycle regulators are expressed dependent on BCS  
 
The cell cycle may be regulated by a global mechanism, given that multiple 
cell proliferation pathways were repressed in L. crispatus and L. jensenii BCS 
exposed cells. Figure 3.6 shows the Cyclins and Cell Cycle Regulation canonical 
Figure 3.4 Longitudinal relative expression patterns for IL6 and IL8. 
Shown are gene’s log2 fold change values for 4h, 13h, and 22h BCS exposure vs. cell culture medium. 
Line color indicates BCS exposure. Horizontal dotted lines within each plot indicate log2 fold change 







pathway from IPA. Differentially expressed genes within the pathway are colored by 
the mean logFC of both L. crispatus and L. jensenii comparisons at 13h after BCS 
exposure. Key transcriptional regulators of this pathway are histone deacetylase 
enzymes (HDACs, circled on Figure 3.6) which regulate gene transcription by 
chromatin remodeling [328]. This study found that the longitudinal expression of 
HDAC4 has a decreased logFC pattern at 13h after L. crispatus or L. jensenii BCS 
exposure (Figure 3.7). Interestingly, the histone acetyltransferase enzyme (HAT) E1A 
binding protein p300 (EP300, known to oppose the action of HDACs) exhibits the 
opposite longitudinal expression pattern of HDAC4 logFC at 13h (Figure 3.7). 
It has previously been shown that HDAC4 negatively regulates the 
transcription of cyclin dependent kinase inhibitor 1A (CDKN1A) [329], which in turn 
Figure 3.5 IL6/IL1 signaling pathways gene expression after exposure to L. crispatus BCS for 
13h compared to cell culture medium. 
Upstream differentially expressed genes show mostly decreased (green) logFC (IL-1), while 
downstream differentially expressed genes show increased (red) logFC, resulting in z-score 1.3.  
Pathway generated in IPA.  
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inhibits the activity of cyclin dependent kinase 4 (CDK4) and thus the cell cycle. 
Figure 3.7 shows that the CDKN1A longitudinal logFC expression is greatest in L. 
crispatus BCS exposed cells at 13h, followed by L. jensenii BCS exposed cells, with 
L. iners and G. vaginalis exposed cells having logFC < 1 at 13h after BCS exposure. 
CDK4, on the other hand, shows logFC is most negative at 13h in L. crispatus BCS 
exposed cells, followed by L. jensenii, L. iners and finally G. vaginalis vs. cell culture 
medium (Figure 3.7). Chapter 2 showed that decreased protein expression of CCND1 
Figure 3.6 Cyclins and Cell Cycle Regulation pathway for averaged logFC of L. crispatus BCS and L. jensenii 
BCS 13h after exposure. 
Genes in pathway colored by differentially expressed genes with logFC > 0 (red) or log FC < 0 (green). Encircled is 




occurs 13h after exposure to L. crispatus and L. jensenii BCSs. Figure 3.7 reveals that 
although CCND1 logFC increases from 4h to 22h over all comparisons relative to cell 
culture medium, the value is more negative for L. crispatus BCS, followed by L. 
jensenii BCS and finally L. iners BCS and G. vaginalis BCS. Cell cyclin E2 
(CCNE2) is a regulator of late G1/S phase cell progression and shows decreased 
expression vs. cell culture medium in L. crispatus BCS and L. jensenii BCS at 13h 
relative to L. iners BCS or G. vaginalis BCS comparisons (Figure 3.7). The opposing 
logFC expression profiles of CDKN1A versus CDK4, CCND1 and CCNE2 at 13h 
after L. crispatus or L. jensenii BCS exposure are aligned with decreased cell 
Figure 3.7 Longitudinal relative expression patterns for selected cell cycle and chromatin remodeling 
genes. 
Shown are gene’s log2 fold change values for 4h, 13h, and 22h BCS exposure vs. cell culture medium. Line 
color indicates BCS exposure. Horizontal dotted lines within each plot indicate log2 fold change -1, 0 and 1 







proliferation observed in Chapter 2 and that differential transcription of histone 
modification genes HDAC4 and EP300 further suggest global regulation of CDKN1A 
and the cell cycle.  
Estrogen Receptor Alpha and Epidermal Growth Factor Receptor 1 gene expression 
are significantly decreased after L. crispatus and L. jensenii BCS exposure  
 
Chapter 2 identified CCND1 as a target of miR-193b in cells exposed to 
Lactobacillus spp. BCS using experimentally validated targets from miRTarBase 
[284]. Another experimentally validated target of miR-193b is Estrogen Receptor 
Alpha (ESR1), which when expressed induces cell growth via estrogen [312], [313]. 
Figure 3.7 shows differential logFC expression (FDR <0.01) of ESR1 in L. crispatus 
and L. jensenii BCS exposed cells at 13h and 22h BCS exposure. This may be 
reflective of miRNA-193b-mediated regulation of ESR1 transcriptional expression in 
L. crispatus or L. jensenii BCS exposed cells.  
Chapter 2 also found decreased cell proliferation was required for C. 
trachomatis infection. Epidermal Growth Factor Receptor 1 (EGFR) is required for 
internalization of elementary bodies into the host cell [316]. EGFR’s logFC 
expression becomes more negative from 4h to 22h (Figure 3.7) with L. crispatus BCS 
and L. jensenii BCS exposed cells having FDR <0.01 at 13h and 22h. This suggests 
that decreased EGFR expression may be mediated by Lactobacillus spp. BCS 





This chapter revealed global transcriptomics expression patterns in VK2 
vaginal epithelial cells when exposed to Lactobacillus spp. or G. vaginalis BCS for 
4h, 13h and 22h. The results described in this chapter show that both cell cycle and 
immune pathways were among the most activated or repressed pathways shared 
among all BCS and exposure times. In Chapter 2, Lactobacillus spp. BCS exposure 
decreased vaginal epithelial cell proliferation associated with increased expression of 
miR-193b resulting in reduced CCND1 protein expression, the target of miR-193b. 
Results from Chapter 3 suggest BCS-mediated cell cycle control is more broadly 
regulated by chromatin remodeling genes and other cell cycle regulators. On the other 
hand, exposure to L. iners and G. vaginalis BCS resulted mainly in immune pathway 
activation.  
A family of enzymes that regulate the cell cycle are HDACs and HATs, which 
control gene expression by deacetylating or acetylating histones, respectively [328]. 
After exposure to L crispatus and L. jensenii BCSs, HDAC4 expression is decreased 
while that of EP300 is increased. This is illustrated in Figure 3.6 and Figure 3.7 which 
depict the cell cycle pathway ‘Cyclins and Cell Cycle Regulation’ and the 
longitudinal expression profile of these genes. Histone modifications via HDAC 
regulation, which result in decreased access to DNA to transcriptional regulators, is 
known to be coupled with the immune response, for example through MAPK and NF-
kB signaling pathways, leading to increased or decreased IL-6 or IL-8 expression 
[330], [331]. Interestingly, bacterial-derived small chain fatty acid (SCFA), including 
butyrate, have been shown to activate HATs and inhibit HDACs in the 
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gastrointestinal tract [332], [333] in addition to modulating the immune response, for 
example via IL-8, IL-6, and IL-1β [332], [334], [335]. Butyrate is known to be 
transported into the cell by solute carrier family 5 member 8 (SMCT1) [336] thus 
potentially having a more direct effect on intracellular proteins. Lactic acid, a SCFA 
produced in copious amounts by Lactobacillus spp., has been shown to stimulate the 
release of IL-1β  and IL-8 in poly(I:C) stimulated vaginal cells [102] and IL-23 [101] 
in PBMCs in a dose-dependent manner. Similar to butyrate, lactate can be transported 
across the cell though proton-linked monocarboxylate transporters in some cells such 
as rat or human intestinal epithelial cells (IEC-6 and Caco-2, respectively) [337]-
[339]. The probiotic species Lactobacillus plantarum reverses decreased SMCT1 
expression induced by TNF-a, suggesting that Lactobacillus may play an active role 
in butyrate uptake in the gut [337]. An unanswered question is whether lactate is 
transported into cells through a similar mechanism in the vaginal environment and 
whether its potential effect on HDACs or immune function has a similar role.  
HDAC4 inhibition reduces cell proliferation by inducing transcription of the 
CDK4 inhibitor CDKN1A [340] [341] [329]. In line with this data, CDKN1A logFC 
expression is greatest at 13h post-exposure to L. crispatus and L.  jensenii BCSs 
(Figure 3.7). Chapter 2 showed that the amount of CCND1 protein is decreased after 
13h exposure to L. crispatus and L. jensenii BCSs. As miRNA mechanisms can also 
include transcriptional degradation, decreased CCND1 protein and transcript 
abundance is supported by results from Chapter 2 and Chapter 3. The findings 
presented here further suggest that decreased cell proliferation is mediated by 
HDAC4 de-repression of CDKN1A transcript expression.   
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The HAT EP300 regulates ESR1 by mediating ligand binding to the estrogen 
receptor [342]. The results presented here suggest an inverse relationship between 
EP300 expression and ESR1 transcripts (Figure 3.7). Estrogen is a mediator of 
maturation and cell growth of the vaginal epithelium [312], [313]. Thus, the observed 
inhibition of cell proliferation via Lactobacillus spp. BCS exposure in Chapter 2 and 
the known regulation of ESR1 by EP300 suggest a mechanism to maintain cell 
homeostasis. As this is a potentially complex feedback mechanism, the interpretation 
of this data in the context of the vaginal microbiota warrants further investigation.  
A significant finding from Chapter 2 is that decreased cell proliferation 
decreases the efficiency of C. trachomatis infection in vitro. Key to the internalization 
of C. trachomatis elementary bodies into the host target epithelial cells is their 
attachment to EGFR [316]. Interestingly, EGFR expression is decreased over time 
after exposure to L. crispatus and L. jensenii BCS (Figure 3.7). Control of EGFR by 
these two Lactobacillus species may contribute to host increased resistance to C. 
trachomatis when L. crispatus and L. jensenii dominate the vaginal ecosystem. Here 
we show that EGFR expression is still occurring after exposure to L. iners and G. 
vaginalis BCS, which may result in a lack of resistance to C. trachomatis infection 
after exposure to these species. (Figure 3.7). Further research is needed to better 
understand the interaction between EGFR expression, vaginal microbiota and C. 
trachomatis infectivity.   
Previous studies have found that relative to cell culture medium control, 
cytokine IL-1β or IL-8 secretion is reduced in L. crispatus and L. jensenii exposed 
cells [59]. Instead, exposure to L. iners induces the pro-inflammatory cytokine tumor 
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necrosis factor (TNF), the cytokine signaling gene interleukin 1 receptor associated 
kinase 2 (IRAK2) and the pro-inflammatory transcriptional regulators interferon 
regulatory factor 1 (IRF1) and nuclear factor kappa B inhibitor alpha (NFKBIA) [59], 
[67], [87]. The BV-associated species G. vaginalis induces IL-6 secretion [87]. L. 
crispatus BCS was found to activate IL-6 and IL-8 pathways relative to cell culture 
medium 4h post-exposure (Figure 3.2). An explanation for inconsistencies between 
the reported literature and these results may be a disconnect between cellular 
transcriptional measurement performed here and the protein level measurement 
reported in the literature. In addition, the in vitro nature of the experimental methods 
might have an impact on the results. However, pathway-level analysis results are 
more aligned with expected reduced or activated immune responses. For example, IL-
6 has a relatively low z-score of 1.3 13hafter exposure to L. crispatus BCS. This is 
explained by the reduced expression of genes upstream from IL-6, such as IL-6 
receptor (IL-1R), while IL-6 itself is slightly over-expressed. (Figure 3.2, Figure 3.4, 
and Figure 3.5). This observation suggests that the unexpected gene expression 
patterns may not result in activation of the pathway that ultimately determines 
epithelial cell response. Thus, although gene expression patterns are slightly 
unexpected, each BCS exposure aligns with previously reported cellular responses 
when pathway level analysis are performed.  
Pathway activation suggests the L. iners BCS host response is more similar to 
that of G. vaginalis BCS than that of L. crispatus or L. jensenii BCS, even at later 
time points. Some strains of L. iners have been shown to induce inflammatory 
responses and encode inerolysin, a cholesterol dependent cytolysin (CDC), which is 
 115 
known to activate pro-inflammatory responses and is similar to vaginolysin, a CDC 
produced by G. vaginalis [42][[112] [112]. Additionally, L. iners only produces the 
L(+) lactic acid isomer [311]. In one study, acidic L(+)-lactic acid with poly(I:C) 
TRL3 stimulation produced IL-6 and IL-8 while the racemic lactic acid only 
produced IL1RA [100]. Therefore, there may also be an isomer-specific component 
wherein L(+)-lactic acid produces different responses than D(-) or D/L-lactic acid. 
These findings highlight the need for strain-specific studies in microbiome research.  
Concluding remarks 
 
This chapter aimed to characterize the transcriptomic response of VK2 vaginal 
epithelial cells to Lactobacillus spp. and G. vaginalis BCS, the latter as a surrogate to 
dysbiotic microbiota. Immune-related pathways including IL-6 and IL-8 were mostly 
activated in L. iners or G. vaginalis exposed BCS cells while cell proliferation 
pathways were inhibited by L. crispatus and L. jensenii at 13h after BCS exposure. Of 
note, immune functions have been linked to cell proliferation in other cells, and the 
results presented here posit that decreased cell proliferation upon Lactobacillus spp. 
exposure may be partially mediated by HDAC or lactate-specific effects via shared 
pathways. EGFR and ESR1 may be additionally regulated by L. crispatus and L. 
jensenii mediated exposed mechanisms such as HDAC inhibition. There is further 
need to understand strain or species specific effects as this may have profound 
consequences on vaginal health by modulating vaginal cell homeostasis.  
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Chapter 4 Future work and conclusions 
Future Work 
Studying the microbiota-host dynamic in more complex in vitro cell systems  
 
The effects of the vaginal microbiota were studied using bacteria culture 
supernatants containing lactic acid. Although these BCS provided valuable insights, 
adding viable bacteria to the mammalian cells would better approximate the vaginal 
environment. However, this task is technically challenging as optimal bacterial and 
mammalian growth media and conditions differ. For example, many of the BV-
associated microbes are difficult to culture, while others do not grow optimally in 
VK2s medium [343]. While it might be desirable to include bacterial cells in the 
system, in the case of Lactobacillus spp., it might not represent their interactions with 
the vaginal epithelium. Indeed, Lactobacillus spp. do not adhere to the vaginal 
epithelium and interact with the host epithelium through the panoply of metabolites 
and small molecules they are known to produce. Further, the system lacks epithelial 
shedding, which occurs in vivo, but is not observed in vitro, highlighting the 
limitation of working with cell cultures. However, the lack of animal models that 
mimic humans to study the vaginal environment is still the main limitation. In vitro 
findings need to be validated by measuring them directly in human from samples 
prospectively collected.  
Chapter 2 and Chapter 3 findings suggest species-specific host responses. 
Many factors can explain these differences, first of which are genomic differences 
between species and strains of Lactobacillus or between strains of G. vaginalis [277]. 
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Lactobacillus spp. are known to produce different amounts and ratios of D(-) and 
L(+)-lactic acid [104]. While Figure 2.6 did not show any significant differences 
between isomers in miR-193b expression, it might be involved in the regulation of 
other pathways through HDAC, for example. In addition to lactic acid isomer 
production differences, L. iners carries inerolysin, a cytolysin whose function is still 
unknown but believed to be involved in innate immune activation [42]. Thus, for L. 
iners, carriage of inerolysin might have significant impact on vaginal homeostasis, 
and experiments using differing strains within the species, isolated from a woman 
with and without BV, would therefore be valuable to compare and further explain the 
findings presented here. Additionally, G. vaginalis was used as the prototypical BV-
associated species. Experiments using other BV-associated bacteria should yield 
further insight into differences contributed by Lactobacillus spp. to the host 
homeostasis.  
Using a three-dimensional cell system instead of a VK2 vaginal epithelial cell 
monolayer may better mimic in vivo processes. The vaginal epithelium is a polarized 
squamous stratified epithelium such that there is an apical and basal side, where cells 
become flattened and keratinized and shed when reaching the apical surface [5], 
[344]. With transwells, organotypic or organ-on-a-chip systems, it is possible to study 
the effect of basal vs. apical surface changes including basal estrogen or nutrient 
supply (as would be provided by the vasculature underlying the basal lamina in the 
vagina), microbial stimulation, and immune cells (such as macrophages) [345]. Using 
these models may allow the use of physiological pH for prolonged periods of time to 
better study the effect of reduced pH on the apical surface. Organ-on-a-chip systems 
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have demonstrated the requirement of peristalsis for replication of gut cell 
morphology as seen in vivo [346]. Adding movements that mimic the vaginal 
physical dynamic may provide additional improvements currently unknown to the 
model.  
Further characterization of the role of miR-193b and mechanism of action 
 
Results from Chapter 2 shows how Lactobacillus spp. exposure triggers miR-
193b expression, which is known to directly target CCND1, so that after exposure to 
L. crispatus and L. jensenii BCS the amount of CCND1 is decreased. To further 
characterize the role of miR-193b, it would be valuable to manipulate the effect of 
miR-193b by increasing or decreasing its expression. This can be achieved by 
transfecting cells with a construct from which miR-193b can be overexpressed, 
allowing its expression in in vitro condition where it is usually repressed (exposure to 
G. vaginalis BCS or L. iners BCS at a certain time after exposure). Alternatively, 
interfering RNAs, RNA complementary to its target, would decrease available 
miRNA-193b and reverse the effects, confirming its role in the identified function 
[347]. There are several technical challenges to cell transfection, including the ability 
of the cell line to be transfected or infected by transducing viruses carrying the 
genetic constructs, unintended immune responses of the transfected cells or unknown 
genome mutagenesis associated with the process (as in the case of virus-mediated 
transduction) [348]. However, transfection of plasmids using cationic-lipid based 
methods has demonstrated that VK2s are receptive to DNA transfection [349] [350]. 
Cationic-lipid based methods are advantageous in that they have low cytotoxicity and 
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not associated with genome mutagenesis [348]. Transfection reporter assays are also 
advantageous for studying the effect of varying miRNA target sequence to protein 
expression efficiency. A dual luciferase reporter assay in which the luciferase amino 
acid would be coupled to CCND1 amino acid could demonstrate miR-193b direct role 
in CCND1 translational inhibition [351]. 
Evaluate the effect of HDAC inhibitors on cell proliferation, miR-193b expression 
and C. trachomatis infectivity  
 
Chapter 3 found that HDAC4 is decreased in Lactobacillus spp. BCS cells. 
HDACs are known to have an active role in increasing cell proliferation and broad 
regulatory changes through histone modifications [352]. HDAC inhibitors are a class 
of commercially available molecules used primarily in cancer therapy to reduce cell 
proliferation [353]. Thus, a key experiment would be to test the effect of HDAC 
inhibitors on cell proliferation in VK2s while simultaneously measuring miR-193b 
expression, CCND1 expression and C. trachomatis infectivity. This may allow 
repurposing of a safe HDAC inhibitor for approved use as a microbicide after 
exposure to C. trachomatis, fostering a novel approach to STI treatment and 
prevention.  
Elucidate the regulatory pathways leading to miR-193b expression 
 
Transcription factors that govern the expression of miRNAs are largely 
unknown [146]. miR-193b may be transcribed along with other key regulatory 
mRNAs including regulators of immune pathways. Identifying miR-193b 
transcriptional regulators will help further link vaginal microbiota composition and 
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cell proliferation. This can be accomplished using chromatin studies including CHIP-
seq in which all binding of a given transcription factor is sequenced.  
 
Conclusions  
This dissertation aimed to characterize miRNA and miRNA-associated 
mRNA regulatory pathways as a function of vaginal microbiota community 
composition differences. Chapter 2 applied Random Forest models to small RNA-seq 
expression profiles from 100 Lactobacillus spp.-dominated and CST-IV microbiota 
vaginal samples and uncovered miRNAs targeting functions such as transcription 
regulation, cell cycle, signaling, hypoxia, development and the immune response. In 
vitro experiments confirm that miRNA-193b expression was induced in vaginal 
epithelial cells exposed to Lactobacillus spp. bacterial culture supernatants, which 
was simultaneously shown to decrease cell proliferation and coincide with decreased 
CCND1 protein expression. Decreased C. trachomatis infectivity was observed 
because of decreased cell proliferation (Figure 4.1). These findings have profound 
implications for women’s health as having a Lactobacillus spp.-dominated microbiota 
is critical for the reduction of cell proliferation and therefore C. trachomatis 
infectivity, thus raising important questions about the implications of not having 
Lactobacillus spp.-dominated microbiota. One can characterize non-Lactobacillus 
spp.-dominated microbiota as a normal state (as it is found in many women who are 
asymptomatic) that carry risk (as it is associated with increased risk of STIs). From a 
clinical point of view, it might be necessary to redefine the treatment guidelines 








Figure 4.1 Summary of Chapter 2 findings  
Chapter 2 demonstrated that a Lactobacillus-spp. dominated CST or BCS induces expression of miR-193b, 
which in turn decreases CCND1, a regulator of cell cycle, and therefore results in decreased cell proliferation. A 
critical finding from Chapter 2 is that cell proliferation is required for C. trachomatis infectivity, and that 
conversely, inhibiting cell proliferation via Lactobacillus spp. exposure may reduce C. trachomatis infection. 
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There might be instances where treatment might be recommended even though no 
symptoms are reported. However, efficient treatments are still lacking, as current 
treatment with metronidazole is associated with high recurrence. This research might 
lead to novel treatments to modulate the microbiota but also improve preventive and 
curative measures for C. trachomatis infection or exposure. 
Given that the miRNA regulatory cascade is most likely mediated by a global 
response to vaginal microbiota, Chapter 3 sought to characterize whole transcriptomic 
changes associated with Lactobacillus spp. and non-Lactobacillus BCS. The direction 
and magnitude that each BCS activated or repressed genes and pathways suggest that 
the effects of BCS exposure are mainly mediated through modulation of immune and 
cell cycle pathways (Figure 4.2). Interestingly, all three Lactobacillus supernatants 
showed at least mild activation of immune response pathways at 4h BCS exposure, 
but L. iners maintained an activation of immune genes and pathways 13h after BCS 
exposure. L. crispatus and L. jensenii BCS exposure repressed cell cycle pathways 
whereas L. iners and G. vaginalis BCS were not as effective. These results suggest L. 
iners induces a host response more similar to that of G. vaginalis than other 
Lactobacillus spp. In line with this finding, L. iners did not induce high miR-193b 
expression in Aim1 which coincided with increased CCND1 protein expression. This 
highlights the importance of considering species, strains or specific metabolites when 
studying vaginal microbial species.  
The cell cycle is positively regulated in part by chromatin remodeling via 
HDAC4-mediated repression of CDKN1A [329]. In concordance with this, HDAC4 
and CDKN1A have opposing differential mRNA expression in L. crispatus and        
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L. jensenii BCS exposed cells, corresponding to the observed decreased cell cycle in 
Chapter 2. Furthermore, expression of ESR1, a target of miR-193b, was decreased in 
L. crispatus and L. jensenii BCS exposed cells, which may additionally desensitize 
cells to estrogen-mediated proliferation (Figure 4.2). An additional protective 
mechanism against C. trachomatis infection is supported by decreased EGFR 
transcript abundance mediated by of L. crispatus or L. jensenii BCS (Figure 4.2). 
Taken together, these findings suggest that through decreased epithelial cell 
proliferation and miRNA-mediated regulation after exposure to L. crispatus, L. 
jensenii, and to a lesser extent L. iners, the vaginal microbiota protects the vaginal 
epithelium against STI such as C. trachomatis. Decreasing cell proliferation can be 
achieved potentially though Lactobacillus probiotics, lactic acid, or directly through 
HDAC inhibitors. These results highlight the need to better understand the host 
response to microbiota, as potential therapeutics including lactate, probiotics or 
HDAC inhibitors could be repurposed for novel prevention or treatment methods of 




Appendix 1 Steven Smith’s contributions to thesis  
Chapter 1 
- Subsection 1 is a published review in the Journal of Physiology (2017). I 
performed secondary research for this review, and Jacques and I wrote the 
manuscript (May 2015 – October 205). I created Figure 1.4 as part of the 
review’s abstract figure. 
- I performed research for the content in the sections on miRNA 
biogenesis/mechanism, RNA challenges and bioinformatic/computational 
approaches. I created all remaining figures in this chapter (Figure 1.3, Figure 
1.5, Figure 1.6). 
Chapter 2 
- I designed and executed the project, experiments and analyses, and wrote the 
chapter that is currently under review as a manuscript submitted to mBio 
(2017). Specifically: 
o I optimized the total RNA extraction protocol from archived vaginal 
swabs to achieve consistent yield and optimal RINe quality metrics 
(October 2013 – November 2014).  
o I evaluated and identified a small RNA-seq library construction 
method to achieve consistent libraries containing reduced adapter-
dimer formation (November 2013-April 2015) 
o I extracted over 130 vaginal swab samples and constructed over 113 
small RNA-seq libraries (May 2015- July 2016). 
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o I designed and built a bioinformatic pipeline to trim and QC reads, 
align reads to references, and count overlaps (January 2015 –April 
2015).  
o I designed, built and executed a computational pipeline to preform QC, 
and implement the Random Forest algorithm to analyze the small 
RNA-seq data (April 2015 – December 2015). 
o I cultured vaginal bacteria involved in all bacterial culture supernatant 
experiments (April 2016 – April 2017).  
o I cultured and maintained vaginal epithelial VK2 cells for in vitro 
experiments (April 2016 – April 2017). 
o I designed, optimized and executed VK2 culture experiments 
including the VK2 BCS exposure time-course miR-qPCR, VK2 cell 
BCS exposure scratch/proliferation assay and VK2 cell lactic acid 
exposure miR-qPCR/scratch assay (May 2016 – April 2017).  
o I designed, optimized and executed the BCS exposed VK2 Western 
blot for CCND1 and ß-actin (December 2016 – March 2017). 
o I generated all figures and tables within the chapter. 
o I extracted approximately 2,000 vaginal swabs for 16S rRNA gene 
sequencing, with assistance from Bilal Iqbal and Latey Bradford (June 
2013 – September 2016). 
o I executed Pawel Gajer and Johanna Holm’s “Pecan”/MCMC-based 
16S rRNA metataxonomic pipeline to classify reads to taxonomy 
(May 2016 – October 2016). 
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- Parts where I had assistance:  
o The Institute for Genome Science Genome Resource Center sequenced 
small RNA-seq libraries.  
o Pawel Gajer initially created the “subject-specific” Random Forest 
script. I modified it to include permuted Random Forest 
implementation.  
o Vonetta Edwards designed and executed C. trachomatis infection 
experiments and analyses. She also edited the manuscript. 
o Michael Humphrys tracked and coordinated 16S rRNA sequencing 
samples.  
o Larry Forney and Patrik Bavoil contributed to interpretation of the data 
and edited the manuscript. 
o Jacques conceived the project and experiments and helped me analyze 




- I designed and executed the project, experiments and analyses, and wrote the 
chapter that will be shortly converted into a manuscript. Specifically: 
o I cultured vaginal bacteria involved in all bacterial culture supernatant 
experiments (November 2016 – February 2017). 
o I grew VK2 epithelial cells for 4h, 13h and 22h in triplicate exposed to 
BCS (November 2016 – February 2017). 
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o I extracted total RNA from 45 samples of VK2 cells exposure to BCS 
(February 2017). 
o I constructed 44 rRNA-reduced RNA-seq libraries (February 2017). 
o I designed, built and executed a bioinformatic pipeline to trim and QC 
the reads, align to reference and count overlaps (April 2015 – 
December 2015).  
o I designed, built and executed a computational pipeline to preform QC, 
differential expression and pathway enrichment analysis (March 
2017). 
o I generated all figures and tables within the chapter. 
- Parts where I had assistance:  
o The Institute for Genome Science Genome Resource Center sequenced 
rRNA-reduced RNA-seq libraries.  
o Jacques conceived the project and experiments and helped me analyze 
and interpret the data. He also helped write thesis chapter. 
Chapter 4 









## This script runs RF k-fold cross validation on the subject level 
## Subject-specific implementation written by Pawel Gajer, updated 7/13/16, and 







rfSubjectSpecific <- function(X, y, subjID, nfolds=10, verbose=FALSE,nrep=100, 
permute=TRUE,... ) 
   
  ## Arguments: 
  ## X      - predictors; data frame or matrix 
  ## y      - response; vector of the samle length as nrow(X) 
  ## subjID - vector of length nrow(X) with subject assignment to each sample (used 
in ) 
  ## nfolds - number of folds 
  ## nrep   - number of permutations (ignored if permute=FALSE) 
  ## permute- whether rfPermute() should be used instead of randomForest() 
  ## verbose -print progress/output 
  ## ... - parameters to pass to randomForest() or rfPermute() 
 
## Values: 
## - error:  list of differences between prediction and true values for 
##   regression and pred==true logical vectors for classification (one for each 
##   fold) 
## - rmse: root mean squared error 
## - nmse: normalized MSE = MSE/MSE(mean(y) as predictor) for regression and 
##   MSE/MSE(the highest frequency class as predictor ) for classification 
## - mae: mean absolute error 
## - nmae: normalized MAE 
## - cl.err: classification error = accuracy = sum(pred!=y)/length(y) 
 
{ 
  if(!is.numeric(y)){ ## Classification has 2 more importance metrics that regression 
does, plus one for each class 
    nMetrics<-2+length(unique(y)) 
  }else{ ## regression only has 2 RF metrics: IncNodPurity & IncMSE 
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    nMetrics<-2 
  } 
  n <- length(y) 
   
  if ( !is.numeric(y) && !is.factor(y) ) 
    stop("y should be either numeric or factor") 
   
  if ( !is.data.frame(X) && !is.matrix(X) ) 
    stop("X is neither data frame nor matrix") 
   
  if ( n!= nrow(X) ) 
    stop("n!= nrow(X)") 
   
  if ( n!= length(subjID) ) 
    stop("n!= length(subjID)") 
   
  if ( !is.numeric(nfolds) ) 
    stop("nfolds is not numeric") 
   
  if ( nfolds < 1 ) 
    stop("nfolds < 1") 
   
  if ( nfolds > n ) 
    stop("nfolds > n") 
   
  if ( length(y[is.na(y)]) > 0 ) 
  { 
    warning("y has some NAs; removing them and the corresponding rows of X and 
subjID") 
    idx <- !is.na(y) 
    y <- y[idx] 
    X <- X[idx,] 
    subjID <- subjID[idx] 
  } 
   
  subjID <- as.character(subjID) 
  uqSubjIDs <- unique(subjID) 
  nSubj <- length(uqSubjIDs) 
   
  if ( nfolds > nSubj ) 
  { 
    warning(paste("nfolds needs to be not greater than number of subjects. Changing it 
to number of subjects: ",nSubj, sep="")) 
    nfolds <- nSubj; 
  } 
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  sp <- split(1:n, list(factor(subjID))) # list with each entry being a 
  # vector of indices of y that 
  # correspond to the same subjID 
  # (used as the label of the list 
  # element) 
  y.mean <- 0 
  y.mostFr <- 0 
  if ( is.numeric(y) ) 
  { 
    y.mean <- mean(y) 
  } 
   
  ##     # The splitting of data is done on the subject level. In particular, if 
  ##     # nfolds is equal to the number of subjects, we get a jack-knife 
  ##     # leave-one-out CV. 
  ##     # Note that y does not have to be constant over subjects. 
   
  s0 <- split(sample(nSubj),rep(1:nfolds,length=nSubj)) # nfolds split of all subjects 
  ## Turning each element of s0 from vector of subject indices to vector of 
  ## sample indices corresponding to the given subjects 
  s <- list() 
  for ( i in seq(s0) ) 
  { 
    v <- uqSubjIDs[s0[[i]]] 
    s[[i]] <- as.vector(unlist(sp[v])) 
  } 
   
  x.null <- rep(y.mostFr, n) 
   
 
  error <- list()      # list of prediction errors: prediction - y 
  error.null <- list() # list of null model prediction errors: mean(y) - y; 
  imp_permute<-list() ## container for importance metrics for rfPermute 
  mdl<-list() 
  # mean(y) is predicted value for each coordinate - null 
  # model; I am returning error.null so we can test if the 
  # current model is significantly better than the null 
  # model - that is if the mean(abs(errors)) is 
  # significantly different from the 
  # mean(abs(null.errors)) 
   
  sampleIdx <- c()     # vector of sample indices from each run of cross validation, so 
we can match errors with samples 
  r2.loc <- numeric(nfolds) 
  r2.pearson.loc <- numeric(nfolds) 
  r2.spearman.loc <- numeric(nfolds) 
 132 
  rmse.loc <- numeric(nfolds) 
  nmse.loc <- numeric(nfolds) 
  mae.loc <- numeric(nfolds) 
  nmae.loc <- numeric(nfolds) 
  cl.err.loc <- numeric(nfolds) 
  ncl.err.loc <- numeric(nfolds) # normalized classification error 
  gError <- numeric(n) # "global" error array whose i-th entry is 1 is in the 10 fold CV 
the prediction of y[i] was correct 
  imp <- matrix(0, nrow=ncol(X), ncol=nMetrics) 
  importance_w_pval <- matrix(0, nrow=ncol(X), ncol=2*nMetrics) ##stores P vals 
and metrics, used in permutation 
  for (i in seq(nfolds)) 
  { 
    #i<-1 
    if ( verbose ) 
      print(paste(" i=",i, sep="")) 
    sampleIdx <- c(sampleIdx, s[[i]]) 
    trIdx <- setdiff(1:n, s[[i]]) 
            if(permute){ 
              print(paste0("Running CV fold ",i," out of ",nfolds ," using rfPermute")) 
              m.rf <- rfPermute( X[trIdx,], y[trIdx], importance=TRUE,nrep = nrep, ... ) ## 
returns rfPErmute object, which is radnomForest object with additional results 
              importance.i<-rp.importance(m.rf) ## includes p values calculated from 
rermutation model 
            }else{ 
              print(paste0("Running CV fold ",i," out of ",nfolds ," using randomForest 
(no NULL distirbutions will be generated)")) 
              m.rf <- randomForest( X[trIdx,], y[trIdx], importance=TRUE, ... ) 
              importance.i<-NULL 
            } 
            model.i<-m.rf ## saves the rf model object for iteration i 
     
    ##m.rf <- randomForest( X, y, subset=setdiff(1:n, s[[i]]), importance=TRUE, ... ) 
    ##m.rf <- randomForest( X, y, subset=setdiff(1:n, s[[i]]), importance=TRUE) 
    x <- predict(m.rf, newdata=X[s[[i]],], type="response") 
     
    if ( is.numeric(y) ) ## If regression 
    { 
      error[[i]] <- x - y[s[[i]]] 
      error.null[[i]] <- y.mean - y[s[[i]]] 
      rmse.loc[i] <- sqrt(mean( error[[i]]^2 )) 
      r2.loc[i] <- 100 * ( 1 - sum( error[[i]]^2 ) / sum( (x - y.mean)^2 ) ) # percentage of 
variance explained 
      r2.pearson.loc[i] <- 100*cor(x, y[s[[i]]])^2 
      r2.spearman.loc[i] <- 100*cor(x, y[s[[i]]], method="spearman")^2 
      nmse.loc[i] <- mean( error[[i]]^2 ) / mean( (x - y.mean)^2 ) 
 133 
      mae.loc[i] <- mean( abs( error[[i]] ) ) 
      nmae.loc[i] <- mean( abs( error[[i]] ) ) / mean( abs(x - y.mean) ) 
      imp <- imp + importance(m.rf) 
 
    } else { ## If classification 
      m <- length(s[[i]]) 
      error[[i]] <- as.character(x) != as.character(y[s[[i]]]) 
      error.null[[i]] <- as.character(x.null[1:m]) != as.character(y[s[[i]]]) 
      cl.err.loc[i] <- sum(error[[i]]) / m 
      ncl.err.loc[i] <- cl.err.loc[i] / ( sum(error.null[[i]]) / m ) # NOTE that this will be 
NaN when the denominator is 0 (null model has no errors for the given y[s[[i]]] 
      ##print(cbind(as.character(x),as.character(y[s[[i]]]))) 
      imp <- imp + importance(m.rf)#[,3:4] ##why were only the last 2 being used? 
      #head(importance(m.rf)) 
    } 
    gError[s[[i]]] <- as.integer(error[[i]]) 
    imp_permute[[i]]<-importance.i 
    mdl[[i]]<-model.i 
    if(permute){ 
      importance_w_pval<-importance_w_pval+rp.importance(m.rf) 
      head(importance_w_pval) 




    list(    #imp_permute=imp_permute, 
             importance_w_pval=importance_w_pval/nfolds, 
                  mdl=mdl, 
             error=error, 
       error.null=error.null, 
       sampleIdx=sampleIdx, 
       imp=imp/nfolds, 
       rmse=mean(rmse.loc), nmse=mean(nmse.loc), 
       mae=mean(mae.loc), nmae=mean(nmae.loc), 
       r2=mean(r2.loc), 
       r2.pearson=mean(r2.pearson.loc), 
       r2.spearman=mean(r2.spearman.loc), 
       gError=gError, 
       cl.err=cl.err.loc, 
       mean.cl.err=mean(cl.err.loc), 
       ncl.err=ncl.err.loc, 
       mean.ncl.err=mean(ncl.err.loc) 





## normalized accuracy and classification error for a two-class classification 
## problem 
 
## predVals <- pls.sPTB.v2.predict 
## trueVals <- sptb2.char.f 
 
normClErr <- function(predVals, trueVals) 
  ## predVals - predicted values 
  ## trueVals - true values 
{ 
  if ( length(trueVals) != length(predVals) ) 
  { 
    stop("ERROR: length(trueVals) != length(predVals)") 
  } 
   
  if ( !is.factor(trueVals) ) 
  { 
    trueVals <- factor(trueVals) 
  } 
   
  predVals <- factor(predVals, levels=levels(trueVals)) 
   
  nElts <- length(trueVals) 
   
  ## confusion matrix 
  cm <- table(predVals, trueVals) 
   
  ## accuracy 
  acc <- (cm[1,1] + cm[2,2])/ nElts 
   
  ## classification error 
  clErr <- (cm[1,2] + cm[2,1])/ nElts 
   
   
  ## accuracy of the naive classifier 
  tt <- table(trueVals) 
  i.mostFr <- which.max(tt)[[1]] 
  true.mostFr <- names(tt)[i.mostFr] 
   
  pred.null <- rep(true.mostFr, nElts) 
   
  ## confusion matrix for the null model 
  cm.null <- table(pred.null, trueVals) 
   
  ## accuracy of the null model 
  acc.null <- cm.null[1, i.mostFr] / nElts 
 135 
   
  ## classification error of the null model 
  if ( i.mostFr == 1 ) 
  { 
    clErr.null <- cm.null[1,2]/ nElts 
  } else { 
    clErr.null <- cm.null[1,1]/ nElts 
  } 
   
  ## normalized accuracy 
  norm.acc <- acc / acc.null 
   
  ## normalized classification error 
  norm.clErr <- clErr / clErr.null 
   
  print(paste("Accuracy:", acc)) 
  print(paste("Accuracy of the naive classifier:", acc.null)) 
  print(paste("Relative Accuracy:", norm.acc, " ## Should be way greater than 1")) 
  print(paste("Classification error:", clErr)) 
  print(paste("Classification error of the naive classifier:", clErr.null)) 
  print(paste("Relative Classification Error:", norm.clErr, " ## Should be very close to 
0")) 
   
  invisible(list(cm=cm, cm.null=cm.null, acc=acc, acc.null=acc.null, 
norm.acc=norm.acc, clErr=clErr, clErr.null=clErr.null, norm.clErr=norm.clErr)) 
} 
##-------------------------------------------- 























































## ##------ Wed May 31 23:50:58 2017 ------##	
# Clear enviornment variables, set root 	
rm(list=ls())	
	




## Supress warnings to make knit PDF shorter... but turn these back on since 






## Load libraries 	




## Note that some override/mask functions from others. Had to explicitly use 
	 138	
the "dplyr" package for all "select" statements	
library(reshape)	
library(ggbiplot)	
## Loading required package: ggplot2	
## Loading required package: plyr	
## 	
## Attaching package: 'plyr'	
## The following objects are masked from 'package:reshape':	
## 	
##     rename, round_any	
## Loading required package: scales	






## Loading required package: limma	
library(Biobase)	
## Loading required package: BiocGenerics	
## Loading required package: parallel	
## 	
## Attaching package: 'BiocGenerics'	
## The following objects are masked from 'package:parallel':	
## 	
##     clusterApply, clusterApplyLB, clusterCall, clusterEvalQ,	
##     clusterExport, clusterMap, parApply, parCapply, parLapply,	
##     parLapplyLB, parRapply, parSapply, parSapplyLB	
## The following object is masked from 'package:limma':	
## 	
##     plotMA	
## The following object is masked from 'package:gridExtra':	
## 	
##     combine	
## The following objects are masked from 'package:stats':	
## 	
##     IQR, mad, xtabs	
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## The following objects are masked from 'package:base':	
## 	
##     anyDuplicated, append, as.data.frame, cbind, colnames,	
##     do.call, duplicated, eval, evalq, Filter, Find, get, grep,	
##     grepl, intersect, is.unsorted, lapply, lengths, Map, mapply,	
##     match, mget, order, paste, pmax, pmax.int, pmin, pmin.int,	
##     Position, rank, rbind, Reduce, rownames, sapply, setdiff,	
##     sort, table, tapply, union, unique, unsplit, which, which.max,	
##     which.min	
## Welcome to Bioconductor	
## 	
##     Vignettes contain introductory material; view with	
##     'browseVignettes()'. To cite Bioconductor, see	




## Attaching package: 'psych'	
## The following objects are masked from 'package:scales':	
## 	
##     alpha, rescale	
## The following objects are masked from 'package:ggplot2':	
## 	
##     %+%, alpha	
library(randomForest) 	
## randomForest 4.6-12	
## Type rfNews() to see new features/changes/bug fixes.	
## 	
## Attaching package: 'randomForest'	
## The following object is masked from 'package:psych':	
## 	
##     outlier	
## The following object is masked from 'package:Biobase':	
## 	
##     combine	
## The following object is masked from 'package:BiocGenerics':	
## 	
##     combine	
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## The following object is masked from 'package:gridExtra':	
## 	
##     combine	
## The following object is masked from 'package:ggplot2':	
## 	
##     margin	
library(rfPermute)	
library(tidyverse)	
## Loading tidyverse: tibble	
## Loading tidyverse: tidyr	
## Loading tidyverse: readr	
## Loading tidyverse: purrr	
## Loading tidyverse: dplyr	
## Conflicts with tidy packages ---------------------------------------------
-	
## %+%():        ggplot2, psych	
## alpha():      ggplot2, psych, scales	
## arrange():    dplyr, plyr	
## col_factor(): readr, scales	
## combine():    dplyr, randomForest, Biobase, BiocGenerics, gridExtra	
## compact():    purrr, plyr	
## count():      dplyr, plyr	
## discard():    purrr, scales	
## expand():     tidyr, reshape	
## failwith():   dplyr, plyr	
## filter():     dplyr, stats	
## id():         dplyr, plyr	
## lag():        dplyr, stats	
## margin():     ggplot2, randomForest	
## mutate():     dplyr, plyr	
## Position():   ggplot2, BiocGenerics, base	
## rename():     dplyr, plyr, reshape	
## summarise():  dplyr, plyr	





## Attaching package: 'plotly'	
## The following objects are masked from 'package:plyr':	
## 	
##     arrange, mutate, rename, summarise	
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## The following object is masked from 'package:ggplot2':	
## 	
##     last_plot	
## The following object is masked from 'package:reshape':	
## 	
##     rename	
## The following object is masked from 'package:stats':	
## 	
##     filter	
## The following object is masked from 'package:graphics':	
## 	




## Attaching package: 'nlme'	
## The following object is masked from 'package:dplyr':	
## 	
##     collapse	
library(caret)	
## Loading required package: lattice	
## 	
## Attaching package: 'caret'	
## The following object is masked from 'package:purrr':	
## 	
##     lift	
## The following object is masked from 'package:rfPermute':	
## 	
##     confusionMatrix	
library(gplots)	
## 	
## Attaching package: 'gplots'	
## The following object is masked from 'package:squash':	
## 	
##     bluered	
## The following object is masked from 'package:stats':	
## 	
##     lowess	
	 142	
## Source the Random Forest wrapper script	
source(paste0(root_directory,"Scripts/rfSubjectSpecific.R"))	
	
## Set output directories for tables, figures and data structures. 	
if(!dir.exists(file.path(root_directory, "Figures"))){	
  dir.create(file.path(root_directory, "Figures"))  	
}	
if(!dir.exists(file.path(root_directory, "Tables"))){	
  dir.create(file.path(root_directory, "Tables"))  	
}	
if(!dir.exists(file.path(root_directory, "Script_output"))){	




R_script_input_directory<-paste0(root_directory,"Script_input/") ## Contains 





seed_val<-4543 ## Needed for exact results obtained in thesis	
pval_threshold<-0.05 ## Signifgance value threshold	
npermutes<-500 ## Number of permutations to generate emperical null 
distribution in RF models	
nfolds<-10 #Number of cross-fold validation in customized RF script	
training_prop<-0.7 ## Proportion of input data for use in training models	
nSpecies<-9 ## Max # of species to plot in Fig 1	
sizes<-1 ## Default sizes for plots	
raThreshold <-0.02 ## Min relative abundance threshold to plot in Fig 1	
margins<-unit(c(-2.5,40,-2.5,5),units="points") ## Default margins for plots	
ph_normalization_factor<-3 ## rescales y axis so that plot doesn't bein at 0	
alpha_rect<-0.7 ## Fig 1 greyed out rectangle opacity	
rect_fill<-"grey" ## Fig 1 greyed out color	
removed_samples<-data.frame(Pre_QC_ID=NULL,QC_removal_stage=NULL)## Keep a 
list of removed samples, and the stage of removal	
	
## Set global plot theme	
mBio <- theme_bw() + theme(text = element_text(family = "Arial", colour = 
"black",size=12))	
	
## Set standardized color table	
load(file=paste0(R_script_input_directory,"subject_long_taxa_colors.Rdata"))	
color_scheme_BCS<- c("L. crispatus"= 
unname(subject_long_taxa_colors["Lactobacillus_crispatus"]),	
                     "L. jensenii" = 
unname(subject_long_taxa_colors["Lactobacillus_jensenii"]),	
                     "L. iners" = 
unname(subject_long_taxa_colors["Lactobacillus_iners"]),	
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                     "G. vaginalis" = 
unname(subject_long_taxa_colors["Gardnerella_vaginalis"]),	
                     "Cell Culture Medium"='blue'	
) #c("L. crispatus"='red1',"G. vaginalis"='lightseagreen',"L. 
iners"='orange',"Cell Culture Medium"='blue',"L. jensenii"='#8c510a')	
	
cst.colors<-c("I-A"="red1",	
              "I-B"="#990000",	
              "I" = 
unname(subject_long_taxa_colors["Lactobacillus_crispatus"]),	
              "II"=unname(subject_long_taxa_colors["Lactobacillus_gasseri"]),	
              "III-A"="darkorange" ,	
              "III-B"="#cc7a00" ,	
              "III"=unname(subject_long_taxa_colors["Lactobacillus_iners"]),	
              "IV-A"="lightseagreen",	
              "IV-B"="mediumblue",	
              "V"=unname(subject_long_taxa_colors["Lactobacillus_jensenii"]),	
              "DUMMY"='grey'	
)	
	
























































## SRL_meta and SRL_counts were prepared in separate script- 	
load(file=paste0(R_script_input_directory,"SRL_counts_meta.RData"))	
	












## Adds samples in sample_list to running removed_samples data.frame. Tracks 
the reaon for removal	
remove_poorQC_samples<-function(removed_samples=removed_samples,	
                                sample_list=c(""),	


















## Plots PCA and calcualtes gPCA-based p value. Outputs a list with PCA plot 
object and p value (if plotly=F). Otherwise, just a plotly plot object 	
	
plot_pca<-function(ES, ## Expression Set object	
                   plot_title="", ## Title for PCA plot	
                   center=TRUE, ## pcrcomp centering?	
                   scale=TRUE, ##prcomp scaling?	
                   color_by='SID', ## What to color plots by	
                   logt=TRUE, #Whether counts in ES should be log transformed	
                   obs.scale = 1, ##prcomp scale factor	
                   var.scale = 1, ##prcomp var scaling	
                   ellipse = FALSE, ## draw ellipse around groups in PCA plot	
                   circle = FALSE, ## or circle	
                   var.axes=FALSE, ##option for prcomp	
                   ploly=FALSE, ##whether to generate a ploty interactive 
plot. This option will not return gPCA p value	
                   margins=unit(c(0,0,0,0),units = "points"),	
                   seed_val=4543, ## seed needed for gPCA	
                   ...){ 	
  	
  ## es = ExpressionSet object  	
  ## ** Assumes ES counts data is log transformed. Set logt=FALSE to logt 
data first. 	
  ## **Assumes columns named "Batch", "SID" ,"BVGroup" and "NUGENT_CLASS" 
exist in pData in ES. 	
  	
  set.seed(seed_val) ## Repeatable results in Guided PCA	
  ##calcualte variance of counts	
  variable_counts<-t(exprs(ES))[,apply(t(exprs(ES)), 2, var, na.rm=TRUE) != 
0]	
  	
  ## log transform data if needed	
  if(logt){	
    cnts <- log(variable_counts+1,base = 2)	
  }else{	
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    cnts<-variable_counts	
  }	
  	
  ## extract metadata from ES to decorate tree. Assumes these variables are 
present	
  batch <- as.numeric(pData(ES)[, 'Batch']) 	
  sid<-pData(ES)[, 'SID']	
  bvgroup<-pData(ES)[,'BVGroup']	
  bvclass<-pData(ES)[,'NUGENT_CLASS']	
  ##color mappings for different metadata	
  if(color_by=="SID"){	
    group<-as.character(sid)	
    group.gpca<-as.numeric(as.factor(group))	
  }else if(color_by=="Batch"){	
    group<-as.character(batch)	
    group.gpca<-batch	
  }else if (color_by=="NugentC"){	
    group<-as.character(bvclass)	
    group.gpca<-as.numeric(as.factor(group))	
  }	
  else{	
    group<-as.character(bvgroup)	




  counts.pca <- prcomp(cnts,center = center, scale. = scale) 	
  	
  #PCA plot	
  pca.p <- ggbiplot(counts.pca, groups = group, 	
                    obs.scale = obs.scale, var.scale = var.scale , 	
                    ellipse = ellipse, 	
                    circle = circle,var.axes =var.axes, ...)	
  pca.p <- pca.p + 	
    scale_color_discrete(name = '')+	
    mBio+	




  ##Optional plotly functionality... returns a list with plot object in an 















## Function to subset ExpressionSet objects based on vector of sample/rows 
names to remove. Returns an expression set without filterout samples	
	
subset_ExpressionSet<-function(expSet, ##expression set	
                               filterOut=c(""), ##vector of samples to drop 
from expSet	
                               samples=TRUE){ ## filter samples names or row 
names	
  	
  ## Drop sample (columns) from expSet	
  if(samples){	
    ## Remove count data in filterOut vector	
    counts_meta<-exprs(expSet)[,!colnames(exprs(expSet)) %in% filterOut]	
    ## Remove metadata in filterOut vector	
    design.subset<-pData(expSet)[!row.names(pData(expSet)) %in% filterOut,]	
    ## Return a re-packaged filtered count and metadata into ExpressionSet	
  }	
  else{## Drop miRNAs (rows) from expSet	
    counts_meta<-exprs(expSet)[!row.names(exprs(expSet)) %in% filterOut,]	
    design.subset<-pData(expSet)[,!colnames(pData(expSet)) %in% filterOut]	
    	
  }	
  return(ExpressionSet(assayData = as.matrix(counts_meta),	











## Generates predicted vs acutal tables and plots the predicted vs actual 
values on plot	
	
plot_accuracy<-function(rfp, ## Random Forest object	
                        testing_fullset, ## vector of sample names that were 
held out of training/used for testing	
                        
index_of_response=match("NUGENT_SCORE",names(testing_fullset)), ## index 
corresponding to response variable in input data	
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                        index_of_sid=match("SID",names(testing_fullset)),## 
index corresponding to subject ID in input data (if subj_spec=T)	
                        subj_spec=TRUE, ## whether RF was run with 
'subject_spec' option	




  accuracy_table<-data.frame(fold=0,predicted=0,actual=0) ## hold values for 
actual, predicted values	
  	
  ## Subject specific rfp have a model for each cross fold, so need to loop 
through and aggregate each fold	
  if(subj_spec){	
    	
    for(m in 1:nfold){	
      #m<-1	
      ## Compare predicted to hold out set	
      p1<-predict(rfp$mdl[[m]], 	
                  testing_fullset[,-c(index_of_response,index_of_sid)], 
type='response')	
      	
      accuracy_table<-
rbind(accuracy_table,data.frame(fold=m,predicted=p1,actual=testing_fullset[,i
ndex_of_response]))	
    }	
  }else{	
    p1<-predict(rfp,testing_fullset[,-c(index_of_response,index_of_sid)], 
type='response')	










    ggtitle("Predicted vs Actual Values from plot_accuracy")+	
    mBio+	
    scale_x_continuous(limits=c(0,10),breaks = 1:10)+	
















## Wrapper to run Random Forest model building. Can run RandomForest, 
rfPermute or rfSubjectSpecific. Takes care of subsetting data for 
training/testing and outputting accuracy/error/etc etstimates. Saves/loads 
previous models. 	
#Note if load_prev=T, most of the parameters are ignored	
run_randomForest<-function(predictors_response_table,	
                           response_variable_name,	
                           nfold=10,	
                           nreps=105,	
                           permute=TRUE,	
                           save_model=FALSE,	
                           load_prev_model=TRUE,	
                           file_n="rf_model",	
                           verbose=TRUE,	
                           pval_thres=pval_threshold,	
                           subj_spec=TRUE,	
                           importance_thres=10,	
                           training_prop=0.7,	
                           seed=seed_val,	
                           R_script_output_directory,	
                           ...)	
{	
  	
  # predictors_response_table - data frame of predictors + response variable. 
If it contains a column called 'SID', sets subj_spec=TRUE	
  # response_variable_name    - column name as string of response variable 
(as found in predictors_response_table)	
  # nfold                     - number of k-fold validations to run	
  # nreps                     - number of permutations to run to compute null 
distribution. Ignored if permute=FALSE	
  # permute                   - whether or not to run rfPermute (generate 
null distribution permutation p-values for each feature)	
  # save_model                - save model as Rdata to outout directory? Uses 
'file_n' as file name	
  # load_prev_model           - load model outout directory? Uses 'file_n' as 
file name	
  # file_n                    - file name to use when reading or writing a 
model to disk	
  # verbose                   - detailed output of model results, etc	
  # pval_thres                -p value threshold to call signifigant 	
  # subj_spec                 - whether or not to run rfSubjectSpecific.R. 
Looks for a column called 'SID' in predictors_response_table	
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  # importance_thres          -	
  #training_prop              - proportion of input data to use as training. 
remaining is used as hold out set for testing	
  # seed                      -seed value to produce repeatable results	





  ## First major control point: loading from previously saved model, or 
generating a new trained model? 	
  	
  #### ///////	
  # Start New Model	
  #### //////	
  	
  if(!load_prev_model){	
    	
    #Find the column index corresponding to response & subject ID	
    index_of_response<-
match(response_variable_name,names(predictors_response_table))	
    index_of_sid<-match("SID",names(predictors_response_table))	
    if(is.na(index_of_sid) & subj_spec){	
      print("SID could not be found. Setting to non-subject specific")	
      subj_spec<-FALSE	
      index_of_sid<-0	
    }else if (is.na(index_of_sid)){	
      index_of_sid<-0	
    } else if(index_of_sid>0 & !subj_spec){	
      print("Found a SID column. Setting to subject-spefic. ")	
      subj_spec<-TRUE	
    }	
    	
    #Partition input data into training and testing	
    	
    inTrain<-
createDataPartition(y=predictors_response_table[,index_of_response],p 
=training_prop,list = F)	
    if(is.character(predictors_response_table[,index_of_response])){	
      predictors_response_table[,index_of_response]<-
as.factor(predictors_response_table[,index_of_response])	
    }	
    	
    ##Subjet training and testing data	
    training_fullset<-predictors_response_table[inTrain,]	
    testing_fullset<-predictors_response_table[-inTrain,]	
    table(predictors_response_table[,index_of_response])	
    table(training_fullset[,index_of_response])	
    table(testing_fullset[,index_of_response])	
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    response<-training_fullset[,index_of_response]	
    	
    # Determine whether to run classification or regression depending on 
response variable type	
    if(is.numeric(predictors_response_table[,index_of_response])){# 
regression	
      rf_type<-"regression"	
    }else{	
      rf_type<-"classification"	
    }	
    	
    #Determine whether to run rfSubjectSpecific.R	
    if(subj_spec){	
      print(paste0("Starting subject-specific rfSubjectSpecific with permute 
set to : ",permute))	
      rfp<-rfSubjectSpecific(training_fullset[,-
c(index_of_response,index_of_sid)],response,subjID = 
as.character(training_fullset[,index_of_sid],nrep=nrep),nfolds = 
nfold,verbose=verbose,nrep = nreps,permute=permute) ## This will be sourced 
at the setup section. It is an external script.	
    }else{	
      print("Starting non subject-specific rfPermute")	
      rfp<-rfPermute(training_fullset[,-c(index_of_response)],response,nrep = 
nreps,...)	
    }	
    	
    ## The accuracy, etc output varies depending on whether which combination 
of RF were run	
    	
    ## /////	
    ## Regression + Subject-Specific	
    ## ////	
    	
    if(rf_type=="regression" & subj_spec){ ## If it's a regression model	
      accuracy_table<-plot_accuracy(rfp,testing_fullset = 
testing_fullset,index_of_response = index_of_response, index_of_sid = 
index_of_sid,subj_spec = subj_spec,nfold = nfold) ## see above for this 
function	
      	
      ## /////	
      ## Classification + Non Subject-Specific	
      ## ////	
      	
    }else if (rf_type=="classification" & !subj_spec){	
      p1<-predict(rfp, testing_fullset[,-c(index_of_response,index_of_sid)], 
subj_spec = subj_spec,type='response')	
      (accuracy_table<-
table(Var1=p1,Var2=testing_fullset[,index_of_response]))	
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      ## /////	
      ## Classification + Subject-Specific	
      ## ////	
      	
    }else if (rf_type=="classification" & subj_spec){	
      p1<-predict(rfp$mdl, testing_fullset[,-
c(index_of_response,index_of_sid)], subj_spec = subj_spec,type='response')	
      (accuracy_table<-lapply(p1, function(x) 
table(x,testing_fullset[,c(index_of_response)])))	
      	
      ## /////	
      ## All else (Regression + Non Subject-Specific)	
      ## ////	
      	
    }else{	
      accuracy_table<-NULL	
    }	
    	
    ## Write model to file + accuracy table and training/testing info	
    	
    if(save_model){	
      save(rfp,file=paste0(R_script_output_directory,file_n,".RData"))	
      
save(accuracy_table,file=paste0(R_script_output_directory,file_n,"_accuracyTa
ble.RData"))	
      training_testing<-
list(training_fullset=training_fullset,testing_fullset=testing_fullset)	
      
save(training_testing,file=paste0(R_script_output_directory,file_n,"_training
_testing.RData"))	
    }	
    	
    #### ///////	
    # Load Previous Model	
    #### //////	
  }else{	
    	
    rfp.pointer<-load(file=paste0(R_script_output_directory,file_n,".RData"))	
    rfp<-get(rfp.pointer)	
    	
    accuracy_table.pointer<-
load(file=paste0(R_script_output_directory,file_n,"_accuracyTable.RData"))	
    accuracy_table<-get(accuracy_table.pointer)	
    	
    training_testing.pointer<-
load(file=paste0(R_script_output_directory,file_n,"_training_testing.RData"))	
    training_testing<-get(training_testing.pointer)	
    training_fullset<-training_testing$training_fullset	




    print(rfp)	
    print(rfp$mdl)	
  }	
  	
  if(permute & subj_spec){	
    importance<-data.frame(rfp$importance) ##only happens if 
rfSubjectSpecific is run with permute	
    importance.pval<-dplyr::select(importance,ends_with("pval"))	
  }else{	
    if(!subj_spec){	
      importance<-data.frame(rp.importance(rfp))	
    }else{	
      importance<-data.frame(rfp$imp)	
    }	
  }	
  return(list(rfp=rfp, ##model	
              accuracy_table=accuracy_table,	
              importance=importance,	
              training_ids=row.names(training_fullset),	












## Is there an effect due to RIN and number of reads miRNAs?	
### # Wrapper for plot of reads miRNAs vs RIN	
	
plot_RIN_meta<-function(SRL_meta_table, ## Table containing SRL metadata	
                        y_series="reads_surviving.percent", ## y axis column 
name to be plotted	
                        col_by="Batch", ## color by	
                        vjust = 0,  ## vertical justification	
                        nudge_y = 0.05, ## nudge y by...	
                        angle = 0, ## y axis angle	
                        hjust = 0, ## hortizontal adjustment	
                        nudge_x = 0.05, ## nudge x by..	
                        check_overlap = FALSE, ## check for points overlap- 
try to minimize	
                        y_series_label=y_series # y label on plot	
){	
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    geom_point()+	
    ylab(y_series_label)+	
    xlab("RINe")+	
    # ggtitle(paste(y_series," vs RIN"))+	
    geom_text(check_overlap = check_overlap,vjust = vjust, nudge_y = 
nudge_y,angle = angle,hjust = hjust, nudge_x = nudge_x)+	
    mBio+	












## Generate simple mapping stats given an Expression Set pData object	
mapping_stats<-function(column=pData(counts_meta.qc)$number_reads_mirs){	













## Plot RF Importance variables. Output is a plot	
	
plot_importance<-function(importance_df=Nugent_RF$importance, ## Data frame 
holding importance results	
                          
ntopfeats=length(Nugent_RF$top_features$top_features.all), ## number of 
features to plot	
                          nfeats=25,#max # of features to plot	
                          rankBy="IncMSE", ## Importance variable to rank by	
                          model_name="",	
                          size_font=12,	
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                          size_points=5	
){	
  if(nfeats<ntopfeats){	
    stop("Number of top features less than total # of features plotted")	
  }	
  names(importance_df)<-gsub(pattern = "X\\.",replacement  = "",x = 
names(importance_df))	
  importance_df<-importance_df[order(importance_df[,rankBy],decreasing = T),]	
  importance_df.cut<-importance_df[1:nfeats,]	
  importance_df.cut$features<-factor(row.names(importance_df.cut),levels = 
rev(row.names(importance_df.cut)),ordered = T)	
  	
  importance_df.cut.tmp<-separate(melt(importance_df.cut,id.vars = 





  importance_df.cut<-spread(data=importance_df.cut.tmp,key = SUFFIX,value = 
value)	
  cutoff<-nfeats+0.5-ntopfeats 	
  	
  ggplot(importance_df.cut)+	
    geom_point(aes(y=features,x=metric_val,col=-
log(pval,10),pch=metric),size=size_points)+    	
    xlab("Importance Metric")+	
    ylab("Predictor")+	
    scale_colour_gradient(high="red", low="blue",guide = guide_legend(title = 
"-Log(p-value)"))+	
    mBio+	
    theme(text=element_text(size = size_font),panel.border = 
element_rect(size=1))+	













## A t test using sumamry statistics ( and not the entire sample dataset as 
with t.test)	
## Returns p value, difference of means, standard error and t statistc	
t.test2 <- function(m1, ## mean of sample set 1	
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                    m2, ## mean of sample set 2	
                    s1, ## standard dev of sample set 1	
                    s2, ## standard dev of sample set 2	
                    n1, ## number of samples in sample set 1	
                    n2, ## number of samples in sample set 1	
                    m0=0, ## the null for hypothesis to test (mean value)=	




  if( equal.variance==FALSE ) 	
  {	
    ## "normalize" standard deviations if unequal variance to compute 
standard error	
    se <- sqrt( (s1^2/n1) + (s2^2/n2) )	
    # welch-satterthwaite df	
    df <- ( (s1^2/n1 + s2^2/n2)^2 )/( (s1^2/n1)^2/(n1-1) + (s2^2/n2)^2/(n2-1) 
)	
  } else	
  {	
    # pooled standard deviation, scaled by the sample sizes	
    se <- sqrt( (1/n1 + 1/n2) * ((n1-1)*s1^2 + (n2-1)*s2^2)/(n1+n2-2) )	
    	
    df <- n1+n2-2	
  }      	
  t <- (m1-m2-m0)/se## calcualte t statistic	
  dat <- c(m1-m2, se, t, 2*pt(-abs(t),df))    ## calculate p value based on 
Student's t distribution	
  names(dat) <- c("Difference of means", "Std Error", "t", "p-value")	
















  ## Loop through each test comparison and apply stat test. Store in 
dataframe	
  for(sigtest in 1:nrow(sigtest_results)){	
    print(sigtest)	
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    #sigtest<-1	
    x1<-as.character(sigtest_results[sigtest,"xref"]) 	
    y1<-as.character(sigtest_results[sigtest,"reference"])	
    	
    ## Apply a t test to x1 vs y1	
    if(test_function=="t.test"){	
      tes<-t.test(x=filter(summary_stats,BCS==x1 
)$percent_cells,y=filter(summary_stats,BCS==y1)$percent_cells,alternative = 
"two.sided") 	
      delta_mean<-tes$estimate[2]-tes$estimate[1]	
      pval<-tes$p.value	
    }else if(test_function=="t.test2"){	
      obs<-as.character(sigtest_results[sigtest,"Observation"])	
      m1<-filter(summary_stats,Observation==obs & Treatment==x1 )$grand_mean	
      m2<-filter(summary_stats,Observation==obs & Treatment==y1 )$grand_mean	
      s1<-filter(summary_stats,Observation==obs & Treatment==x1 )$grand_sd	
      s2<-filter(summary_stats,Observation==obs & Treatment==y1 )$grand_sd	
      n1<-filter(summary_stats,Observation==obs & Treatment==x1 )$n	
      n2<-filter(summary_stats,Observation==obs & Treatment==y1 )$n	
      print(obs)	
      tes<-t.test2(m1 = m1,s1 = s1, m2=m2,s2=s2,n1=n1,n2=n2) #less	
      print(tes)	
      delta_mean<-tes["Difference of means"]	
      pval<-tes["p-value"]	
      	
      	
    }else{	
      print(paste0(test_function," not found"))	
    }	
    	
    ## Store p value and difference of means	
    sigtest_results[sigtest,"pval"]<-pval	
    sigtest_results[sigtest,"mean_diff"]<-delta_mean	
  }	
  	
















setup_sigtest<-function(pval_threshold = pval_threshold,raw_data = 
raw_data,test_function = "t.test",Experiment="Scratch"){	
  ## Set up a significance test df to store inference testing data	
  if(Experiment=="Scratch"){	
    sigtest<-data.frame(xref=c(rep("L. crispatus",times=4),rep("L. 
jensenii",times=3),rep("L. iners",times=2),"G. vaginalis"),reference=c("L. 
jensenii","L. iners","G. vaginalis","Cell Culture Medium","L. iners","G. 
vaginalis","Cell Culture Medium","G. vaginalis","Cell Culture Medium","Cell 
Culture Medium"))	
    	
    ## Factor labels	
    sigtest$xref<-factor(sigtest$xref,levels =c("L. crispatus","L. 
jensenii","L. iners","G. vaginalis","Cell Culture Medium"),ordered = T)	
    sigtest$reference<-factor(sigtest$reference,levels = c("L. jensenii","L. 
iners","G. vaginalis","Cell Culture Medium"),ordered = T)	
    	
    sigtest<-apply_ttest(sigtest_results = sigtest,pval_threshold = 
pval_threshold,summary_stats = raw_data,test_function = "t.test")	
    ## Summarize scratch assay data with mean and sd	
    summary_stats<-
ddply(dplyr::select(raw_data,c(BCS,percent_cells)),c("BCS"),summarise,mean=me
an(percent_cells),sd=sd(percent_cells))	
    	
  }else if(Experiment=="Infection"){	
    	




Culture Medium","Cell Culture Medium"))	
    	
    sigtest$xref<-factor(sigtest$xref,ordered = T,levels = c("CAS 546102-60-
7","Fascaplysin"))	
    sigtest$reference<-factor(sigtest$reference,ordered = T,levels = 
c("Fascaplysin","Cell Culture Medium"))	
    	
    	
    raw_data.spread<-spread(raw_data,key = Observation,value = percent_cells)	
    
plot(raw_data.spread$Infectivity,raw_data.spread$Proliferation,col=raw_data.s
pread$Treatment)	
    	
    summary_stats.pre<-
ddply(raw_data,c("Observation","Treatment","Coverslip"),summarise,mean=mean(p
ercent_cells,na.rm = T),sd=sd(percent_cells,na.rm = T))	
    	




    	
    for(obs in c("Infectivity","Proliferation")){	
      for(treat in unique(summary_stats$Treatment)){	
        #treat<-"Control"	
        gm<-summary_stats[summary_stats$Observation==obs & 
summary_stats$Treatment==treat,"grand_mean"]	
        means<-summary_stats.pre[summary_stats.pre$Treatment==treat & 
summary_stats.pre$Observation==obs,"mean"]	
        n<- length(means[!is.na(means)])	
        summary_stats[summary_stats$Treatment==treat & 
summary_stats$Observation==obs,"grand_sd"]<-sqrt(sum((means-gm)^2,na.rm = 
T)/(n-1))	
        summary_stats[summary_stats$Observation==obs & 
summary_stats$Treatment==treat,"n"]<-n	
      }	
    }	
    	
    sigtest<-apply_ttest(sigtest_results = sigtest,pval_threshold = 
pval_threshold,summary_stats = summary_stats,test_function = "t.test2")	
    	
    	
  }else{	





                       x=as.numeric(sigtest$xref)+.05,	
                       xend=(as.numeric(sigtest$reference)+1)-.05)	
  if(Experiment=="Scratch"){	
    	
    statbars[statbars$reference=="Cell Culture Medium","y"]<-rep(seq(100,91,-
3),times=1)	
    statbars[statbars$reference=="G. vaginalis","y"]<-rep(seq(91,by=-
3,length.out = 3),times=1)	
    statbars[statbars$reference=="L. iners","y"]<-rep(c(85,94),times=1)	
    statbars[statbars$reference=="L. jensenii","y"]<-rep(94,times=1)	
    statbars[statbars$reference=="Cell Culture Medium" & statbars$xref=="L. 
iners","y"]<-85	
    statbars[statbars$reference=="G. vaginalis" & statbars$xref=="L. 
iners","y"]<-94	
    	
  }else if(Experiment=="Infection"){	
    	
    statbars[statbars$reference=="Cell Culture Medium","y"]<-rep(seq(100,97,-
3),times=2)	
    statbars[statbars$reference=="Fascaplysin","y"]<-rep(c(91,94),times=1)	
    statbars[statbars$reference=="CAS 546102-60-7","y"]<-rep(90,times=2)	
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    statbars[statbars$xref=="CAS 546102-60-7" 
&statbars$reference=="Fascaplysin" ,"y"] <-97	
    	
  }else{	






                        y=rep(statbars$y,times=2),	
                        yend=rep(statbars$y-1.5,times=1))	
  statbars2$xend<-statbars2$x	
  	

























    cnts<-log(exprs(eset)+1,base = 2)	
  }else{	
    cnts<-exprs(eset)	
  }	
  if(rmlow){	
    	
    cnts<-cnts[rowSums(cnts>lowcnt)==ncol(cnts),]	
  }	
  	
































##          min   median       max	
## trimmed 3225 27087178 107477660	
## hg19     607  4499861  17195821	
## miRNome  159  1102119   4642910	
Quality	Control	(QC)	small	RNA-seq	count	data	
print(paste("Number of samples in inital counts 
table:",ncol(SRL_counts_table)))	
## [1] "Number of samples in inital counts table: 113"	
print(paste("Number of miRNAs in inital counts 
table:",nrow(SRL_counts_table)))	
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## [1] "Number of miRNAs in inital counts table: 1869"	
## Determine number of miRNAs without any counts across all samples 	
missing<-rowSums(SRL_counts_table)==0 
#rowSums(is.na(SRL_counts_table))==ncol(SRL_counts_table) | 	
print(paste("Number of miRNAs without any counts across 
all",ncol(SRL_counts_table),"samples:",sum(missing)))	
## [1] "Number of miRNAs without any counts across all 113 samples: 323"	
print(paste0("which leaves ",100*(1-sum(missing)/nrow(SRL_counts_table))," 
percent of all annotated miRNAs with at least 1 read"))	
## [1] "which leaves 82.7180310326378 percent of all annotated miRNAs with at 
least 1 read"	




plot_QC.preQC.batch<-plot_pca(SRL_counts_meta,"Log miRNA Raw Count Distance, 






plot_QC.preQC.sid<-plot_pca(SRL_counts_meta,"Log miRNA Raw Count Distance, 













## Get a *ROUGH* idea of miRNA coverage by dividing counts by # of annotated 
miRNAs in genome 	
(number_mirs_genome<-nrow(SRL_counts_meta)) ## number of annotated miRNAs	
## Features 	
##     1869	




## Number of miRNAs completley removed due to non-detection	
nrow(SRL_counts_meta)	
## Features 	
##     1546	
(plot_QC.RIN.percent.batch<-
plot_RIN_meta(SRL_meta_table,"number_reads_mirs.percent_hgmapped",col_by="Bat
















= "Number of miRNA Reads"))	
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## Range of miRNA coverage based on simple reads/#annotated miRNAs	
print(summary(colSums(SRL_counts_table))/number_mirs_genome)	
##      Min.   1st Qu.    Median      Mean   3rd Qu.      Max. 	




##        Pre_QC_ID avg_coverage	
## 1      EM12_W5D2 5.821814e+02	
## 2      EM12_W5D3 8.298529e+02	
## 3      EM12_W5D4 5.437319e+02	
## 4      EM12_W5D5 1.258753e+03	
## 5      EM12_W5D6 5.969540e+02	
## 6    UAB003_W5D6 9.440787e+02	
## 7    UAB003_W6D1 6.720284e+02	
## 8    UAB003_W6D2 1.467211e+03	
## 9    UAB003_W6D3 2.817180e+02	
## 10   UAB003_W6D4 2.377742e+02	
## 11   UAB003_W6D5 3.938844e+02	
## 12   UAB003_W6D6 5.896838e+02	
## 13   UAB003_W6D7 6.799176e+02	
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## 14   UAB003_W7D1 6.317940e+02	
## 15   UAB003_W7D2 1.393483e+03	
## 16   UAB003_W7D3 1.065232e+03	
## 17   UAB003_W7D5 7.140310e+02	
## 18   UAB003_W7D6 2.752729e+02	
## 19   UAB003_W7D7 1.561850e+03	
## 20   UAB003_W8D1 5.939187e+02	
## 21   UAB003_W8D2 1.003773e+03	
## 22   UAB005_W4D7 1.816241e+03	
## 23   UAB005_W5D1 1.508920e+03	
## 24   UAB005_W5D2 1.676461e+03	
## 25   UAB005_W5D3 2.577314e+01	
## 26   UAB005_W5D4 1.974515e+03	
## 27   UAB005_W5D5 2.484168e+03	
## 28   UAB006_W3D1 5.126613e+02	
## 29   UAB006_W3D3 1.242925e+03	
## 30   UAB006_W3D4 3.796479e+02	
## 31   UAB006_W3D5 6.575725e+02	
## 32   UAB006_W3D6 9.406057e+02	
## 33   UAB006_W3D7 3.035163e+02	
## 34   UAB006_W4D2 9.091423e+02	
## 35   UAB006_W4D3 1.067289e+03	
## 36   UAB006_W4D4 7.653917e+02	
## 37   UAB006_W4D5 5.108480e+02	
## 38   UAB006_W4D6 1.240235e+00	
## 39   UAB006_W4D7 3.098208e+02	
## 40   UAB006_W5D1 2.580749e+02	
## 41   UAB007_W3D7 1.683195e+03	
## 42   UAB007_W4D1 1.188735e+03	
## 43   UAB007_W4D2 7.899422e+02	
## 44   UAB007_W4D3 3.108406e+02	
## 45   UAB007_W4D4 1.085003e+03	
## 46  UAB008_W10D1 1.179684e+02	
## 47  UAB008_W10D2 2.383264e+02	
## 48   UAB008_W9D5 1.046533e+02	
## 49   UAB008_W9D6 6.643826e+02	
## 50   UAB008_W9D7 9.899674e+02	
## 51   UAB015_W4D3 1.701653e+03	
## 52   UAB015_W4D4 8.764815e+02	
## 53   UAB015_W4D5 2.096003e+02	
## 54   UAB015_W4D7 1.426799e+03	
## 55   UAB015_W5D1 2.021888e+03	
## 56   UAB015_W5D2 4.693895e+02	
## 57   UAB015_W5D3 6.060877e+02	
## 58   UAB015_W5D4 3.483291e+02	
## 59   UAB015_W5D5 1.305746e+02	
## 60   UAB015_W5D7 6.715677e+02	
## 61   UAB015_W6D1 2.496645e+02	
## 62   UAB015_W6D2 4.994072e+02	
## 63   UAB015_W6D3 6.873087e+02	
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## 64   UAB015_W6D4 6.197250e+02	
## 65   UAB021_W1D4 3.699508e+02	
## 66   UAB021_W1D5 4.337148e+02	
## 67   UAB021_W1D7 1.449508e+02	
## 68   UAB021_W2D2 1.139957e+02	
## 69   UAB022_W7D5 6.055661e+02	
## 70   UAB022_W7D6 1.071701e+02	
## 71   UAB022_W7D7 1.095501e+03	
## 72   UAB022_W8D1 2.092547e+02	
## 73   UAB022_W8D2 9.373751e+02	
## 74   UAB055_W2D1 7.657517e+02	
## 75   UAB055_W2D2 5.755693e+02	
## 76   UAB055_W2D3 3.015522e+02	
## 77   UAB055_W2D4 1.686811e+02	
## 78   UAB055_W2D5 1.282814e+02	
## 79   UAB055_W2D6 4.453451e+01	
## 80   UAB093_W6D5 1.055765e+03	
## 81   UAB093_W6D6 3.812033e+02	
## 82   UAB093_W6D7 1.968737e+02	
## 83   UAB102_W4D6 8.767737e+01	
## 84   UAB102_W5D1 1.119551e+02	
## 85   UAB102_W5D2 2.917887e+02	
## 86   UAB115_W3D7 4.359042e+02	
## 87   UAB115_W4D3 1.105002e+03	
## 88   UAB115_W4D4 8.179583e+02	
## 89   UAB115_W4D5 1.705125e+03	
## 90   UAB115_W4D6 2.974179e+02	
## 91   UAB115_W5D2 1.155358e+03	
## 92   UAB115_W5D3 7.861445e+02	
## 93   UAB115_W5D5 1.667892e+02	
## 94   UAB115_W5D7 1.417144e+03	
## 95   UAB116_W2D5 1.440792e+02	
## 96   UAB116_W2D6 1.961594e+02	
## 97   UAB116_W3D1 2.916645e+02	
## 98   UAB116_W3D2 3.231621e+02	
## 99   UAB116_W3D3 8.325147e+01	
## 100  UAB117_W7D1 1.419449e+02	
## 101  UAB117_W7D2 3.295152e+02	
## 102  UAB117_W7D3 8.492167e+02	
## 103  UAB117_W7D4 1.340304e+03	
## 104  UAB121_W3D3 5.511017e+02	
## 105  UAB121_W3D4 1.048689e-01	
## 106  UAB121_W3D5 3.092622e+02	
## 107  UAB121_W3D6 1.049983e+03	
## 108  UAB121_W3D7 2.265420e+02	
## 109  UAB121_W4D2 1.407170e-01	
## 110  UAB121_W4D3 8.314880e+02	
## 111  UAB121_W4D4 8.507223e-02	
## 112  UAB121_W4D5 2.409049e+03	








##    186.9	




125 * 1869 	
## [1] 233625	
## An idea of the samples with "low coverage":	
print(head(SRL_counts_table[,low_coverage]))	
##              UAB005_W5D3 UAB006_W4D6 UAB008_W10D1 UAB008_W9D5 UAB021_W2D2	
## hsa-let-7a-2         602          36         2241        2463        2788	
## hsa-let-7a-3         618          37         2288        2529        2905	
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## hsa-let-7b          1868         229         7186       11804       17191	
## hsa-let-7c           657          61         2766        5179        4186	
## hsa-let-7d            98           1          271         262         338	
## hsa-let-7e            10           2           88          81          36	
##              UAB022_W7D6 UAB055_W2D6 UAB102_W4D6 UAB102_W5D1 UAB116_W3D3	
## hsa-let-7a-2        3438        1652        2340        2646        1296	
## hsa-let-7a-3        3531        1621        2487        2713        1302	
## hsa-let-7b         20351        6993       19034       27855       11430	
## hsa-let-7c         11309        3736        6052       12083        5938	
## hsa-let-7d           792         206         305         413         180	
## hsa-let-7e           161          48          54          64          33	
##              UAB121_W3D4 UAB121_W4D2 UAB121_W4D4	
## hsa-let-7a-2          10           9          10	
## hsa-let-7a-3           9          15          10	
## hsa-let-7b            25          23          10	
## hsa-let-7c             5           9          10	
## hsa-let-7d             0           1           0	




##       Pre_QC_ID QC_removal_stage	
## 1   UAB005_W5D3     Low_Coverage	
## 2   UAB006_W4D6     Low_Coverage	
## 3  UAB008_W10D1     Low_Coverage	
## 4   UAB008_W9D5     Low_Coverage	
## 5   UAB021_W2D2     Low_Coverage	
## 6   UAB022_W7D6     Low_Coverage	
## 7   UAB055_W2D6     Low_Coverage	
## 8   UAB102_W4D6     Low_Coverage	
## 9   UAB102_W5D1     Low_Coverage	
## 10  UAB116_W3D3     Low_Coverage	
## 11  UAB121_W3D4     Low_Coverage	
## 12  UAB121_W4D2     Low_Coverage	
## 13  UAB121_W4D4     Low_Coverage	
## Remove those samples with low coverage 	












## Re-plot after QC	
plot_QC.postQC.batch<-plot_pca(counts_meta.qc,"Log miRNA Raw Count Distance, 
POST QC",color_by ="Batch",ploly = F,seed_val = seed_val)##FIGURE	
plot_QC.postQC.batch$pca.p	
	
plot_QC.postQC.sid<-plot_pca(counts_meta.qc,"Log miRNA Raw Count Distance, 




plot_pca(counts_meta.qc,"Log miRNA Raw Count Distance, POST QC",color_by = 
"BVGroup",ploly = F,seed_val = seed_val)$pca.p##FIGURE	
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plot_pca(counts_meta.qc,"Log miRNA Raw Count Distance, POST QC",color_by = 
















## null device 	
##           1	
median_RIN<-median(pData(counts_meta.qc)$RIN,na.rm = T)	
	
print(paste0("The median RINe score was ",median_RIN,", with 
",round(100*sum(pData((counts_meta.qc))$RIN<7,na.rm = 
T)/length(pData((counts_meta.qc))$RIN),digits = 1),"% of the samples having a 
RINe greater than 7."))	










print(paste0("The median (minimum/maximum) percentage of post-QC miRNA reads 
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respectively. However, the  median number of post-QC hg19 mapped miRNA reads 
was ",number_miRNAs$median,", with a minimum ",number_miRNAs$min," and 
maximum ",number_miRNAs$max,". Thus, despite low relative miRNA read counts, 
the estimated coverage ranged from 
",round(number_miRNAs$min/number_mirs_genome,digits = 0),"X-
",round(number_miRNAs$max/number_mirs_genome,digits = 0),"X across the entire 
miRnome (",number_mirs_genome," annotated miRNAs)."))	
## [1] "The median (minimum/maximum) percentage of post-QC miRNA reads 
relative to all hg19 mapped and total reads was 26.6% (3%/58.2%) and 4.2% 
(0.5%/21%), respectively. However, the  median number of post-QC hg19 mapped 
miRNA reads was 1204913, with a minimum 239758 and maximum 4642910. Thus, 
despite low relative miRNA read counts, the estimated coverage ranged from 









## null device 	
##           1	
cairo_ps(file = 




## null device 	
##           1	
cairo_ps(file = 




## null device 	
##           1	
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cairo_ps(file = 




## null device 	
##           1	
cairo_ps(file = 




## null device 	
##           1	
cairo_ps(file = 




## null device 	









## Generate a model using clinical visit data. The model uses 16S relative 















## NBV PBV 	




print(paste0('Therefore, a proxy-Amsel diagnosis was developed by applying a 
Random Forest model trained with metataxonomic data and metadata from 
',nuniq_subjs_amsel,' subjects of the parent cohort that included 
',nrow(CV_16S_AMSEL),' samples for which both metataxonomic data and Amsel 
diagnosis was available (Amsel subset)(',TABLE_PROXY_AMSEL_INPUT,').'))	
## [1] "Therefore, a proxy-Amsel diagnosis was developed by applying a Random 
Forest model trained with metataxonomic data and metadata from 117 subjects 
of the parent cohort that included 281 samples for which both metataxonomic 





print(paste0("In the Amsel subset, asymptomatic or symptomatic BV diagnoses 
represented ",round(100*PBV.amsel/(NBV.amsel+PBV.amsel),digits = 1),"% 
(",PBV.amsel,"/",NBV.amsel+PBV.amsel,") of the Amsel diagnoses 
(",TABLE_PROXY_AMSEL_INPUT,"), a figure closely matching the reported 
prevalence of 29.2% for BV in similar populations [REF]."))	
## [1] "In the Amsel subset, asymptomatic or symptomatic BV diagnoses 
represented 25.3% (71/281) of the Amsel diagnoses (TABLE_A7.csv), a figure 
closely matching the reported prevalence of 29.2% for BV in similar 
populations [REF]."	
##Sanity check for Amsel	
pairs.panels(dplyr::select(CV_16S_AMSEL,Lactobacillus_iners,Gardnerella_vagin
alis,Lactobacillus_crispatus,Atopobium_vaginae,BVAB1,Megasphaera_sp._type_1,A
msel_BV),scale = F,density = F)	
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## See run_randomForest function above for paramaters. Note that you can load 
a previously-built model to save time. 	
	
Clinical_Visit_RF<-run_randomForest(predictors_response_table = CV_16S_AMSEL,	
                                    response_variable_name = "Amsel_BV",	
                                    subj_spec = FALSE,	
                                    nfold = nfolds,	
                                    nreps = npermutes,	
                                    save_model = F,	
                                    file_n = "Clinical_Visit_RF",	
                                    verbose = F,	
                                    permute = T,	
                                    load_prev_model = T,	





##      Var2	
## Var1  NBV PBV	
##   NBV  55   5	










##  [1] "Parvimonas_micra"               "Megasphaera_sp._type_1"        	
##  [3] "BVAB2"                          "Eggerthella"                   	
##  [5] "Dialister_sp._type_2"           "Leptotrichia_amnionii"         	
##  [7] "BVAB3"                          "BVAB1"                         	
##  [9] "PH"                             "Prevotella_genogroup_3"        	
## [11] "Prevotella_genogroup_1"         "Mobiluncus_mulieris"           	
## [13] "Porphyromonas_sp._type_1"       "Gardnerella_vaginalis"         	
## [15] "Prevotella_genogroup_2"         "Peptoniphilus_lacrimalis"      	
## [17] "Atopobium_vaginae"              "MENSTRUATION_NORMALIZED_PHASED"	
## [19] "Prevotella_genogroup_4"         "Candidate_Division_TM7_vaginal"	
## [21] "Lactobacillus_crispatus"        "Prevotella_genogroup_5"        	
## [23] "Porphyromonas_uenonis"          "Gemella"                       	
## [25] "Anaerococcus_vaginalis"         "Lactobacillus_helveticus"      	
## [27] "Prevotella_melaninogenica"      "Lactobacillus_vaginalis"       	
## [29] "Porphyromonas_endodontalis"     "Sutterella_stercoricanis"      	
## [31] "Firmicutes"                     "Anaerococcus"	
print(paste0("Multiple 
(",length(Clinical_Visit_RF$top_features$top_features.all),") important 
microbial (taxa and their relative abundance) or metadata features were 
predictive of the Amsel diagnosis: 
",str_c(sort(Clinical_Visit_RF$top_features$top_features.all),collapse = ", 
")," (",TABLE_RF_SUMMARY.CV,")")) 	
## [1] "Multiple (32) important microbial (taxa and their relative abundance) 
or metadata features were predictive of the Amsel diagnosis: Anaerococcus, 
Anaerococcus_vaginalis, Atopobium_vaginae, BVAB1, BVAB2, BVAB3, 
Candidate_Division_TM7_vaginal, Dialister_sp._type_2, Eggerthella, 
Firmicutes, Gardnerella_vaginalis, Gemella, Lactobacillus_crispatus, 
Lactobacillus_helveticus, Lactobacillus_vaginalis, Leptotrichia_amnionii, 
Megasphaera_sp._type_1, MENSTRUATION_NORMALIZED_PHASED, Mobiluncus_mulieris, 
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Parvimonas_micra, Peptoniphilus_lacrimalis, PH, Porphyromonas_endodontalis, 
Porphyromonas_sp._type_1, Porphyromonas_uenonis, Prevotella_genogroup_1, 
Prevotella_genogroup_2, Prevotella_genogroup_3, Prevotella_genogroup_4, 
Prevotella_genogroup_5, Prevotella_melaninogenica, Sutterella_stercoricanis 
(TABLE_A8.csv)"	
print(paste0("The Amsel Random Forest model accuracy was tested using a hold-
out set and found to be ",round(100*Clinical_Visit_RF.accuracy["NBV"],1),"% 
accurate in correctly assigning NBV diagnosis and 
",round(100*Clinical_Visit_RF.accuracy["PBV"],1),"% accurate in correctly 
assigning PBV diagnosis."))	
## [1] "The Amsel Random Forest model accuracy was tested using a hold-out 
set and found to be 91.7% accurate in correctly assigning NBV diagnosis and 
66.7% accurate in correctly assigning PBV diagnosis."	
proxy_amsel_predictions.classprobs<-predict(Clinical_Visit_RF$rfp, SRL_16S, 
type = "prob")	
(proxy_amsel_predictions<-predict(Clinical_Visit_RF$rfp, SRL_16S, type = 
"response"))	
## UAB003_W5D6 UAB003_W6D1 UAB003_W6D2 UAB003_W6D3 UAB003_W6D4 UAB003_W6D5 	
##         NBV         NBV         NBV         NBV         NBV         NBV 	
## UAB003_W6D6 UAB003_W6D7 UAB003_W7D1 UAB003_W7D2 UAB003_W7D3 UAB003_W7D5 	
##         NBV         NBV         NBV         NBV         NBV         NBV 	
## UAB003_W7D6 UAB003_W7D7 UAB003_W8D1 UAB003_W8D2 UAB005_W4D7 UAB005_W5D1 	
##         NBV         NBV         NBV         NBV         NBV         NBV 	
## UAB005_W5D2 UAB005_W5D4 UAB005_W5D5 UAB006_W3D3 UAB006_W3D4 UAB006_W3D5 	
##         NBV         NBV         NBV         NBV         NBV         NBV 	
## UAB006_W3D6 UAB006_W3D7 UAB006_W4D2 UAB006_W4D3 UAB006_W4D4 UAB006_W4D5 	
##         NBV         NBV         PBV         PBV         PBV         PBV 	
## UAB006_W4D7 UAB006_W5D1 UAB007_W3D7 UAB007_W4D1 UAB007_W4D2 UAB007_W4D3 	
##         PBV         PBV         NBV         NBV         NBV         NBV 	
## UAB007_W4D4 UAB008_W9D6 UAB015_W4D3 UAB015_W4D4 UAB015_W4D5 UAB015_W4D7 	
##         NBV         PBV         PBV         PBV         PBV         PBV 	
## UAB015_W5D1 UAB015_W5D2 UAB015_W5D3 UAB015_W5D4 UAB015_W5D5 UAB015_W5D7 	
##         PBV         PBV         PBV         NBV         PBV         PBV 	
## UAB015_W6D1 UAB015_W6D2 UAB015_W6D3 UAB015_W6D4 UAB021_W1D5 UAB021_W1D7 	
##         NBV         NBV         PBV         NBV         PBV         PBV 	
## UAB022_W8D1 UAB055_W2D1 UAB055_W2D2 UAB055_W2D3 UAB055_W2D4 UAB055_W2D5 	
##         PBV         PBV         PBV         PBV         PBV         PBV 	
## UAB093_W6D6 UAB115_W3D7 UAB115_W4D3 UAB115_W4D4 UAB115_W4D6 UAB115_W5D2 	
##         NBV         NBV         NBV         NBV         NBV         NBV 	
## UAB115_W5D3 UAB115_W5D5 UAB115_W5D7 UAB116_W2D5 UAB116_W2D6 UAB116_W3D1 	
##         NBV         NBV         NBV         PBV         PBV         PBV 	
## UAB116_W3D2 UAB117_W7D2 UAB117_W7D4 UAB121_W3D6 UAB121_W4D3 UAB121_W4D5 	
##         PBV         NBV         NBV         NBV         NBV         NBV 	
##   EM12_W5D2   EM12_W5D3   EM12_W5D4   EM12_W5D5   EM12_W5D6 	
##         NBV         NBV         NBV         NBV         NBV 	















## NBV PBV 	










pairs.panels(pairs_panel_data,main="proxy-Amsel Prediction Top Features with 




## null device 	
##           1	
Normalize	&	log2	transform	small	RNA-Seq	counts	for	use	in	models	




expSet.sizeDisp<-calcNormFactors(method = "TMM",DGEList(counts = 
exprs(counts_meta.qc)),logratioTrim = 0.10,sumTrim = 0.05) 	
	







## Store log-transformed QC *NON NORMALIZED* count table for PCA. This is not 





## Store log-transformed QC normalized count table. This is the small RNAseq 
count table used in all downstream analysis	
expSet_log.normalized<-ExpressionSet(assayData = 
log(exprs(expSet.normalized)+1,base=2),	
                                     phenoData = 
AnnotatedDataFrame(pData(expSet.normalized))) ## add pseuo counts... so that 
when take log(), all 0 reads become 0 normalized reads log(raw + 1)=log(1)=0. 
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LIttle effect on other counts. This makes it esier to drop raw 0 counts 
later. Also store count table annotation from original Expression Set	
	
## PCA plots after normalization, colored by batch, SID and "BV group"	
plot_QC.normalized.batch<-plot_pca(expSet.normalized,color_by = 




plot_QC.normalized.sid<-plot_pca(expSet_log.normalized,color_by = "SID",ploly 




plot_pca(expSet_log.normalized,color_by = "BVGroup",logt = F)$pca.p	
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plot_pca(expSet_log.normalized,color_by = "NugentC",logt = F)$pca.p	
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## Print for text	
print(paste0("PCA plots before and after sample removal and after 
normalization do not support batch effects (guided PCA p-values 
",plot_QC.preQC.batch$gPCA.result$p.val,", 
",plot_QC.postQC.batch$gPCA.result$p.val,", and 
",plot_QC.normalized.batch$gPCA.result$p.val,", respectively), or subject-
specific effects (guided PCA p-values 
",plot_QC.preQC.sid$gPCA.result$p.val,", 
",plot_QC.postQC.sid$gPCA.result$p.val,", and 
",plot_QC.normalized.sid$gPCA.result$p.val,", respectively, Figure S1)."))	
## [1] "PCA plots before and after sample removal and after normalization do 
not support batch effects (guided PCA p-values 0.994, 0.267, and 0.124, 
respectively), or subject-specific effects (guided PCA p-values 0.288, 0.478, 
and 0.294, respectively, Figure S1)."	
## Store counts data as "features"	
features<-exprs(expSet_log.normalized)	
head(features)[,1:3]	
##              EM12_W5D2 EM12_W5D3 EM12_W5D4	
## hsa-let-7a-2 14.554033 13.956142 13.936057	
## hsa-let-7a-3 14.750121 14.559435 15.451481	
## hsa-let-7b   16.993347 19.089923 18.246961	
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## hsa-let-7c   15.085236 14.779020 15.343028	
## hsa-let-7d   10.933057 10.523169 12.401490	
## hsa-let-7e    8.730594  9.655014  9.324838	
## Replace NA values with half the minimum normalized count values so that 





## Remove low count miRNAs	











features<-features[keep_features,] ## At least half of normalized miRNA 
counts should be >1. 	




































##    BVGroup    SID  N	
## 1      NBV   EM12  5	
## 2      NBV UAB007  5	
## 3      NBV UAB093  3	
## 4      NBV UAB102  1	
## 5      NBV UAB117  4	
## 6      PBV UAB008  3	
## 7      PBV UAB021  3	
## 8      PBV UAB022  4	
## 9      PBV UAB055  5	
## 10     PBV UAB116  4	
## 11     TBV UAB003 16	
## 12     TBV UAB005  5	
## 13     TBV UAB006 12	
## 14     TBV UAB015 14	
## 15     TBV UAB115  9	
## 16     TBV UAB121  7	
(summary_group<-
ddply(pData(counts_meta.qc),c("BVGroup"),summarise,N=length(SID)))	
##   BVGroup  N	
## 1     NBV 18	
## 2     PBV 19	





##   BVGroup N	
## 1     NBV 5	
## 2     PBV 5	




##   BVGroup Race N	
## 1     NBV      1	
## 2     NBV    B 3	
## 3     NBV    W 1	
## 4     PBV    B 5	
## 5     TBV    B 5	
## 6     TBV    W 1	
print(paste0("A total of ",sum(summary_sid.group$N)," samples, representing 
",sum(summary_group.uniqSID$N)," unique subjects from one of 3 longitudinal 
groups were used in the final analysis"))	
## [1] "A total of 100 samples, representing 16 unique subjects from one of 3 
longitudinal groups were used in the final analysis"	




,MENSTRUATION_NORMALIZED_PHASED,CST)) ## CSTs are *NOT* used in model input, 
but are instead passed along to top mir expression plot/table downstream. 
Remove CST from running in model.  	
	







## Combine non zero log transformed normalized counts with selected metadata 










##/// Subset model_input into the inputs for Amsel and Nugent RF	
model_input_Amsel<-
dplyr::select(model_input[!is.na(model_input$AMSEL_prediction),],-




c(AMSEL_prediction,CST)) ## Keep CSTs in model_input, just not Amsel or 
Nugent input	
	
model_input_Amsel[is.na(model_input_Amsel)]<-0 ## RF can not have missing 
values. Replacing with 0's isn't technically valid, but should have a minimal 
effect on outcome	
model_input_Nugent[is.na(model_input_Nugent)]<-0 ## RF can not have missing 
values. Replacing with 0's isn't technically valid, but should have a minimal 
effect on outcome	
	
##ADD QC STAGE TO SRL_meta_table, then write to disk	
SRL_meta_table<-left_join(SRL_meta_table,removed_samples,by="Pre_QC_ID")	
print(paste0("There were 5 samples removed due to insufficient library 
material or failure to sequence, and 
",sum(!is.na(SRL_meta_table$QC_removal_stage) & 
SRL_meta_table$QC_removal_stage %in% c("Low_Coverage","Visual Outlier"))," 
samples were removed due to low total miRNA reads or outliers."))	
## [1] "There were 5 samples removed due to insufficient library material or 



















## See run_randomForest function above for paramaters. Note that you can load 
	 199	
a previously-built model to save time.  Note that if loaded from previous, 
most of the input is ignored. 	
	
Amsel_RF<-run_randomForest(predictors_response_table = model_input_Amsel,	
                           response_variable_name = "AMSEL_prediction",	
                           subj_spec =T,	
                           nfold = nfolds,	
                           nreps = npermutes,	
                           permute = T,	
                           save_model = F,	
                           file_n = "Amsel_RF",	
                           load_prev_model = T,	
                           verbose = F,	
                           training_prop = training_prop,	
                           
R_script_output_directory=R_script_output_directory) 	
	






##  [1] "let-7e"   "miR-203b" "miR-184"  "miR-193b" "let-7a-2" "miR-7-3" 	
##  [7] "miR-182"  "miR-183"  "miR-378a" "miR-3607" "miR-100"  "miR-320a"	
## [13] "miR-10b"  "miR-362"  "miR-324"  "miR-146a" "miR-16-1" "miR-4510"	







print(paste0("The accuracy of the proxy-Amsel-RF model classification was 
",round(NBV.accuracy.AMSEL,digits = 1),"% for NBV and 
",round(PBV.accuracy.AMSEL,digits = 1),"% for PBV. There were 
",length(Amsel_RF$top_features$top_features.all)," significant miRNAs using 
proxy-Amsel RF."))	
## [1] "The accuracy of the proxy-Amsel-RF model classification was 82.3% for 








                            response_variable_name = "NUGENT_SCORE",	
                            subj_spec = T,	
                            nfold = nfolds,	
                            nreps = npermutes,	
                            permute = T,	
                            save_model = F,	
                            file_n = "Nugent_RF",	
                            load_prev_model = T,	
                            verbose = F,	
                            training_prop = training_prop,	
                            
R_script_output_directory=R_script_output_directory) 	
	





##  [1] "miR-193b"  "miR-203b"  "miR-324"   "miR-130a"  "miR-224"  	
##  [6] "miR-182"   "miR-149"   "miR-3607"  "miR-375"   "miR-15a"  	
## [11] "miR-3653"  "miR-21"    "miR-223"   "miR-15b"   "miR-378a" 	
## [16] "miR-203a"  "miR-200b"  "miR-146a"  "miR-205"   "miR-16-2" 	
## [21] "miR-152"   "miR-199b"  "miR-20a"   "miR-95"    "miR-197"  	
## [26] "miR-365a"  "miR-101-2" "miR-191"   "miR-140"   "miR-500a"	











## [1] "miR-193b" "miR-203b" "miR-324"  "miR-182"  "miR-3607" "miR-378a"	
## [7] "miR-146a" "miR-500a"	
print(paste0("The Nugent-RF model correctly predicted the Nugent score within 
",round(mean_absolute_error.Nugent,digits = 0)," values on average. There 
were ",length(Nugent_RF$top_features$top_features.all)," significant miRNAs 
using Nugent-RF."))	
## [1] "The Nugent-RF model correctly predicted the Nugent score within 2 
values on average. There were 30 significant miRNAs using Nugent-RF."	
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## //////////	




## Write model input table to file, keeping only variables that were used in 







print(paste0("The Nugent-RF and proxy-Amsel-RF models used 
",length(predictor_names)," predictors including ",predictor_names.miRs," 
non-zero log2 transformed miRNA read counts and ",length(predictor_names)-
predictor_names.miRs," metadata variables as inputs to rank feature 
importance (",TABLE_MODEL_INPUT,")."))	
## [1] "The Nugent-RF and proxy-Amsel-RF models used 178 predictors including 
169 non-zero log2 transformed miRNA read counts and 9 metadata variables as 
inputs to rank feature importance (TABLE_A5.csv)."	
















































##        miRNA  RF_Group	
## 31    let-7e  Amsel-RF	
## 32   miR-184  Amsel-RF	
## 33  let-7a-2  Amsel-RF	
## 34   miR-7-3  Amsel-RF	
## 35   miR-183  Amsel-RF	
## 36   miR-100  Amsel-RF	
## 37  miR-320a  Amsel-RF	
## 38   miR-10b  Amsel-RF	
## 39   miR-362  Amsel-RF	
## 40  miR-16-1  Amsel-RF	
## 41  miR-4510  Amsel-RF	
## 42   miR-342  Amsel-RF	
## 1   miR-193b      Both	
## 2   miR-203b      Both	
## 3    miR-324      Both	
## 6    miR-182      Both	
## 8   miR-3607      Both	
## 15  miR-378a      Both	
## 18  miR-146a      Both	
## 30  miR-500a      Both	
## 4   miR-130a Nugent-RF	
## 5    miR-224 Nugent-RF	
## 7    miR-149 Nugent-RF	
## 9    miR-375 Nugent-RF	
## 10   miR-15a Nugent-RF	
## 11  miR-3653 Nugent-RF	
## 12    miR-21 Nugent-RF	
## 13   miR-223 Nugent-RF	
	 203	
## 14   miR-15b Nugent-RF	
## 16  miR-203a Nugent-RF	
## 17  miR-200b Nugent-RF	
## 19   miR-205 Nugent-RF	
## 20  miR-16-2 Nugent-RF	
## 21   miR-152 Nugent-RF	
## 22  miR-199b Nugent-RF	
## 23   miR-20a Nugent-RF	
## 24    miR-95 Nugent-RF	
## 25   miR-197 Nugent-RF	
## 26  miR-365a Nugent-RF	
## 27 miR-101-2 Nugent-RF	
## 28   miR-191 Nugent-RF	
## 29   miR-140 Nugent-RF	
## Text	
print(paste0("A total of 
",length(top_mirs_table[top_mirs_table$RF_Group=="Both","miRNA"])," miRNAs 
were common to both proxy-Amsel-BV and Nugent-BV Random Forest models: ", 
str_c(top_mirs_table[top_mirs_table$RF_Group=="Both","miRNA"],collapse=", 
"),"."))	
## [1] "A total of 8 miRNAs were common to both proxy-Amsel-BV and Nugent-BV 





significant miRNAs unique to each ofproxy-Amsel classification (proxy-Amsel-
RF) and Nugent score regression (Nugent-RF), respectively"))	
## [1] "There were 12 and 22 statistically significant miRNAs unique to each 




p$importance_w_pval) %in% top_mirs_table[top_mirs_table$RF_Group %in% 
c("Amsel-RF","Both"),"miRNA"],]),contains("Mean"))	
##          MeanDecreaseAccuracy MeanDecreaseAccuracy.pval MeanDecreaseGini	
## let-7e               5.607872               0.002195609        0.9470099	
## miR-203b             4.630648               0.003193613        0.7717181	
## miR-184              4.224487               0.003792415        0.5855550	
## miR-193b             3.882583               0.005588822        0.4847252	
## let-7a-2             3.626207               0.006786427        0.3909026	
## miR-7-3              3.378600               0.009181637        0.4143229	
## miR-182              3.235782               0.010778443        0.4662138	
## miR-183              3.065067               0.012375250        0.4495199	
## miR-378a             2.909091               0.012375250        0.3701688	
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## miR-3607             2.801747               0.016367265        0.3678346	
## miR-100              2.687550               0.020958084        0.3507171	
## miR-320a             2.597080               0.022754491        0.2273535	
## miR-10b              2.506643               0.026746507        0.3665795	
## miR-362              2.426444               0.026746507        0.2311134	
## miR-324              2.327208               0.034131737        0.2919702	
## miR-146a             2.257027               0.038123752        0.3095903	
## miR-16-1             2.154749               0.043313373        0.2736763	
## miR-4510             2.096317               0.046706587        0.2717785	
## miR-500a             2.020440               0.048103792        0.2481224	
## miR-342              1.973390               0.049900200        0.1733185	
##          MeanDecreaseGini.pval	
## let-7e             0.002195609	
## miR-203b           0.002994012	
## miR-184            0.006986028	
## miR-193b           0.020558882	
## let-7a-2           0.057285429	
## miR-7-3            0.041916168	
## miR-182            0.022355289	
## miR-183            0.069261477	
## miR-378a           0.047704591	
## miR-3607           0.102395210	
## miR-100            0.135728543	
## miR-320a           0.257285429	
## miR-10b            0.103393214	
## miR-362            0.250299401	
## miR-324            0.258283433	
## miR-146a           0.185828343	
## miR-16-1           0.150698603	
## miR-4510           0.167664671	
## miR-500a           0.202994012	





RF","Both"),"miRNA"],]),contains("Accuracy")),ntopfeats =  20,rankBy = 






RF","Both"),"miRNA"],]),contains("MSE")),ntopfeats = 30,rankBy = 



















##                 2	
plot_importance(dplyr::select(Clinical_Visit_RF$importance,contains("BV")),nt
opfeats = 20,rankBy = "PBV",model_name = "Amsel")	
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## Calcualte linear model fit for miRNA expression data vs Nugent score to 
rank miR expression plots in figure	
	
fitness<-apply(model_input[,names(model_input) %in% 









##          adjr2 variable	
## miR-193b 0.379 miR-193b	
## miR-182  0.214  miR-182	
## miR-203b 0.182 miR-203b	
## miR-378a 0.140 miR-378a	
## miR-3607 0.134 miR-3607	
## miR-324  0.124  miR-324	
## miR-500a 0.075 miR-500a	
## miR-146a 0.001 miR-146a	
topmir_plot_data<-join(topmir_plot_data,fitness.r2)	





## Liner correlation coeff for miRNA expression data:	
paste(apply(unique(dplyr::select(topmir_plot_data,c(variable,adjr2))),MARGIN 
= 1,FUN = function(x) paste(sep =":" ,x[1],x[2])),sep=",")	
## [1] "miR-146a:0.001" "miR-182:0.214"  "miR-193b:0.379" "miR-203b:0.182"	
## [5] "miR-324:0.124"  "miR-3607:0.134" "miR-378a:0.140" "miR-500a:0.075"	




## Plot the miRNA expression figure	
PLOT_EXPRESSION<-	
  ggplot(topmir_plot_data,aes(x=NUGENT_SCORE,y=value))+	
  stat_smooth(method = "lm",col='#FF5733',se=F)+ #	
  geom_point(aes(col=as.factor(CST),pch=AMSEL_prediction),size=3,show.legend 
= T)+	
  facet_wrap(~variable,scales = "free_y",nrow=2)+	
  ylab("Normalized Expression")+xlab("Nugent Score")+	
  mBio+	
  theme(text = element_text(size=20),axis.text.x = element_text(size=15))+	
  scale_x_continuous(breaks=0:10)+	
  scale_color_manual(values = cst.colors,guide = guide_legend(title = 
"CST"))+	
  guides(pch=guide_legend(title="proxy Amsel Prediction"))	
	






##                 2	
library(Boruta)	
## Loading required package: ranger	
## 	
## Attaching package: 'ranger'	
## The following object is masked from 'package:randomForest':	
## 	




plot(Nugent_RF.Boruta,main="Nugent-RF Boruta unimportant feature removal")	
Nugent_RF.Boruta$finalDecision[Nugent_RF.Boruta$finalDecision=="Confirmed"]	
##  miR-101-1  miR-101-2  miR-128-1  miR-128-2   miR-130a    miR-142 	
##  Confirmed  Confirmed  Confirmed  Confirmed  Confirmed  Confirmed 	
##    miR-143    miR-149    miR-15a    miR-182   miR-193b  miR-194-2 	
##  Confirmed  Confirmed  Confirmed  Confirmed  Confirmed  Confirmed 	
## miR-199a-1   miR-199b   miR-203a   miR-203b    miR-205    miR-223 	
##  Confirmed  Confirmed  Confirmed  Confirmed  Confirmed  Confirmed 	
## miR-320b-1    miR-324   miR-3607   miR-365a   miR-378a    miR-486 	
##  Confirmed  Confirmed  Confirmed  Confirmed  Confirmed  Confirmed 	
## Levels: Tentative Confirmed Rejected	
Amsel_RF.Boruta<-Boruta(x=dplyr::select(model_input_Amsel,-
c(SID,AMSEL_prediction)),y=as.factor(model_input_Amsel$AMSEL_prediction))	
plot(Amsel_RF.Boruta,main="proxy-Amsel-RF Boruta unimportant feature 
removal")	
Amsel_RF.Boruta$finalDecision[Amsel_RF.Boruta$finalDecision=="Confirmed"]	
##  let-7a-2   miR-100  miR-146a   miR-182   miR-183   miR-184  miR-193b 	
## Confirmed Confirmed Confirmed Confirmed Confirmed Confirmed Confirmed 	
##  miR-203b   miR-223  miR-320a  miR-3607   miR-486 	
## Confirmed Confirmed Confirmed Confirmed Confirmed 	














### miRNA <-> Taget (gene) <-> Gene Ontology Process (direct)	
### miRNA <- - - - - - - -- >  Gene Ontology Process (direct)	
	
## Read in miRTarBase Experimentally Validated Target List	
mir_targets<-
read.table(paste0(R_script_input_directory,"miRTarBase_SE_WR_homosapiens.txt"




## Format targets list,pattern = "hsa.",replacement = "")	
mir_targets$miRNA.format<-gsub(gsub(gsub(mir_targets$miRNA,pattern = 
"mir.",replacement = "miR-"),replacement ="-",pattern = "\\."),pattern = "-
.p",replacement = "-")	
	
## Map miRNA names to target List	
for(mir in as.character(top_mirs_table$miRNA)){	
  	
  target_list<-mir_targets[grep(mir_targets$miRNA.format,pattern = 
paste0("hsa-",mir,"-"),ignore.case = T,perl = 
T),c("miRNA","Target.Gene","References..PMID.")]	
  #if(!nrow(target_list)==0){target_list$source<-"canonical"}	
  if(!nrow(target_list)==0 ){	
    top_mirs_table[top_mirs_table$miRNA==mir,"targets"]<-
str_c(sort(unique(target_list$Target.Gene)),collapse = ",")	
    top_mirs_table[top_mirs_table$miRNA==mir,"sanityCheck"]<-
str_c(sort(unique(target_list$miRNA)),collapse = ",")	






ETS),sep="\t",quote = F,row.names = F) ## Needs to be tab delimited due to 
"," separating gene targets. 	
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### Read in miR-Go-Gene mapping table mapping targets/miRNAs to GO processes. 
Gene targets mapped to miRNAs using a Python script. 	
mir_go<-
read.csv(paste0(R_script_input_directory,"miR_GODirect_Gene_Map.csv"),strings
AsFactors = F) 	
	
	
## Filter just the miR-GO map to 'top' miRNAs discovered above belonging to 





##        mir  n	
## 1 miR-146a 48	
## 2  miR-182 46	
## 3 miR-193b 12	
## 4  miR-324  6	
## 5 miR-378a 16	
## 6 miR-500a  3	






##         mir number_targets	
## 9  miR-378a             16	
## 13 miR-193b             13	
## 19 miR-203b              1	
## 21 miR-3607              1	
## 22  miR-324              6	
## 27  miR-182             48	
## 33 miR-146a             51	
## 41 miR-500a              3	
## Determine the number of genes associated with each miRNA- need to 








am of Non-zero miRNA Target Frequency",xlab="Proportion of Targets")	
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## Somewhere above 0.2 might capture the interesting/common GO processes 
across miRNAS. 	
	
## Make miR-GO counts into wide format (i.e., each GO process is a column, 
miRNAs are rows, values are proportion of targets in that GO/miRNA 
combination)	
mir_go.wide<-tidyr::spread(dplyr::select(mir_go.counts,-





## Get a better idea of how to plot common GO processes by determining 
cutoffs for target proportions	
## Balanace between proportion of targets across all miRNAs and total # 
across targets	
	

















df1$ncol>=5,"ncol"]),]) ## What are the optimal cutoffs for somewhere between 
5 and 25 GO processes on the plot?	
##   i   j ncol	
## 8 0 0.7   19	
## 9 0 0.8   19	
## Take the max i/j pair as the cutoffs:	
i<-0	
j<-0.8	
## Note that 19 in the "nc" column is the number of GO processes that will be 
plotted	
	











## The names of the GO processes to be used in plot:	
names(mir_go.wide.filtered[,order(colSums(mir_go.wide.filtered>0),decreasing 
= T)])	
##  [1] "GO:0000122~negative regulation of transcription from RNA polymerase 
II promoter"              	
##  [2] "GO:0001666~response to hypoxia"                                                               	
##  [3] "GO:0001701~in utero embryonic development"                                                    	
##  [4] "GO:0001934~positive regulation of protein phosphorylation"                                    	
##  [5] "GO:0006351~transcription<COMMA> DNA-templated"                                                	
##  [6] "GO:0006355~regulation of transcription<COMMA> DNA-templated"                                  	
##  [7] "GO:0006366~transcription from RNA polymerase II promoter"                                     	
##  [8] "GO:0006955~immune response"                                                                   	
##  [9] "GO:0007049~cell cycle"                                                                        	
## [10] "GO:0007165~signal transduction"                                                               	
## [11] "GO:0007275~multicellular organism development"                                                	
## [12] "GO:0008284~positive regulation of cell proliferation"                                         	
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## [13] "GO:0010628~positive regulation of gene expression"                                            	
## [14] "GO:0030335~positive regulation of cell migration"                                             	
## [15] "GO:0043066~negative regulation of apoptotic process"                                          	
## [16] "GO:0043547~positive regulation of GTPase activity"                                            	
## [17] "GO:0045893~positive regulation of transcription<COMMA> DNA-
templated"                         	
## [18] "GO:0045944~positive regulation of transcription from RNA polymerase 
II promoter"              	





= "~.*",replacement = "") ## Store the GO number only in case needed	
	
## For this plot, summarize the mean gene target proprotion and # of miRNAs 




##                                                                                         
variable	
## 1                GO:0000122~negative regulation of transcription from RNA 
polymerase II promoter	
## 2                                                                 
GO:0001666~response to hypoxia	
## 3                                                      GO:0001701~in utero 
embryonic development	
## 4                                      GO:0001934~positive regulation of 
protein phosphorylation	
## 5                                                  
GO:0006351~transcription<COMMA> DNA-templated	
## 6                                    GO:0006355~regulation of 
transcription<COMMA> DNA-templated	
## 7                                       GO:0006366~transcription from RNA 
polymerase II promoter	
## 8                                                                     
GO:0006955~immune response	
## 9                                                                          
GO:0007049~cell cycle	
## 10                                                                
GO:0007165~signal transduction	
## 11                                                 
GO:0007275~multicellular organism development	
## 12                                          GO:0008284~positive regulation 
of cell proliferation	
## 13                                             GO:0010628~positive 
regulation of gene expression	
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## 14                                              GO:0030335~positive 
regulation of cell migration	
## 15                                           GO:0043066~negative 
regulation of apoptotic process	
## 16                                             GO:0043547~positive 
regulation of GTPase activity	
## 17                          GO:0045893~positive regulation of 
transcription<COMMA> DNA-templated	
## 18               GO:0045944~positive regulation of transcription from RNA 
polymerase II promoter	
## 19 GO:0051091~positive regulation of sequence-specific DNA binding 
transcription factor activity	
##            s n	
## 1  1.5555241 6	
## 2  0.7194570 5	
## 3  0.6161388 5	
## 4  0.5043363 5	
## 5  0.8864065 5	
## 6  0.7283183 5	
## 7  0.7479261 5	
## 8  0.7077677 5	
## 9  0.6761878 5	
## 10 0.9829374 5	
## 11 0.5131976 5	
## 12 0.9694570 5	
## 13 0.6918363 5	
## 14 0.6281109 5	
## 15 1.0101810 5	
## 16 0.4457956 5	
## 17 1.3226810 5	
## 18 1.4440045 5	
## 19 0.3881976 5	
## TO make plot simplier to read, group GO terms in logical super groupings. 





## How many GO terms in each super group	
(group_freq<-data.frame(table(group_go_map$Group))) 	
##            Var1 Freq	
## 1    Cell cycle    4	
## 2   Development    2	
## 3       Hypoxia    1	
## 4        Immune    1	
## 5     Signaling    3	
## 6 Transcription    8	
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names(group_freq)<-c("Group","n_group")	
# MErge the super groups and data found above	
group_go_map<-merge(group_go_map,group_freq)	
	




#FOrmat the GO term for plot	
mir_go.wide.filtered.m$GO_format<-
factor(mir_go.wide.filtered.m$variable,levels =group_go_map$variable ,ordered 







  theme(axis.text.x = element_text(angle=45,hjust = 
1,size=10),text=element_text(size=12),plot.margin = 
unit(c(10,25,10,170),units = "pt"))+	
  scale_fill_brewer(type = "qual",palette = "Set1")+	
  xlab("GO Term")+	











## NOTE: the # of miR targets table is added later. See above for table. 	
	







## Make a GO process bar chart for miR-193b only (for thesis presentation, 












  theme(axis.text.x = element_text(angle=45,hjust = 
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1),text=element_text(size=25),plot.margin = unit(c(10,25,10,170),units = 
"pt"))+	
  scale_fill_brewer(type = "qual",palette = "Set1")+	
  scale_y_continuous(breaks=c(2,4,6,8))+	
  xlab("GO process")+	
  ylab("Number miR-193b targets")	
	
cairo_ps(paste0(R_script_output_directory,"miR193b_GOProcess_presentation.eps















remove NA from data	
	
## Create a mixed-effects linear model as a function of BVGroup of dCt 
values, using subject ID as the random effect	
seq_validation.lme <- lme(deltaCt ~ BVGroup,	
                          random = ~ 1|SID,	
                          data = miR_qPCR_results.deltaCt)	
	







## Linear mixed-effects model fit by REML	
##  Data: miR_qPCR_results.deltaCt 	
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##        AIC      BIC    logLik	
##   19.19847 18.36551 -5.599237	
## 	
## Random effects:	
##  Formula: ~1 | SID	
##         (Intercept) Residual	
## StdDev:   0.6267906 0.107014	
## 	
## Fixed effects: deltaCt ~ BVGroup 	
##                 Value Std.Error DF   t-value p-value	
## (Intercept) -1.682609 0.3179302  5 -5.292385  0.0032	
## BVGroupPBV   1.432459 0.4849846  5  2.953617  0.0318	
##  Correlation: 	
##            (Intr)	
## BVGroupPBV -0.656	
## 	
## Standardized Within-Group Residuals:	
##         Min          Q1         Med          Q3         Max 	
## -0.62114365 -0.18105809  0.03265107  0.08253511  0.79729434 	
## 	
## Number of Observations: 8	


















# Calculate mean & s.d. Ct values for each BCS/time point. 	
load(file=paste0(R_script_input_directory,"qPCR_time_course.Rdata")) ## Ct 
values	
load(file=paste0(R_script_input_directory,"qpcr_sigtest.Rdata")) ## Container 





miR193b_Ct,na.rm = T),sd_193b=sd(miR193b_Ct,na.rm = T),	
                                m_R6=mean(RNU6_Ct,na.rm = 
T),sd_R6=sd(RNU6_Ct,na.rm = T))	
	
## Calcualte delta Ct using RNU6 as endogenous control. Calcualte standard 







## calcualte signifigance using delta Ct mean + s.d., which uses a modified 
t.test2 function. 	
## Loop through the comparisons and test pair-wise	
for(sigtest in 1:nrow(qpcr_sigtest)){	
  	
  timei<-as.character(qpcr_sigtest[sigtest,"ExposureTime"]) # TIme point	
  x1<-as.character(qpcr_sigtest[sigtest,"comparison"]) ## Comparison sample	
  y1<-as.character(qpcr_sigtest[sigtest,"reference"]) ## Reference sample	
  	





  # Standard deviations, as computed above 	
  sx <- filter(qPCR_time_course.summary,BCS==x1 & ExposureTime==timei & 
Study==study.x)$deltaCt.RNU6.sd	
  sy<-filter(qPCR_time_course.summary,BCS==y1 & ExposureTime==timei  & 
Study==study.y)$deltaCt.RNU6.sd	
  	
  # deltaCt mean	
  mx<-filter(qPCR_time_course.summary,BCS==x1 & ExposureTime==timei & 
Study==study.x)$deltaCt.RNU6	
  my<-filter(qPCR_time_course.summary,BCS==y1 & ExposureTime==timei & 
Study==study.y)$deltaCt.RNU6	
  	
  ## Compute t statistic/p value using mean, s.d. and sample size for two 
groups	
  tes<-t.test2(m1 = mx,	
               m2= my,	
               s1=sx,	
               s2=sy,	
               n1=3,	








  ## ddCt >0 implies x transcript is less abundant than y and ddCt<0 implies 
x is more abudnact than y. The relative magnatitude on a plot of 2^(-x) != 
2(x) although the interpretability is the same (transcript is either 2^-x 
less abudnant than y or 2^x more abudnant than y). Therefore, take absolute 
ddCt before raising it to 2.   	
  ##Note ddct is actually 2^-ddct	
  	
  if(-qpcr_sigtest[sigtest,"mean_diff"]<0){	
    	
    qpcr_sigtest[sigtest,"ddct"]<-(-2^(tes["Difference of means"]))	
    qpcr_sigtest[sigtest,"ddct_se"]<-(-2^(tes["Difference of means"]+	
                                            qpcr_sigtest[sigtest,"se"]))	
    qpcr_sigtest[sigtest,"ddct_se_m"]<-(-2^(tes["Difference of means"]-	
                                              qpcr_sigtest[sigtest,"se"]))	
  }else{	
    	
    qpcr_sigtest[sigtest,"ddct"]<-2^(-tes["Difference of means"]) 	
    	
    qpcr_sigtest[sigtest,"ddct_se"]<-2^((-tes["Difference of means"])+	
                                          qpcr_sigtest[sigtest,"se"])	
    qpcr_sigtest[sigtest,"ddct_se_m"]<-2^((-tes["Difference of means"])-	
                                            qpcr_sigtest[sigtest,"se"])	








##convert exposure time to numeric for plot	
qpcr_sigtest$ExposureTime.n<-









idth = 11.5,height = 6)	
## Plot qPCR Timecourse (put lactic acid comparison in sep. figure)	
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PLOT_QPCR_TIMECOURSE<-	
  ggplot(filter(qpcr_sigtest,reference=="G. vaginalis" & 
!grepl(qpcr_sigtest$comparison,pattern = "_10|_766|0_")), #& 
qpcr_sigtest$reference== "G. vaginalis"),	
         aes(x=ExposureTime.n,y=-mean_diff,col=comp))+	
  theme_bw()+	
  geom_hline(yintercept = 0,col="#9e9ac8",size=2.5)+	
  theme(plot.margin=unit(c(0,0,0,0),units = "pt"), 
text=element_text(size=16))+	
  geom_line(size=1.5,show.legend = T,aes(linetype=ref))+ 	
  geom_errorbar(aes(ymax=-mean_diff+se,ymin=-mean_diff-se),size=1,show.legend 
= F)+	
  geom_point(size=6,show.legend = F)+ 	
  ylab(expression(paste(-Delta,Delta,"Ct")))+	
  xlab("Exposure Time (hours)")+	
  scale_color_manual(name=expression(paste("Lactobacillus 
",Delta,"Ct")),values = color_scheme_BCS)+	
  scale_x_continuous(breaks=c(0.5,1,4,11,13,22),minor_breaks = NULL)+	
  scale_linetype_manual(name=expression(paste("Reference 
",Delta,"Ct")),values=as.numeric(qpcr_sigtest$lt))+	








##                 2	
qpcr_sigtest$comparison<-factor(qpcr_sigtest$comparison,levels = c("L. 
crispatus", "L. jensenii","L. iners","G. vaginalis", 
"PH_766","D_10","L_10","0_06_D","0_06_L"),ordered = T,labels = c("L. 
crispatus", "L. jensenii","L. iners","G. vaginalis", "1% lactic acid, pH 
7.66","0.1% D-lactic acid","0.1% L-lactic acid","0.06% D-lactic acid","0.06% 
L-lactic acid"))	
	
qpcr_sigtest$reference<-factor(qpcr_sigtest$reference,levels = c("L. 
jensenii","L. iners","G. vaginalis", "Cell Culture Medium", 
"L_10","0_06_D","0_06_L"),ordered = T,labels = c( "L. jensenii","L. 
iners","G. vaginalis", "Cell Culture Medium","0.1% L-lactic acid","0.06% D-
lactic acid","0.06% L-lactic acid"))	
	
## Show D and L lactic acid qPCR results compared to other references	
ddct_LacticAcid_plot<-	





  geom_hline(yintercept = 0,col="#9e9ac8",size=2.5)+	
  theme(plot.margin=unit(c(0,0,0,0),units = "pt"), 
text=element_text(size=14))+	
  geom_errorbar(aes(ymax=-mean_diff+se,ymin=-mean_diff-
se),width=.2,show.legend = F,position = position_dodge(width = .2))+	
  geom_point(size=6,show.legend = T,position = position_dodge(width = .2))+ 	
  ylab(expression(paste(-Delta,Delta,"Ct")))+	
  xlab(expression(paste("Reference ",Delta,"Ct")))+	
  scale_color_manual(name=expression(paste("Exposure ",Delta,"Ct")),values = 
c(color_scheme_BCS,"0.1% D-lactic acid"="#4dac26","0.1% L-lactic 
acid"="#d01c8b","1% lactic acid, pH 7.66"="#386cb0","0.06% L-lactic 
acid"="#f1b6da","0.06% D-lactic acid"="#b8e186"))+	







##                 2	
paste0("Additionally, the ∆∆Ct of miR-193b expression after 4 hours of 
exposure to 0.06% D-lactic acid relative to 0.06% L-lactic acid was found to 
be non-significant ( p=",qpcr_sigtest[qpcr_sigtest$comparison=="L-lactic 
acid" & qpcr_sigtest$reference=="D-lactic acid","pval"],").") 	
## [1] "Additionally, the ∆∆Ct of miR-193b expression after 4 hours of 
exposure to 0.06% D-lactic acid relative to 0.06% L-lactic acid was found to 
be non-significant ( p=)."	

























## Melt scratch assay data for easier handling	
scratch.m<-filter(in_vitro_experiments,Experiment=="Scratch" & Observation == 
"Proliferation" & !grepl(x = 




## Re-name the melted data	
names(scratch.m)<-c("Observation","BCS","percent_cells","Field")	
	
#Factor BCS so that order is enforced	
scratch.m$BCS<-factor(scratch.m$BCS,ordered = T,levels = c("L. crispatus","L. 
jensenii","L. iners","G. vaginalis","Cell Culture Medium"))	
	
## Create a significance testing data frame to hold results	
setup_sigtest.data<-setup_sigtest(pval_threshold = pval_threshold,raw_data = 





















  geom_errorbar(aes(x=BCS,ymin=mean-sd,ymax=mean+sd),width=.3,show.legend = 
F)+	
  mBio+	
  ylab("Filled Scratch Area (%)")+	
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  xlab("BCS")+	
  theme(plot.margin=unit(c(0,0,0,0),units = "pt"), 
text=element_text(size=16),axis.text.x=element_text(face="italic",angle = 
45,vjust = 1,hjust = 1))+	

























## Melt EdU assay data for easier handling, clean up input	
EdU.m<-filter(in_vitro_experiments,Experiment=="Scratch" & Observation == 
"EdU") %>% dplyr::select(-c(Experiment)) #melt(scratch)	
EdU.m<-rename(EdU.m,BCS=Treatment)	
	
#Factor BCS so that order is enforced	
EdU.m$BCS<-factor(EdU.m$BCS,ordered = T,levels = c("L. crispatus","L. 
jensenii","L. iners","G. vaginalis","Cell Culture Medium"))	
	
## Create a significance testing data frame to hold results	
setup_sigtest.data<-setup_sigtest(pval_threshold = pval_threshold,raw_data = 


























  ylab("Epithelial Cells Positive for EdU (%)")+	
  xlab("BCS")+	
  theme(plot.margin=unit(c(0,0,0,0),units = "pt"), 
text=element_text(size=16),axis.text.x=element_text(face="italic",angle = 
45,vjust = 1,hjust = 1))+	
















##                 2	


























paste0("Percent cell proliferation between 20% NYC-III and TSB bacterial 
culture media as evaluated by scratch assay was not significant (mean +/- 
standard deviation NYC-III cell proliferation=",control_meds.nyc.mean,"% +/- 
",control_meds.nyc.sd,"%, mean +/- standard deviation TSB  cell 
proliferation=,",control_meds.tsb.mean,"% +/- ",control_meds.tsb.sd,"%, 
p=",control_meds.sig$p.value,")")	
## [1] "Percent cell proliferation between 20% NYC-III and TSB bacterial 
culture media as evaluated by scratch assay was not significant (mean +/- 
standard deviation NYC-III cell proliferation=45.94945353125% +/- 
9.11375283414706%, mean +/- standard deviation TSB  cell 
proliferation=,50.704530715% +/- 14.5706994714208%, p=0.449364642797794)"	
## Combine proliferation sig tests and write to file	
proliferation_sigtests<-
rbind(data.frame(Figure=gsub(FIGURE_SCRATCH_QUANT,replacement = "",pattern = 
".eps"),scratch_sigtest),data.frame(Figure=gsub(FIGURE_EDU_QUANT,replacement 
















PLOT_nyc_v_tsb<-ggplot(data.frame(media=c("NYC (Lactobacillus spp.)","TSB (G. 
vaginalis)"),scratch.mean=c(control_meds.nyc.mean,control_meds.tsb.mean),scra
tch.sd=c(control_meds.nyc.sd,control_meds.tsb.sd)))+	




  mBio+ylab("Percent Scratch Area Filled")+	






























t.test(x = scratch.m[scratch.m$BCS=="Cell Culture Medium","percent_cells"],y 
= DL_PH766_percent_proliferation$DL_1pct_766)	
## 	
##  Welch Two Sample t-test	
## 	
## data:  scratch.m[scratch.m$BCS == "Cell Culture Medium", "percent_cells"] 
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and DL_PH766_percent_proliferation$DL_1pct_766	
## t = 6.0479, df = 2.0264, p-value = 0.02546	
## alternative hypothesis: true difference in means is not equal to 0	
## 95 percent confidence interval:	
##   19.92453 114.08363	
## sample estimates:	
## mean of x mean of y 	
## 74.223251  7.219173	
t.test(x = scratch.m[scratch.m$BCS=="G. vaginalis","percent_cells"],y = 
DL_PH766_percent_proliferation$DL_1pct_766)	
## 	
##  Welch Two Sample t-test	
## 	
## data:  scratch.m[scratch.m$BCS == "G. vaginalis", "percent_cells"] and 
DL_PH766_percent_proliferation$DL_1pct_766	
## t = 6.0415, df = 2.2459, p-value = 0.01982	
## alternative hypothesis: true difference in means is not equal to 0	
## 95 percent confidence interval:	
##   8.070304 37.070274	
## sample estimates:	
## mean of x mean of y 	













## Factor Treatment to enforce order and make labels	
pi.m$Treatment<-factor(pi.m$Treatment,levels = c("Cdk4 400nM","Fascaplysin 
350nM","Cell Culture Medium"),ordered = T,labels = c("CAS 546102-60-
7","Fascaplysin","Cell Culture Medium"))	
	
## Create a significance testing data frame to hold results	
setup_sigtest.data<-setup_sigtest(pval_threshold = pval_threshold,raw_data = 





## Difference of means           Std Error                   t 	
##          -6.6236985           3.8807666          -1.7068016 	
##             p-value 	
##           0.1488428 	
## [1] 2	
## [1] "Proliferation"	
## Difference of means           Std Error                   t 	
##       -3.515431e+01        4.999389e+00       -7.031721e+00 	
##             p-value 	
##        6.107794e-05 	
## [1] 3	
## [1] "Proliferation"	
## Difference of means           Std Error                   t 	
##       -2.853061e+01        5.386636e+00       -5.296555e+00 	
##             p-value 	
##        3.539033e-04 	
## [1] 4	
## [1] "Infectivity"	
## Difference of means           Std Error                   t 	
##         -8.79632006          2.06013167         -4.26978536 	
##             p-value 	
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##          0.01525339 	
## [1] 5	
## [1] "Infectivity"	
## Difference of means           Std Error                   t 	
##       -5.338663e+01        7.813379e+00       -6.832720e+00 	
##             p-value 	
##        3.346066e-04 	
## [1] 6	
## [1] "Infectivity"	
## Difference of means           Std Error                   t 	
##       -44.590306829         7.736338543        -5.763748132 	
##             p-value 	
















  scale_fill_manual(values=c("Cell Culture 
Medium"='blue',"Fascaplysin"="#fdb863","CAS 546102-60-7"="#b2df8a"))+	
  mBio+	
  theme(plot.margin=unit(c(0,0,0,0),units = "pt"), 



















##                 2	







"Cell Culture Medium"='blue',SIS3="#c2a5cf","Fascaplysin"="#fdb863","CAS 
546102-60-7"="#b2df8a"))+ylab("Epithelial Cells Positive for EdU (%)")+	
  theme(plot.margin=unit(c(0,0,0,0),units = "pt"), 














##                 2	
## Print text describing results	
	
## Create variables to hold values for printing	
ct_sigtest<-unique(ct_sigtest)	
pro_C<-ct_sigtest[ct_sigtest$Observation=="Proliferation" & 
ct_sigtest$reference=="Cell Culture Medium" & ct_sigtest$xref=="CAS 546102-
60-7" ,c("mean_diff","pval")]	
pro_F<-ct_sigtest[ct_sigtest$Observation=="Proliferation" & 




ct_sigtest$reference=="Cell Culture Medium" & ct_sigtest$xref=="CAS 546102-
60-7" ,c("mean_diff","pval")]	
ct_F<-ct_sigtest[ct_sigtest$Observation=="Infectivity" & 




paste0("Epithelial cell proliferation was decreased by ",-pro_C$mean_diff,"% 
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(p=",pro_C$pval,") in CAS 546102-60-7 and ",-pro_F$mean_diff,"% 
(p=",pro_F$pval,") in Fascaplysin treated cells relative to Cell Culture 
Medium treated cells, respectively")	
## [1] "Epithelial cell proliferation was decreased by 35.1543095335083% 
(p=6.10779413826187e-05) in CAS 546102-60-7 and 28.530611023625% 
(p=0.000353903348334145) in Fascaplysin treated cells relative to Cell 
Culture Medium treated cells, respectively"	
paste0("C. trachomatis infection was decreased by ",-ct_C$mean_diff,"% 
(p=",ct_C$pval,") in CAS 546102-60-7 and ",-ct_F$mean_diff,"% 
(p=",ct_F$pval,") in Fascaplysin treated cells relative to Cell Culture 
Medium treated cells, respectively")	
## [1] "C. trachomatis infection was decreased by 53.3866268869905% 
(p=0.000334606564696431) in CAS 546102-60-7 and 44.5903068287238% 
(p=0.00100026580119664) in Fascaplysin treated cells relative to Cell Culture 
Medium treated cells, respectively"	
## Calcualte correlation between mean infectivity and mean proliferation	
corr_mx<-spread(pi.m,Observation, value=percent_cells)	
ggplot(corr_mx,aes(y=Infectivity,x=Proliferation,col=Treatment))+geom_point()
















## lm(formula = Infectivity ~ Proliferation, data = 
data.frame(corr_mx[!rowSums(is.na(corr_mx)) > 	
##     0, ]))	
## 	
## Residuals:	
##     Min      1Q  Median      3Q     Max 	
## -37.707  -9.275  -1.017   9.703  47.669 	
## 	
## Coefficients:	
##               Estimate Std. Error t value Pr(>|t|)    	
## (Intercept)   -1.79531    3.29799  -0.544    0.588    	
## Proliferation  1.19670    0.09104  13.145   <2e-16 ***	
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## ---	
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1	
## 	
## Residual standard error: 15.21 on 63 degrees of freedom	
## Multiple R-squared:  0.7328, Adjusted R-squared:  0.7286 	




## lm(formula = Infectivity ~ Proliferation, data = 
spread(dplyr::select(pi.summary, 	
##     -c(grand_sd, n)), Observation, grand_mean))	
## 	
## Residuals:	
##       1       2       3 	
##  0.6049 -0.7453  0.1404 	
## 	
## Coefficients:	
##                Estimate Std. Error t value Pr(>|t|)  	
## (Intercept)   -14.27998    1.06922  -13.36   0.0476 *	
## Proliferation   1.53185    0.03672   41.72   0.0153 *	
## ---	
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1	
## 	
## Residual standard error: 0.9701 on 1 degrees of freedom	
## Multiple R-squared:  0.9994, Adjusted R-squared:  0.9989 	
## F-statistic:  1740 on 1 and 1 DF,  p-value: 0.01526	











### Load previously prepared 16S metataxonomic data. metatdata	
load(file=paste0(R_script_input_directory,"subject_plot_data.Rdata"))	
OTU_METADATA<-subject_plot_data$OTU_METADATA ## metadata	
rRNA_16S<-subject_plot_data$relativeAbundance ## taxa assignments/relative 
abundances	
sampleInfoColNames<-subject_plot_data$sampleInfoColNames ## holds which 
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column names are associated with metadata	
	
miRNA_extractions<-SRL_meta_table[is.na(SRL_meta_table$QC_removal_stage),] ## 
Samples associated with miRNA libraries used in final study- i.e., don't 
include samples removed due to poor QC. 	
subject_plot_list<- unique(miRNA_extractions$SID) ## Subject IDs to plot	
	
global_species_list<-NULL ## Initialize a container to store all species 
plotted in fig 1 as a legend	
	
for(s in subject_plot_list){  ## iterate through the subject's	
  print(s)	
  #s<-"UAB008"	
  ## ////////////////////////////////// ##	
  ## ///  Subeset Data by Subject   /// ##	
  ## ////////////////////////////////// ##	
  	
  relabundance<-filter(rRNA_16S,SID==s)  ## taxa relative abundance for 
subject	
  otu_count<-OTU_METADATA[OTU_METADATA$SID==s,] ## Metadata for subject	
  	






  ##Nugent score data for subject	
  nugent<-filter(OTU_METADATA,SID==s) %>% dplyr::select(SERIAL,NUGENT_SCORE)	
  nugent$color<-"grey"	





  ## pH data for subject	
  ph<-filter(OTU_METADATA,SID==s) %>% dplyr::select(SERIAL,PH)	






  ##MEtadata for subject	
  dailyDiaryMetadata<-filter(OTU_METADATA,SID==s)	
  	
  ## ////////////////////////////////// ##	
  ##  Determine global plot time scale  ##	





ERIAL)) ## All time points	
  day<-SERIAL_global%%7 ## Day relative to all SERIALized time points	
  day[SERIAL_global%%7==0]<-7 ## the mod calcualtion causes all day 7 to be 
0. Repalce w/ 7. 	
  week<-((SERIAL_global-day)/7)+1 ## Week back calculated from SERIALized 
time points. 	




time_points[time_points$day==7,"week"] ## plot labels every week	
  global_min_time<-
max(c(min(miRNA_extractions[miRNA_extractions$SID==s,"SERIAL"]-
5),min(SERIAL_global,na.rm = T) ))	
  	




global,na.rm = T))) ## max time point across all data	
  removed_samples	
  ## cleaner way to define as variable for X axis:	




  ## Determine the min & max of time points	
  rect_min<-time_breaks[!time_breaks%in% 
miRNA_extractions[miRNA_extractions$SID==s,"SERIAL"]]-.5	
  rect_max<-time_breaks[!time_breaks%in% 
miRNA_extractions[miRNA_extractions$SID==s,"SERIAL"]]+.5	
  	
  ## ////////////////////////////////// ##	
  ## / Determine most adbundant species ##	
  ## ////////////////////////////////// ##	
  	
  # ////////////////////////////////////////////////////////////////////////	
  # Most abundant species defined per subject & based on cutoff. ##	
  # All other taxa binned into "other" #	
  # ////////////////////////////////////////////////////////////////////////	
  	
  ### Grab just relative abundances, no sample info columns:	
  relabundance[is.na(relabundance)]<-0	
  relabundance<-relabundance[relabundance$SERIAL>=time_limits[1] &  
relabundance$SERIAL<=time_limits[2],]	




  ### Calucalte max for each taxa	
  max_relabundances<-apply(relabundance_for_max_calc,2,max)	
  ### number of species whose rel abundance is above a certain threshold	
  numHighAbundSpecies<-sum(max_relabundances>raThreshold,na.rm = T) 	
  	
  ##### Plot either the top X most abundant species, 	
  #####   or the most abundant species above max plottable species, whichever 
is lesser.	
  #####   This helps prevent "taxa overload" on the plot. 	
  	
  most_abundant_species<-"" ## Will hold names of most abundant species. 	
  if(numHighAbundSpecies>nSpecies){ 	
    most_abundant_species<-names(sort(max_relabundances,decreasing = 
T))[1:nSpecies]	
  }else{	




  ##### Pull the most abundant species (defined above), bin the remainder 
into "other".	




  other_relabundance<-rowSums(relabundance[!(names(relabundance) %in% 
most_abundant_species | 	
                                               names(relabundance) %in% 
sampleInfoColNames)],na.rm=T)	
  otu_count_relabundance<-cbind(relabundance[names(relabundance) %in% 
c("SERIAL",sampleInfoColNames)],	
                                
most_abundant_relabundance,Other=other_relabundance)	
  	






  otu_count_reshape<-melt(data = 
otu_count_relabundance,id.vars=reshape_names)	
  names(otu_count_reshape)<-c(reshape_names,"species","count") 	
  	
  ### ///////////////////////////////////////////// ###	
  ### /////////         OTU Plot          ///////// ###	
  ### ///////////////////////////////////////////// ###	
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  otuPlot<- ggplot(otu_count_reshape)+	
    geom_area(aes(x=SERIAL,y=count,fill=species),	
              stat="identity",show.legend=F,position="fill")+#,width=1)+	
    mBio+	
    theme(axis.ticks = element_blank(),	
          axis.title.x=element_blank(),	
          axis.text.x = element_blank(),	
          axis.text.y = element_text(size = rel(1.5)),	
          legend.key.size=unit(8, "points"),	
          legend.title = element_blank(),	
          legend.text = element_text(size = rel(.5),face="italic"),	
          axis.title = element_text(size = rel(sizes)),	
          plot.margin=unit(c(2.5,40,2.5,10),units="points"),#margins	
          panel.grid.major.y=element_line(colour = "grey73"),	
          panel.grid.minor.x  = element_blank())+	
    ylab("Phylotype Relative\nAbundance (%)")+	
    geom_vline(xintercept = 
otu_count_reshape$SERIAL,size=rel(.2),col="grey")+	
    scale_fill_manual(values=subject_long_taxa_colors)+	
    ggtitle(paste0(s))+	
    annotate("rect", xmin=rect_min, xmax=rect_max, ymin=0, ymax=1, 
alpha=alpha_rect, fill=rect_fill)+	
    
scale_x_continuous(breaks=time_breaks,label=time_label,limits=time_limits)	
  	
  ## Determine any dropped sample (post QC) time points and place an * above 	
  dropped_samples.serial<-otu_count[otu_count$Pre_QC_ID %in% 
removed_samples$Pre_QC_ID,"SERIAL"]	
  if(length(dropped_samples.serial)!=0){otuPlot<-otuPlot+annotate("text", x 
=dropped_samples.serial , y = 1.01, label = "*",size=8)}	
  	
  	
  ### ///////////////////////////////////////////// ###	
  ### /////////      Nugent Plot          ///////// ###	
  ### ///////////////////////////////////////////// ###	
  nugentPlot<-ggplot(data=nugent)+	
    geom_bar(aes(x=as.numeric(SERIAL),y=NUGENT_SCORE,width=.9,fill=color),	
             stat="identity",position = position_dodge(width=0.5))+	
    mBio+	
    geom_hline(yintercept = c(3,7),size=rel(1),col="pink")+ ## Defines Nugent 
score 3 & 7 (BV 	
    theme(axis.ticks = element_blank(),	
          axis.title.x=element_blank(),	
          axis.text.x = element_blank(),	
          axis.text.y = element_text(size = rel(1.5*sizes)),	
          legend.position="none",	
          plot.margin=margins,	
          panel.grid.major.y=element_line(colour = "grey73"),	
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          panel.grid.minor.x  = element_blank())+	
    ylab("Nugent\nScore")+	
    scale_fill_manual(values=c('black','red'))+	
    
scale_x_continuous(breaks=time_breaks,label=time_label,limits=time_limits)+	
    annotate("rect", xmin=rect_min, xmax=rect_max, ymin=0, ymax=10, 
alpha=alpha_rect, fill=rect_fill)+	
    scale_y_continuous(breaks=c(0,3,7,10),limits=c(-1.25,10.5))	
  	
  	
  ### ///////////////////////////////////////////// ###	
  ### /////////     Metadata Plot         ///////// ###	
  ### ///////////////////////////////////////////// ###	
  metaPlot<-ggplot(dailyDiaryMetadata, aes(x=as.numeric(SERIAL)))+	
    geom_point(aes(y=1*(as.numeric(VAG_DIS)==1),size=2),	
               pch=16,col='blue',position = position_dodge(width=0.5))+	
    geom_point(aes(y=2*(as.numeric(VAG_ODOR)==1),size=2),	
               pch=16,col='blue',position = position_dodge(width=0.5))+	
    
geom_point(aes(y=3*(as.numeric(MENSTRUATION)>0),size=as.numeric(MENSTRUATION)
),	
               col='red',pch=16, position = position_dodge(width=0.5))+	
    scale_size(range = c(2+2,4+2))+ ## for menstru point sizes. Bounded by 3 
points on a scale. 	
    mBio+	
    theme(legend.position="none",	
          plot.title = element_text(size = rel(sizes)),	
          axis.text = element_text(size = rel(2*sizes)),	
          axis.title = element_text(size = rel(sizes)),	
          axis.title.y=element_text(vjust=.2),	
          axis.title.x=element_text(vjust=-.2),	
          axis.text.y=element_text(size=rel(0.75)), ## change back to 0.75	
          plot.margin=unit(c(-2.5,40,5,5),units="points"),	
          panel.grid.major.y=element_line(colour = "grey73"),	
          panel.grid.minor.x  = element_blank())+	
    xlab("Week")+	
    ylab("")+	
    annotate("rect", xmin=rect_min, xmax=rect_max, ymin=1, ymax=3, 
alpha=alpha_rect, fill=rect_fill)+	
    
scale_x_continuous(breaks=time_breaks,label=time_label,limits=time_limits)+	
    scale_y_continuous(breaks=1:3,labels = c("Discharge",	
                                             "Odor",	
                                             
"Menstruation"),limits=c(0.5,3.5))	
  	





    min<-min(timeTable$SERIAL,na.rm = T)	
    max<-max(timeTable$SERIAL,na.rm = T)	
    middle.x<-(max-min)/2	
    middle.y<<-(16-1)/2	
    metaPlot<-metaPlot + annotate("text", x = middle.x, 	
                                  y = middle.y, label = "?",	
                                  size=rel(40),	
                                  col="grey")	
  }	
  	
  ### ///////////////////////////////////////////// ###	
  ### /////////          pH Plot          ///////// ###	
  ### ///////////////////////////////////////////// ###	
  ph_normalization_factor<-3.5	
  ## Notice the pH value scale is "normalized" by subtracting 
"ph_normalization_factor" from the actual pH value, then re-labeling the y 
axis. This is very dangerous, but ggplot will not permit bar plots that start 




                        y=as.numeric(PH)-
ph_normalization_factor,width=.9,fill=color))+ 	
    geom_bar(stat="identity",position = position_dodge(width=0.5))+	
    scale_fill_manual(values=c('black','red'))+	
    mBio+	
    geom_hline(yintercept = c(4.5-ph_normalization_factor),	
               size=rel(1),col="pink")+ ## Vaginal pH>4.5 one criteria for 
BV. 	
    theme(axis.ticks = element_blank(),	
          axis.title.x=element_blank(),	
          axis.text.x = element_blank(),	
          axis.text = element_text(size = rel(1.5*sizes)),	
          legend.position="none",	
          plot.margin=margins,	
          panel.grid.major.y=element_line(colour = "grey73"),	
          panel.grid.minor.x  = element_blank())+	
    ylab("pH")+	
    annotate("rect", xmin=rect_min, xmax=rect_max, ymin=min(0,min(ph$PH,na.rm 
= T)-ph_normalization_factor-0.25), ymax= max(ph$PH,na.rm = T)+0.25-
ph_normalization_factor, alpha=alpha_rect, fill=rect_fill)+	
    
scale_x_continuous(breaks=time_breaks,label=time_label,limits=time_limits)+	






  ### ///////////////////////////////////////////// ###	
  ### /////////    Tie Plots Together     ///////// ###	
  ### ///////////////////////////////////////////// ###	
  	
  ## ////////////////////////// ##	
  ## //Define plots as Grobs/// ##	
  ## ////////////////////////// ##	
  	
  grob.otuPlot <- ggplotGrob(otuPlot)	
  grob.nugentPlot <- ggplotGrob(nugentPlot)	
  grob.phPlot<-ggplotGrob(phPlot)	
  grob.metaPlot <- ggplotGrob(metaPlot)	
  	
  ## ////////////////////////// ##	
  ## ///   Find max width   /// ##	
  ## ////////////////////////// ##	
  maxWidth = grid::unit.pmax(grob.otuPlot$widths[1:6],	
                             grob.nugentPlot$widths[1:5],	
                             grob.phPlot$widths[1:5],	
                             grob.metaPlot$widths[1:5])	
  	
  ## ////////////////////////// ##	
  ## /Redefine common max width ##	
  ## ////////////////////////// ##	
  grob.nugentPlot$widths[1:6] <- as.list(maxWidth)	
  grob.otuPlot$widths[1:6] <- as.list(maxWidth)	
  grob.metaPlot$widths[1:6] <- as.list(maxWidth)	
  grob.phPlot$widths[1:6]<-as.list(maxWidth)	
  	
  ### ///////////////////////////////////////////// ###	
  ### /////////      Write/Draw Plot     ///////// ###	




= 11,height = 8.5)	
  	
  grid.arrange(grob.otuPlot,	
               grob.nugentPlot,	
               grob.phPlot,	
               grob.metaPlot, 	
               ncol=1,nrow=4,	





















## The following plots the figure legend containing colors for all taxa 








            stat="identity",show.legend=T,position="fill")+#,width=1)+	
  mBio+	
  theme(axis.ticks = element_blank(),	
        axis.title.x=element_blank(),	
        axis.text.x = element_blank(),	
        legend.key.size=unit(8, "points"),	
        legend.title = element_blank(),	
        legend.text = element_text(size = rel(.5),face="italic"),	
        axis.title = element_text(size = rel(sizes)),	
        plot.margin=unit(c(2.5,40,2.5,10),units="points"),#margins	
        panel.grid.major.y=element_line(colour = "grey73"))+	
  scale_fill_manual(values=subject_long_taxa_colors)+	
  ggtitle("Global Species List Color Codes")	
	
##Write legend to file	
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cairo_ps(paste0(thesis_figures_directory,FIGURE_SUBJECT_PLOTS,"GlobalSpeciesL




##                 2	
Ribo-reduced	RNA-seq	Analysis	







("Number of Samples")+geom_vline(xintercept = 
median(TRL_RNA_Sample_QuantQual$V1),col='red')+mBio	
plot(p)	
## `stat_bin()` using `bins = 30`. Pick better value with `binwidth`.	
dev.off()	
## quartz_off_screen 	
##                 2	
plot(p)	




##    Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 	
##   3.100   9.200   9.500   9.366   9.800  10.000	
summary(10*TRL_RNA_Sample_QuantQual[TRL_RNA_Sample_QuantQual$V1!=3.1,"V2"])	
##    Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 	
##   226.0   438.5   634.0   616.5   767.5  1120.0	
Read	counts	data	in	from	server	
### ---------------------------------	







~/IGS/sshfs_medusa/", intern = FALSE,	
       ignore.stdout = FALSE, ignore.stderr = FALSE,	
       wait = TRUE, input = NULL, show.output.on.console = TRUE,	















  #sub_feature_set<-!new_table$Feature %in% 
c(filtered_out_features,"mirna_info")	
  ## Don't forget about ambigous/none features!	
  #new_table<-new_table[sub_feature_set,]	


















## Filter out ambiguous, no feature reads. Make note of how many there are	
TRL_counts_table[row.names(TRL_counts_table) %in% 
c("alignment_not_unique","no_feature","ambiguous"),]	
##                      VK2_GVAGINALIS_BCS_13HR_rep1	
## alignment_not_unique                      1659810	
## ambiguous                                   72201	
## no_feature                                3075288	
##                      VK2_LCRISPATUS_BCS_13HR_rep2	
## alignment_not_unique                      1412089	
## ambiguous                                   36836	
## no_feature                                3279466	
##                      VK2_LJENSENII_BCS_13HR_rep2 VK2_LINERS_BCS_13HR_rep2	
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## alignment_not_unique                     1568882                   657465	
## ambiguous                                  43491                    24472	
## no_feature                               3468681                  2136668	
##                      VK2_GVAGINALIS_BCS_13HR_rep2 VK2_MEDIA_BCS_13HR_rep1	
## alignment_not_unique                      1019153                  813706	
## ambiguous                                   47530                   32173	
## no_feature                                3914945                 3257161	
##                      VK2_LCRISPATUS_BCS_22HR_rep1	
## alignment_not_unique                       888176	
## ambiguous                                   20079	
## no_feature                                3186044	
##                      VK2_LJENSENII_BCS_22HR_rep1 VK2_LINERS_BCS_22HR_rep1	
## alignment_not_unique                     1547911                   479715	
## ambiguous                                  47238                    22808	
## no_feature                               2931450                  2268805	
##                      VK2_LJENSENII_BCS_4HR_rep2 VK2_LINERS_BCS_4HR_rep2	
## alignment_not_unique                    1056023                 1259736	
## ambiguous                                 48041                   43226	
## no_feature                              3037420                 3488226	
##                      VK2_GVAGINALIS_BCS_4HR_rep2 VK2_MEDIA_BCS_4HR_rep2	
## alignment_not_unique                      712114                1230561	
## ambiguous                                  26952                  44876	
## no_feature                               2369104                3902295	
##                      VK2_LCRISPATUS_BCS_4HR_rep1	
## alignment_not_unique                     3511899	
## ambiguous                                  79107	
## no_feature                               5717691	
##                      VK2_LJENSENII_BCS_4HR_rep1 VK2_LINERS_BCS_4HR_rep1	
## alignment_not_unique                     673805                  968908	
## ambiguous                                 19770                   33938	
## no_feature                              4664422                 4209178	
##                      VK2_GVAGINALIS_BCS_4HR_rep1 VK2_MEDIA_BCS_4HR_rep1	
## alignment_not_unique                     1596106                1336499	
## ambiguous                                  51607                  52997	
## no_feature                               3658460                4357425	
##                      VK2_LCRISPATUS_BCS_13HR_rep1	
## alignment_not_unique                      1467776	
## ambiguous                                   41804	
## no_feature                                2886596	
##                      VK2_LJENSENII_BCS_13HR_rep1 VK2_LINERS_BCS_13HR_rep1	
## alignment_not_unique                     1009315                   378146	
## ambiguous                                  25940                    11378	
## no_feature                               3342529                  3070524	
##                      VK2_MEDIA_BCS_22HR_rep1 VK2_LCRISPATUS_BCS_4HR_rep2	
## alignment_not_unique                 1531300                      774318	
## ambiguous                              66155                       20755	
## no_feature                           5086258                     3881756	
##                      VK2_MEDIA_BCS_13HR_rep2 VK2_LCRISPATUS_BCS_22HR_rep2	
## alignment_not_unique                 3011458                      3026810	
## ambiguous                              92696                        60297	
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## no_feature                           3169404                      4151315	
##                      VK2_LJENSENII_BCS_22HR_rep2 VK2_LINERS_BCS_22HR_rep2	
## alignment_not_unique                     1190320                   462056	
## ambiguous                                  30935                    14413	
## no_feature                               4117821                  3010909	
##                      VK2_GVAGINALIS_BCS_22HR_rep2	
## alignment_not_unique                       453069	
## ambiguous                                   16728	
## no_feature                                3168877	
##                      VK2_GVAGINALIS_BCS_4HR_rep3 VK2_MEDIA_BCS_4HR_rep3	
## alignment_not_unique                     2380178                1313853	
## ambiguous                                  93189                  60327	
## no_feature                               4742894                4355267	
##                      VK2_LCRISPATUS_BCS_13HR_rep3	
## alignment_not_unique                       188513	
## ambiguous                                    2133	
## no_feature                                2477532	
##                      VK2_LJENSENII_BCS_13HR_rep3 VK2_LINERS_BCS_13HR_rep3	
## alignment_not_unique                     1389726                  3545491	
## ambiguous                                  54050                   108724	
## no_feature                               4957907                  4458395	
##                      VK2_GVAGINALIS_BCS_13HR_rep3 VK2_MEDIA_BCS_13HR_rep3	
## alignment_not_unique                      5904365                 2844329	
## ambiguous                                  230423                   73038	
## no_feature                                5816169                 5443374	
##                      VK2_LCRISPATUS_BCS_22HR_rep3	
## alignment_not_unique                      7539963	
## ambiguous                                  171506	
## no_feature                                5283834	
##                      VK2_LJENSENII_BCS_22HR_rep3 VK2_LINERS_BCS_22HR_rep3	
## alignment_not_unique                     6003165                  2546317	
## ambiguous                                 195482                   101360	
## no_feature                               5238683                  4494104	
##                      VK2_GVAGINALIS_BCS_22HR_rep3 VK2_MEDIA_BCS_22HR_rep3	
## alignment_not_unique                      2979388                 2308331	
## ambiguous                                   87512                  104417	
## no_feature                                4729799                 4141951	
## Percentage of ambiguous/no feature/non unique reads & alignment stats	
(ambig_nofeat<-colSums(TRL_counts_table[row.names(TRL_counts_table) %in% 
c("alignment_not_unique","no_feature","ambiguous"),]))	
## VK2_GVAGINALIS_BCS_13HR_rep1 VK2_LCRISPATUS_BCS_13HR_rep2 	
##                      4807299                      4728391 	
##  VK2_LJENSENII_BCS_13HR_rep2     VK2_LINERS_BCS_13HR_rep2 	
##                      5081054                      2818605 	
## VK2_GVAGINALIS_BCS_13HR_rep2      VK2_MEDIA_BCS_13HR_rep1 	
##                      4981628                      4103040 	
## VK2_LCRISPATUS_BCS_22HR_rep1  VK2_LJENSENII_BCS_22HR_rep1 	
##                      4094299                      4526599 	
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##     VK2_LINERS_BCS_22HR_rep1   VK2_LJENSENII_BCS_4HR_rep2 	
##                      2771328                      4141484 	
##      VK2_LINERS_BCS_4HR_rep2  VK2_GVAGINALIS_BCS_4HR_rep2 	
##                      4791188                      3108170 	
##       VK2_MEDIA_BCS_4HR_rep2  VK2_LCRISPATUS_BCS_4HR_rep1 	
##                      5177732                      9308697 	
##   VK2_LJENSENII_BCS_4HR_rep1      VK2_LINERS_BCS_4HR_rep1 	
##                      5357997                      5212024 	
##  VK2_GVAGINALIS_BCS_4HR_rep1       VK2_MEDIA_BCS_4HR_rep1 	
##                      5306173                      5746921 	
## VK2_LCRISPATUS_BCS_13HR_rep1  VK2_LJENSENII_BCS_13HR_rep1 	
##                      4396176                      4377784 	
##     VK2_LINERS_BCS_13HR_rep1      VK2_MEDIA_BCS_22HR_rep1 	
##                      3460048                      6683713 	
##  VK2_LCRISPATUS_BCS_4HR_rep2      VK2_MEDIA_BCS_13HR_rep2 	
##                      4676829                      6273558 	
## VK2_LCRISPATUS_BCS_22HR_rep2  VK2_LJENSENII_BCS_22HR_rep2 	
##                      7238422                      5339076 	
##     VK2_LINERS_BCS_22HR_rep2 VK2_GVAGINALIS_BCS_22HR_rep2 	
##                      3487378                      3638674 	
##  VK2_GVAGINALIS_BCS_4HR_rep3       VK2_MEDIA_BCS_4HR_rep3 	
##                      7216261                      5729447 	
## VK2_LCRISPATUS_BCS_13HR_rep3  VK2_LJENSENII_BCS_13HR_rep3 	
##                      2668178                      6401683 	
##     VK2_LINERS_BCS_13HR_rep3 VK2_GVAGINALIS_BCS_13HR_rep3 	
##                      8112610                     11950957 	
##      VK2_MEDIA_BCS_13HR_rep3 VK2_LCRISPATUS_BCS_22HR_rep3 	
##                      8360741                     12995303 	
##  VK2_LJENSENII_BCS_22HR_rep3     VK2_LINERS_BCS_22HR_rep3 	
##                     11437330                      7141781 	
## VK2_GVAGINALIS_BCS_22HR_rep3      VK2_MEDIA_BCS_22HR_rep3 	
##                      7796699                      6554699	
(aligned<-colSums(TRL_counts_table[!row.names(TRL_counts_table) %in% 
c("alignment_not_unique","no_feature","ambiguous"),]))	
## VK2_GVAGINALIS_BCS_13HR_rep1 VK2_LCRISPATUS_BCS_13HR_rep2 	
##                      3483930                      3024389 	
##  VK2_LJENSENII_BCS_13HR_rep2     VK2_LINERS_BCS_13HR_rep2 	
##                      2974822                      1729117 	
## VK2_GVAGINALIS_BCS_13HR_rep2      VK2_MEDIA_BCS_13HR_rep1 	
##                      3155228                      2030629 	
## VK2_LCRISPATUS_BCS_22HR_rep1  VK2_LJENSENII_BCS_22HR_rep1 	
##                      1416161                      2950478 	
##     VK2_LINERS_BCS_22HR_rep1   VK2_LJENSENII_BCS_4HR_rep2 	
##                      1532055                      3206459 	
##      VK2_LINERS_BCS_4HR_rep2  VK2_GVAGINALIS_BCS_4HR_rep2 	
##                      3115872                      1880874 	
##       VK2_MEDIA_BCS_4HR_rep2  VK2_LCRISPATUS_BCS_4HR_rep1 	
##                      3207936                      5558855 	
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##   VK2_LJENSENII_BCS_4HR_rep1      VK2_LINERS_BCS_4HR_rep1 	
##                      1533479                      2645213 	
##  VK2_GVAGINALIS_BCS_4HR_rep1       VK2_MEDIA_BCS_4HR_rep1 	
##                      3555610                      3745190 	
## VK2_LCRISPATUS_BCS_13HR_rep1  VK2_LJENSENII_BCS_13HR_rep1 	
##                      3386120                      1921098 	
##     VK2_LINERS_BCS_13HR_rep1      VK2_MEDIA_BCS_22HR_rep1 	
##                       863055                      4670961 	
##  VK2_LCRISPATUS_BCS_4HR_rep2      VK2_MEDIA_BCS_13HR_rep2 	
##                      1648935                      4892080 	
## VK2_LCRISPATUS_BCS_22HR_rep2  VK2_LJENSENII_BCS_22HR_rep2 	
##                      4392899                      2049302 	
##     VK2_LINERS_BCS_22HR_rep2 VK2_GVAGINALIS_BCS_22HR_rep2 	
##                      1021441                      1354926 	
##  VK2_GVAGINALIS_BCS_4HR_rep3       VK2_MEDIA_BCS_4HR_rep3 	
##                      5603541                      5132964 	
## VK2_LCRISPATUS_BCS_13HR_rep3  VK2_LJENSENII_BCS_13HR_rep3 	
##                       161415                      3802258 	
##     VK2_LINERS_BCS_13HR_rep3 VK2_GVAGINALIS_BCS_13HR_rep3 	
##                      6838588                     10538780 	
##      VK2_MEDIA_BCS_13HR_rep3 VK2_LCRISPATUS_BCS_22HR_rep3 	
##                      4873897                      8448815 	
##  VK2_LJENSENII_BCS_22HR_rep3     VK2_LINERS_BCS_22HR_rep3 	
##                      8633553                      5445716 	
## VK2_GVAGINALIS_BCS_22HR_rep3      VK2_MEDIA_BCS_22HR_rep3 	







## Look at proportion of Ambigous/no feature/non-unique	
hist(alignment_stats$aligned.percent,main="Percentage of Aligned 





paste0("The following samples have ambigous reads >80%: ", 
str_c(row.names(ambig_nofeat_readpercent.high),collapse = ", "))	
## [1] "The following samples have ambigous reads >80%: 
VK2_LINERS_BCS_13HR_rep1, VK2_LCRISPATUS_BCS_13HR_rep3"	















## Create replicate #, lactobacillus indicator. Then combine BCS and exposure 
time for 'group1' for eventually creating constrasts	

















as.matrix(TRL_counts_table),phenoData  = AnnotatedDataFrame(TRL_design))	
Plot	Replicates	
## THis may take a while given there are ~20,000 points to plot for each 
comparison. Consdier trimming the lower expresed reads by using rmlow = 
log(10,10) for example	
postscript(paste0(R_script_output_directory,"TRL_RNASeq_Replicate_plots.eps")

















c("VK2_MEDIA_BCS_4HR_rep3","VK2_LCRISPATUS_BCS_13HR_rep3") ## determined from 
replciate plots and # of ambigous (rRNA) reads.	
	









##Summary of # of samples with at least one read across all samples	
summary(rowSums(exprs(TRL_counts_meta.qc)[rowSums(exprs(TRL_counts_meta.qc)>0
)>0,]>0))	
##    Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 	
##     1.0    19.0    38.0    28.8    38.0    38.0	




## Summary of remaining total read counts	
summary(colSums(exprs(TRL_counts_meta.qc)))	
##     Min.  1st Qu.   Median     Mean  3rd Qu.     Max. 	




##           BCS ExposureTime n	
## 1  LCRISPATUS          4HR 2	
## 2  LCRISPATUS         13HR 2	
## 3  LCRISPATUS         22HR 3	
## 4   LJENSENII          4HR 2	
## 5   LJENSENII         13HR 3	
## 6   LJENSENII         22HR 3	
## 7      LINERS          4HR 2	
## 8      LINERS         13HR 3	
## 9      LINERS         22HR 3	
## 10 GVAGINALIS          4HR 3	
## 11 GVAGINALIS         13HR 3	
## 12 GVAGINALIS         22HR 2	
## 13      MEDIA          4HR 2	
## 14      MEDIA         13HR 3	




## take counts table design created above and make edgeR object	
design <-model.matrix(~0+group1,data = pData(TRL_counts_meta.qc))	
edgeR	GLM	FIT	
Not	evualted	as	it	takes	some	time.	Change	to	eval=T	to	re-compute	edgeR	results	











## Go through each pait-wise comparison in constarsts and compute 















































  comp<-glmLRT(TRL_glmFit,contrast = contr[,comparison]) ## DE using 
constrast	
	
  de.table<-comp$table[abs(comp$table$logFC)>1 & comp$table$logCPM>1 & 
p.adjust(comp$table$PValue,method = "fdr")<=0.01,]	
  comp$table$PValue.adj<-p.adjust(comp$table$PValue,method = "fdr")	
  desets[[comparison]]<-list(detags=nrow(de.table),fulltable=comp$table)	







##Timecourse files are from IPA- contain pathway list and activation z 
values.	
	










  newt<-  read.table(paste0(R_script_input_directory,tab),header = T,sep = 
"\t",skip = 1,na.strings = "N/A",stringsAsFactors = F) %>% dplyr::select(-X)	
  pathway_zscores<-merge(newt,pathway_zscores,all = T)	
}	
	



















































                        
data.frame(num_immune.p=colSums(pathway_zscores.matrix.medium[row.names(data.
frame(pathway_zscores.matrix.medium)) %in% 
path_type_map[path_type_map$class=="i","pathway"],]>2)),            	



















## Write table summarizing the number of pathways above or below z score, 







##Sort # of z>2 pathways by negative cycle, positive immune and negative 
immune	
summary_pathways[order(summary_pathways$num_cycle.n,decreasing = T),]	
##    comparison num_cycle.p num_cycle.n num_immune.p num_immune.n	
## 4      LCM.13           1           4            2            0	
## 5      LCM.22           0           3            0            1	
## 6       LCM.4           3           2           11            0	
## 10     LJM.13           0           2            1            1	
## 11     LJM.22           0           2            1            1	
## 3       GVM.4           3           1           18            0	
## 8      LIM.22           0           1            3            0	
## 12      LJM.4           1           1            2            0	
## 1      GVM.13           1           0            8            0	
## 2      GVM.22           0           0            2            0	
## 7      LIM.13           0           0            7            0	
## 9       LIM.4           4           0           16            0	
##    num_immune_pro.n num_immune_pro.p comp ExposureTime  L ref	
## 4                 0                1  LCM           13 LC   M	
## 5                 0                0  LCM           22 LC   M	
## 6                 0                5  LCM            4 LC   M	
## 10                0                1  LJM           13 LJ   M	
## 11                0                1  LJM           22 LJ   M	
## 3                 0                8  GVM            4 GV   M	
## 8                 0                1  LIM           22 LI   M	
## 12                0                2  LJM            4 LJ   M	
## 1                 0                3  GVM           13 GV   M	
## 2                 0                1  GVM           22 GV   M	
## 7                 0                4  LIM           13 LI   M	
## 9                 0                7  LIM            4 LI   M	
summary_pathways[order(summary_pathways$num_immune.p,decreasing = T),]	
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##    comparison num_cycle.p num_cycle.n num_immune.p num_immune.n	
## 3       GVM.4           3           1           18            0	
## 9       LIM.4           4           0           16            0	
## 6       LCM.4           3           2           11            0	
## 1      GVM.13           1           0            8            0	
## 7      LIM.13           0           0            7            0	
## 8      LIM.22           0           1            3            0	
## 2      GVM.22           0           0            2            0	
## 4      LCM.13           1           4            2            0	
## 12      LJM.4           1           1            2            0	
## 10     LJM.13           0           2            1            1	
## 11     LJM.22           0           2            1            1	
## 5      LCM.22           0           3            0            1	
##    num_immune_pro.n num_immune_pro.p comp ExposureTime  L ref	
## 3                 0                8  GVM            4 GV   M	
## 9                 0                7  LIM            4 LI   M	
## 6                 0                5  LCM            4 LC   M	
## 1                 0                3  GVM           13 GV   M	
## 7                 0                4  LIM           13 LI   M	
## 8                 0                1  LIM           22 LI   M	
## 2                 0                1  GVM           22 GV   M	
## 4                 0                1  LCM           13 LC   M	
## 12                0                2  LJM            4 LJ   M	
## 10                0                1  LJM           13 LJ   M	
## 11                0                1  LJM           22 LJ   M	
## 5                 0                0  LCM           22 LC   M	
summary_pathways[order(summary_pathways$num_immune.n,decreasing = T),]	
##    comparison num_cycle.p num_cycle.n num_immune.p num_immune.n	
## 5      LCM.22           0           3            0            1	
## 10     LJM.13           0           2            1            1	
## 11     LJM.22           0           2            1            1	
## 1      GVM.13           1           0            8            0	
## 2      GVM.22           0           0            2            0	
## 3       GVM.4           3           1           18            0	
## 4      LCM.13           1           4            2            0	
## 6       LCM.4           3           2           11            0	
## 7      LIM.13           0           0            7            0	
## 8      LIM.22           0           1            3            0	
## 9       LIM.4           4           0           16            0	
## 12      LJM.4           1           1            2            0	
##    num_immune_pro.n num_immune_pro.p comp ExposureTime  L ref	
## 5                 0                0  LCM           22 LC   M	
## 10                0                1  LJM           13 LJ   M	
## 11                0                1  LJM           22 LJ   M	
## 1                 0                3  GVM           13 GV   M	
## 2                 0                1  GVM           22 GV   M	
## 3                 0                8  GVM            4 GV   M	
## 4                 0                1  LCM           13 LC   M	
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## 6                 0                5  LCM            4 LC   M	
## 7                 0                4  LIM           13 LI   M	
## 8                 0                1  LIM           22 LI   M	
## 9                 0                7  LIM            4 LI   M	
## 12                0                2  LJM            4 LJ   M	





## Clean up some of the pathway names in pathway map	
path_type_map[path_type_map$pathway=="NF-_B Signaling","pathway"]<-"NF-κB 
Signaling"	
path_type_map[path_type_map$pathway=="PKC_ Signaling in T 

















##   c   i   o pro 	
##  11  12   5   7	






















##Clean up the pathway names for better plotting	
pathway_zscores.medium.melt[pathway_zscores.medium.melt$pathway=="Role of IL-
17F in Allergic Inflammatory Airway Diseases","pathway"]<-"IL-17F in Allgc. 
Inflam. Arwy Dis."	
pathway_zscores.medium.melt[pathway_zscores.medium.melt$pathway=="Role of 
Pattern Recognition Receptors in Recognition of Bacteria and 
Viruses","pathway"]<-"PRRs/ Bacteria and Viruses"	
pathway_zscores.medium.melt[pathway_zscores.medium.melt$pathway=="Production 
of Nitric Oxide and Reactive Oxygen Species in Macrophages","pathway"]<-
"Production of NO and ROS in Macrophages"	
pathway_zscores.medium.melt[pathway_zscores.medium.melt$pathway=="PKCθ 
Signaling in T Lymphocytes","pathway"]<-"PKCθ Signaling"	
pathway_zscores.medium.melt[pathway_zscores.medium.melt$pathway=="PI3K 
Signaling in B Lymphocytes","pathway"]<-"PI3K Signaling"	
	
##Subset z-scores table by immune (proinflammatory) pathways or cell cycle 
pathways	
pathway_zscores.medium.melt.immune<-









##    class                                    pathway	
## 1    pro             Acute Phase Response Signaling	
## 2      c            Antioxidant Action of Vitamin C	
## 3      c                              ATM Signaling	
## 4    pro                  B Cell Receptor Signaling	
## 5      c Cholecystokinin/Gastrin-mediated Signaling	
## 6      c     Colorectal Cancer Metastasis Signaling	
## 7      c          Cyclins and Cell Cycle Regulation	
## 8      c                   Death Receptor Signaling	
## 9      i                  Dendritic Cell Maturation	
## 10     c            Estrogen-mediated S-phase Entry	
## 11   pro                            HMGB1 Signaling	
## 12   pro                             IL-1 Signaling	
## 13     i                             IL-6 Signaling	
## 14     i                             IL-8 Signaling	
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## 15     c                              ILK Signaling	
## 16     i                             iNOS Signaling	
## 17     i                       Interferon Signaling	
## 18     o                         LXR/RXR Activation	
## 19   pro          MIF Regulation of Innate Immunity	
## 20     c          Mitotic Roles of Polo-Like Kinase	
## 21     i                            NF-κB Signaling	
## 22     o    NRF2-mediated Oxidative Stress Response	
## 23     i                         p38 MAPK Signaling	
## 24     i                             PI3K Signaling	
## 25     i                             PKCθ Signaling	
## 26     o                             PPAR Signaling	
## 27     i    Production of NO and ROS in Macrophages	
## 28     c              RANK Signaling in Osteoclasts	
## 29     c       Role of BRCA1 in DNA Damage Response	
## 30     i         IL-17F in Allgc. Inflam. Arwy Dis.	
## 31   pro                 PRRs/ Bacteria and Viruses	
## 32   pro               Toll-like Receptor Signaling	
## 33     i                            TREM1 Signaling	
## 34     o         Type I Diabetes Mellitus Signaling	
## 35     o                 UVA-Induced MAPK Signaling	
paste0("Number of pathways belonging to each class:")	




##   c   i   o pro 	
##  11  12   5   7	
paste0(c("the remaining 5 pathways did not belong to either cell cycle or 
immunity:",str_c(unique(dplyr::select(pathway_zscores.medium.melt,c(class,pat
hway))) %>% dplyr::filter(class=="o") %>% dplyr::select(pathway),collapse = 
", ")))	
## [1] "the remaining 5 pathways did not belong to either cell cycle or 
immunity:"                                                                                         	
## [2] "c(\"LXR/RXR Activation\", \"NRF2-mediated Oxidative Stress 





       na.value="yellow", midpoint=0)+facet_wrap(~comp,nrow=1)+	
  #mBio+	
  theme_bw() + theme(text = element_text(colour = "black",size=12))	













       na.value="yellow", midpoint=0)+facet_wrap(~comp,nrow=1)+	
  mBio+	





##                 2	
Extract	and	plot	logFC	values	from	LRT	table	




























##        68%        95% 	
## 0.04733638 2.00227280	
edgeR_results[1:5,1:6]	
##       gene LCGV.4.logFC LCGV.4.logCPM LCGV.4.LR LCGV.4.PValue	
## 1     A1BG    0.1939510     2.4093604 0.1224118     0.7264333	
## 2 A1BG-AS1   -0.3227594     3.4936307 0.9826982     0.3215336	
## 3     A1CF    0.0000000    -0.9245545 0.0000000     1.0000000	
## 4      A2M    0.0000000    -0.9245545 0.0000000     1.0000000	
## 5  A2M-AS1    0.6333559    -0.4253955 0.2134882     0.6440470	
##   LCGV.4.PValue.adj	
## 1         1.0000000	
## 2         0.8634145	
## 3         1.0000000	
## 4         1.0000000	






##        LCM.4.PValue.adj LJM.4.PValue.adj LIM.4.PValue.adj GVM.4.PValue.adj	
## CDKN1A     7.765397e-10     7.132150e-06     5.904157e-11     0.0004304325	
## EGFR       1.000000e+00     6.757156e-01     5.802838e-01     0.4210450337	
## EP300      9.065477e-01     1.000000e+00     5.297162e-01     1.0000000000	
## HDAC4      1.000000e+00     1.000000e+00     7.308229e-01     1.0000000000	
##        LCM.13.PValue.adj LJM.13.PValue.adj LIM.13.PValue.adj	
## CDKN1A      1.098515e-32      2.310890e-15                 1	
## EGFR        1.073840e-09      2.314689e-05                 1	
## EP300       1.352439e-05      6.697016e-02                 1	
## HDAC4       1.539614e-06      9.621443e-02                 1	
##        GVM.13.PValue.adj LCM.22.PValue.adj LJM.22.PValue.adj	
## CDKN1A         0.7364812      2.587257e-21      1.154165e-02	
## EGFR           1.0000000      8.637272e-35      5.610384e-07	
## EP300          1.0000000      2.969729e-05      8.009564e-01	
## HDAC4          1.0000000      8.871445e-05      1.127586e-01	
##        LIM.22.PValue.adj GVM.22.PValue.adj	
## CDKN1A         0.5303285         0.8958338	
## EGFR           0.5905420         1.0000000	
## EP300          0.7554520         1.0000000	
## HDAC4          0.5601210         1.0000000	
write.csv(edgeR_results,paste0(thesis_tables_directory,TABLE_EDGER_RESULTS),q
uote = F,row.names = F)	
#write.table(edgeR_results,paste0(thesis_tables_directory,"TABLE_A11.txt"),qu





## Clean up the table containg the DE expresison information	
edgeR_results.melt<-melt(edgeR_results)	
## Using gene as id variables	































## Format and plot the selected immune gene expression's logFC over the 
timecourse	
immune_genes<-c("IL6","CXCL8")	
immune_genes_expression<- dplyr::filter(edgeR_results.melt,gene %in% 
immune_genes &  ref=="M" ) ## Only include selected immune related genes vs. 
the cell culture medium reference	
immune_genes_expression<-unique(immune_genes_expression)	
immune_genes_expression<-spread(immune_genes_expression,key = 
value_type,value = value) ## This will make the logFC, FDR, and other DE 
attributes into colums for easier plotting. The plot will use logFC and FDR 
information	
immune_genes_expression[immune_genes_expression$Pvalue_adj<0.01,"DE.pval"]<-
"*" ## Annotate which samples are DE by FDR	
immune_genes_expression$gene<-factor(immune_genes_expression$gene,levels = 







  facet_wrap(~gene,scales = "free_y",ncol 
=2)+theme_bw()+scale_color_manual(values = color_map)+	
  geom_hline(yintercept =0)+geom_hline(yintercept =c(-
1,0,1),lty=2)+xlab("Exposure Time (hours)")+	
  geom_text(aes(x=as.numeric(ExposureTime),y=logFC,label=DE.pval),size=8)+	
    mBio+	










##                 2	
## Format and plot the cell cycle pathway-related gene expression's logFC 
over the timecourse	
cycle_genes<-c("HDAC4","EP300","CDKN1A","CDK4","CCND1","CCNE2","ESR1","EGFR") 
## Select which cell cycle genes to plot	
cycle_genes_expression<- dplyr::filter(edgeR_results.melt,gene %in% 
cycle_genes &  ref=="M" ) ## Only include the cell cycle genes and cell 
culture medium as the reference	
cycle_genes_expression<-unique(cycle_genes_expression)	
cycle_genes_expression<-spread(cycle_genes_expression,key = value_type,value 
= value) ## This will make the logFC, FDR, and other DE attributes into 
colums for easier plotting. The plot will use logFC and FDR information	
cycle_genes_expression$gene<-factor(cycle_genes_expression$gene,levels = 
cycle_genes,ordered = T) ## Maintain order of genes- this follows logical 
order discussed in thesis. 	
cycle_genes_expression[cycle_genes_expression$Pvalue_adj<0.01,"DE.pval"]<-"*" 
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  facet_wrap(~gene,scales = "free_y",nrow 
=2)+theme_bw()+scale_color_manual(values = color_map)+	














## Log session info	
filewritable_time<-gsub(gsub(Sys.time(),pattern = " ",replacement = 
"_"),pattern = "-|:",replacement = "")	
(sessionInfo_latex<-toLatex(sessionInfo()))	
## \begin{itemize}\raggedright	
##   \item R version 3.3.1 (2016-06-21), \verb|x86_64-apple-darwin13.4.0|	
##   \item Locale: \verb|en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-
8/en_US.UTF-8|	
##   \item Base packages: base, datasets, graphics, grDevices, grid,	
##     methods, parallel, stats, utils	
##   \item Other packages: Biobase~2.34.0, BiocGenerics~0.20.0,	
##     Boruta~5.2.0, caret~6.0-76, dplyr~0.5.0, edgeR~3.16.5,	
##     ggbiplot~0.55, ggplot2~2.2.1, gPCA~1.0, gplots~3.0.1,	
##     gridExtra~2.2.1, lattice~0.20-35, limma~3.30.13, nlme~3.1-131,	
##     plotly~4.6.0, plyr~1.8.4, psych~1.7.3.21, purrr~0.2.2,	
##     randomForest~4.6-12, ranger~0.7.0, RColorBrewer~1.1-2,	
##     readr~1.1.0, reshape~0.8.6, rfPermute~2.1.5, scales~0.4.1,	
##     squash~1.0.7, stringr~1.2.0, tibble~1.3.0, tidyr~0.6.1,	
##     tidyverse~1.1.1	
##   \item Loaded via a namespace (and not attached): abind~1.4-5,	
##     assertthat~0.2.0, backports~1.0.5, bitops~1.0-6, broom~0.4.2,	
##     car~2.1-4, caTools~1.17.1, cellranger~1.1.0, codetools~0.2-15,	
##     colorspace~1.3-2, DBI~0.6-1, deldir~0.1-14, digest~0.6.12,	
##     evaluate~0.10, forcats~0.2.0, foreach~1.4.3, foreign~0.8-68,	
##     gdata~2.17.0, goftest~1.1-1, gtable~0.2.0, gtools~3.5.0,	
##     haven~1.0.0, hms~0.3, htmltools~0.3.5, htmlwidgets~0.8,	
##     httr~1.2.1, iterators~1.0.8, jsonlite~1.4, KernSmooth~2.23-15,	
##     knitr~1.15.1, labeling~0.3, lazyeval~0.2.0, lme4~1.1-13,	
##     locfit~1.5-9.1, lubridate~1.6.0, magrittr~1.5, mapdata~2.2-6,	
##     maps~3.1.1, MASS~7.3-47, Matrix~1.2-8, MatrixModels~0.4-1,	
##     mgcv~1.8-17, minqa~1.2.4, mnormt~1.5-5, ModelMetrics~1.1.0,	
##     modelr~0.1.0, munsell~0.4.3, nloptr~1.0.4, nnet~7.3-12,	
##     pbkrtest~0.4-7, polyclip~1.6-1, quantreg~5.33, R6~2.2.0,	
##     Rcpp~0.12.10, readxl~1.0.0, reshape2~1.4.2, rmarkdown~1.5,	
##     rpart~4.1-11, rprojroot~1.2, rvest~0.3.2, SparseM~1.77,	
##     spatstat~1.50-0, spatstat.utils~1.4-1, splines~3.3.1,	
##     stats4~3.3.1, stringi~1.1.5, swfscMisc~1.2, tensor~1.5,	






## ##------ Wed May 31 23:54:34 2017 ------##	
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Name	of	Requester:	Steven	Smith	 	 	 						 	Cell	Line	ID:	A2EN	PSS	
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Appendix 4 Small RNA-seq miRNA raw read counts table 
Small RNA-seq miRNA raw read counts table for each sequenced sample from 
Figure 2.1 available at https://github.com/ravel-
lab/smith_thesis_2017/tree/master/AnalysisPipeline/Tables/ as TABLE_A4.csv 
Appendix 5 Post-QC log2 normalized small RNA-seq counts and metadata 
Post-QC log2 normalized small RNA-seq counts and metadata used to test and train 
proxy-Amsel-RF and Nugent-RF of samples used in Figure 2.1 and Figure 2.3 
available at https://github.com/ravel-
lab/smith_thesis_2017/tree/master/AnalysisPipeline/Tables/ as TABLE_A5.csv 
Appendix 6 Small RNA-seq library & subject metadata 
Small RNA-seq library preparation, sequencing & alignment statistics, QC analysis 
annotation & subject metadata used in analysis of samples in Figure 2.1 and 
corresponding data dictionary available at https://github.com/ravel-
lab/smith_thesis_2017/tree/master/AnalysisPipeline/Tables/ as TABLE_A6.csv 
Appendix 7 Metataxonomic data and metadata used to train and test the Amsel 
Random Forest model 
Metataxonomic data and metadata used to train and test the Amsel Random Forest 
model available at https://github.com/ravel-
lab/smith_thesis_2017/tree/master/AnalysisPipeline/Tables/ as TABLE_A7.csv 
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Appendix 8 Importance metrics and p-values for the Amsel Random Forest variable 
selection results 
Importance metrics and p-values for the Amsel Random Forest variable selection 
results available at https://github.com/ravel-
lab/smith_thesis_2017/tree/master/AnalysisPipeline/Tables/ as TABLE_A8.csv 
Appendix 9 Metataxonomic data and metadata used as inputs to classify samples for 
proxy-Amsel diagnosis 
Metataxonomic data and metadata used as inputs to classify samples for proxy-Amsel 
diagnosis available at https://github.com/ravel-
lab/smith_thesis_2017/tree/master/AnalysisPipeline/Tables/ as TABLE_A9.csv 
Appendix 10 Importance metrics and p-values for the proxy-Amsel-RF and Nugent-
RF variable selection results 
Importance metrics and p-values for the proxy-Amsel-RF and Nugent-RF variable 
selection results from Figure 2.3 available at https://github.com/ravel-
lab/smith_thesis_2017/tree/master/AnalysisPipeline/Tables/ as TABLE_A10.csv 
Appendix 11 rRNA-reduced RNA-seq raw read counts table 
rRNA-reduced RNA-seq raw read counts table available at https://github.com/ravel-
lab/smith_thesis_2017/tree/master/AnalysisPipeline/Tables/ as TABLE_A11.csv 
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Appendix 12 edgeR GLM-based LRT results  
edgeR GLM-based LRT results for differential expression analysis and IPA analysis 
available at https://github.com/ravel-
lab/smith_thesis_2017/tree/master/AnalysisPipeline/Tables/ as TABLE_A12.csv 
 
Appendix 13 Canonical pathway z-scores 
IPA-based activation score (z-scores) for each exposure time BCS vs. cell culture 
medium available at https://github.com/ravel-
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